|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
increases expression |
ISO |
berberine increases expression of abca1 protein in mouse liver and human hepatocytes |
RGD |
PMID:29505790 |
RGD:19165131 |
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases expression |
EXP |
Berberine results in increased expression of ABCB1A mRNA |
CTD |
PMID:20410605 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcb1b |
ATP-binding cassette, subfamily B (MDR/TAP), member 1B |
increases expression |
EXP |
Berberine results in increased expression of ABCB1B mRNA |
CTD |
PMID:20410605 |
|
NCBI chr 4:25,242,761...25,325,194
Ensembl chr 4:25,242,798...25,325,199
|
|
G |
Acadm |
acyl-CoA dehydrogenase medium chain |
multiple interactions |
ISO |
Berberine inhibits the reaction [Ethanol results in decreased expression of ACADM mRNA] |
CTD |
PMID:25455889 |
|
NCBI chr 2:242,858,865...242,883,036
Ensembl chr 2:242,858,865...242,883,147
|
|
G |
Acan |
aggrecan |
decreases expression |
ISO |
Berberine results in decreased expression of ACAN mRNA |
CTD |
PMID:26478571 |
|
NCBI chr 1:132,981,034...133,044,416
Ensembl chr 1:132,981,582...133,043,627
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions decreases activity |
EXP ISO |
Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased activity of ACHE protein]; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of ACHE mRNA] Berberine results in decreased activity of ACHE protein |
CTD |
PMID:29170048 PMID:33844597 |
|
NCBI chr12:19,407,359...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Acox1 |
acyl-CoA oxidase 1 |
multiple interactions |
ISO |
Berberine inhibits the reaction [Ethanol results in decreased expression of ACOX1 mRNA] |
CTD |
PMID:25455889 |
|
NCBI chr10:101,406,197...101,431,242
Ensembl chr10:101,406,197...101,431,232
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
decreases expression |
EXP |
Berberine results in decreased expression of ACTA2 protein |
CTD |
PMID:17973934 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
ISO |
Berberine inhibits the reaction [Clozapine results in increased expression of ADIPOQ mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of ADIPOQ mRNA] |
CTD |
PMID:20564506 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Ager |
advanced glycosylation end product-specific receptor |
multiple interactions |
EXP |
Berberine inhibits the reaction [Bortezomib results in increased expression of AGER mRNA] |
CTD |
PMID:35121005 |
|
NCBI chr20:4,148,150...4,151,361
Ensembl chr20:4,147,890...4,151,078
|
|
G |
Ahr |
aryl hydrocarbon receptor |
increases activity |
EXP ISO |
Berberine results in increased activity of AHR protein |
CTD |
PMID:16046213 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions decreases phosphorylation increases phosphorylation |
ISO EXP |
Berberine inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein] Berberine results in decreased phosphorylation of AKT1 protein Berberine inhibits the reaction [Thioacetamide results in increased phosphorylation of AKT1 protein] Berberine results in increased phosphorylation of AKT1 protein |
CTD |
PMID:23954465 PMID:30138605 PMID:33325633 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Akt2 |
AKT serine/threonine kinase 2 |
multiple interactions |
ISO |
Berberine inhibits the reaction [Dexamethasone results in decreased expression of AKT2 mRNA] |
CTD |
PMID:20462044 |
|
NCBI chr 1:82,877,228...82,933,828
Ensembl chr 1:82,883,547...82,933,817
|
|
G |
Alb |
albumin |
multiple interactions |
EXP |
Berberine inhibits the reaction [Thioacetamide results in decreased expression of ALB protein] |
CTD |
PMID:30138605 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
EXP |
Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of APP mRNA] |
CTD |
PMID:29170048 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Aurkb |
aurora kinase B |
decreases expression |
ISO |
Berberine results in decreased expression of AURKB mRNA |
CTD |
PMID:27311644 |
|
NCBI chr10:53,744,290...53,750,831
Ensembl chr10:53,745,142...53,750,837
|
|
G |
Aurkc |
aurora kinase C |
increases expression |
ISO |
Berberine results in increased expression of AURKC mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 1:66,843,653...66,864,348
Ensembl chr 1:66,843,653...66,864,386
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
EXP ISO |
[Berberine co-treated with Thioacetamide] results in increased expression of BAX mRNA; Berberine inhibits the reaction [Mercuric Chloride results in increased expression of BAX protein] Berberine results in increased expression of BAX mRNA; Berberine results in increased expression of BAX protein [Berberine co-treated with Cisplatin] results in increased expression of BAX protein; [Berberine co-treated with Niacinamide] results in increased expression of BAX protein; Acetylcysteine inhibits the reaction [[Berberine co-treated with Cisplatin] results in increased expression of BAX protein]; SRT1720 inhibits the reaction [Berberine results in increased expression of BAX protein] |
CTD |
PMID:16505103 PMID:20656010 PMID:25600690 PMID:26712469 PMID:30138605 PMID:36070022 More...
|
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bbc3 |
Bcl-2 binding component 3 |
increases expression multiple interactions |
ISO |
Berberine results in increased expression of BBC3 mRNA [Berberine co-treated with Niacinamide] results in increased expression of BBC3 mRNA |
CTD |
PMID:26712469 |
|
NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression increases expression multiple interactions |
ISO EXP |
Berberine results in decreased expression of BCL2 mRNA; Berberine results in decreased expression of BCL2 protein Berberine results in increased expression of BCL2 protein Berberine inhibits the reaction [Mercuric Chloride results in decreased expression of BCL2 protein]; Berberine inhibits the reaction [Thioacetamide results in increased expression of BCL2 mRNA] [Berberine co-treated with Cisplatin] results in decreased expression of BCL2 protein; [Berberine co-treated with Niacinamide] results in decreased expression of BCL2 protein; Berberine inhibits the reaction [Glucose results in decreased expression of BCL2 protein] |
CTD |
PMID:16505103 PMID:20656010 PMID:23954465 PMID:24751971 PMID:25600690 PMID:26712469 PMID:30138605 PMID:36070022 More...
|
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
decreases expression |
ISO |
Berberine results in decreased expression of BCL2L1 protein |
CTD |
PMID:16505103 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Bcl2l11 |
Bcl2-like 11 |
multiple interactions increases expression |
ISO |
[Berberine co-treated with Niacinamide] results in increased expression of BCL2L11 mRNA Berberine results in increased expression of BCL2L11 mRNA |
CTD |
PMID:26712469 |
|
NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
increases expression multiple interactions |
ISO |
Berberine results in increased expression of BGLAP mRNA; Berberine results in increased expression of BGLAP protein CTNNB1 mutant form inhibits the reaction [Berberine results in increased expression of BGLAP protein]; DKK1 protein inhibits the reaction [Berberine results in increased expression of BGLAP protein] |
CTD |
PMID:26478571 |
|
NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
affects binding |
ISO |
Berberine binds to BIRC5 promoter |
CTD |
PMID:17968851 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Bnip3 |
BCL2 interacting protein 3 |
multiple interactions increases expression |
ISO |
[Cisplatin co-treated with Berberine] results in increased expression of BNIP3 protein Berberine results in increased expression of BNIP3 protein |
CTD |
PMID:36070022 |
|
NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359
|
|
G |
Bnip3l |
BCL2 interacting protein 3 like |
increases expression multiple interactions |
ISO |
Berberine results in increased expression of BNIP3L protein [Cisplatin co-treated with Berberine] results in increased expression of BNIP3L protein; BNIP3L protein affects the reaction [[Berberine co-treated with Cisplatin] results in increased lipidation of MAP1LC3B protein] |
CTD |
PMID:36070022 |
|
NCBI chr15:41,174,594...41,197,730
Ensembl chr15:41,174,594...41,197,803
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity increases cleavage increases expression |
ISO EXP |
[Berberine co-treated with Cisplatin] results in increased cleavage of CASP3 protein; [Berberine co-treated with Niacinamide] results in increased cleavage of CASP3 protein; Acetylcysteine inhibits the reaction [[Berberine co-treated with Cisplatin] results in increased cleavage of CASP3 protein]; Berberine results in increased cleavage of and results in increased activity of CASP3 protein Berberine increases activity of CASP3 protein in colon epithelial cells Berberine results in increased cleavage of CASP3 protein [Berberine co-treated with Thioacetamide] results in increased expression of CASP3 mRNA; Berberine inhibits the reaction [Mercuric Chloride results in increased activity of CASP3 protein] Berberine results in increased activity of CASP3 protein Berberine results in increased expression of CASP3 mRNA |
CTD RGD |
PMID:16505103 PMID:20656010 PMID:25600690 PMID:26712469 PMID:30138605 PMID:36070022 PMID:29564000 More...
|
RGD:152995489 |
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
increases activity |
ISO |
Berberine results in increased activity of CASP8 protein |
CTD |
PMID:20656010 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
increases cleavage multiple interactions |
ISO EXP |
Berberine results in increased cleavage of CASP9 protein [Berberine co-treated with Thioacetamide] results in increased expression of CASP9 mRNA [Berberine co-treated with Niacinamide] results in increased cleavage of CASP9 protein |
CTD |
PMID:16505103 PMID:26712469 PMID:30138605 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
EXP ISO |
Berberine affects the reaction [[Streptozocin co-treated with Dietary Carbohydrates co-treated with Dietary Fats] affects the activity of CAT protein]; Berberine inhibits the reaction [Bortezomib results in decreased expression of CAT protein]; Berberine inhibits the reaction [Mercuric Chloride results in decreased activity of CAT protein]; Berberine inhibits the reaction [Thioacetamide results in decreased activity of CAT protein] Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of CAT protein] |
CTD |
PMID:20828602 PMID:24751971 PMID:25600690 PMID:30138605 PMID:35121005 PMID:35691465 More...
|
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
Berberine inhibits the reaction [IL1B protein results in increased expression of CCL2 mRNA]; Berberine inhibits the reaction [IL1B protein results in increased secretion of CCL2 protein]; Berberine inhibits the reaction [TNF protein results in increased expression of CCL2 mRNA]; Berberine inhibits the reaction [TNF protein results in increased secretion of CCL2 protein] Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CCL2 protein] |
CTD |
PMID:16391493 PMID:35691465 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression |
ISO |
Berberine results in decreased expression of CCND1 protein |
CTD |
PMID:16505103 PMID:33325633 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccnd2 |
cyclin D2 |
decreases expression |
ISO |
Berberine results in decreased expression of CCND2 protein |
CTD |
PMID:16505103 |
|
NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495
|
|
G |
Ccne1 |
cyclin E1 |
decreases expression |
ISO |
Berberine results in decreased expression of CCNE1 protein |
CTD |
PMID:16505103 |
|
NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
|
|
G |
Ccnt1 |
cyclin T1 |
multiple interactions |
EXP |
Berberine affects the reaction [[Streptozocin co-treated with Dietary Carbohydrates co-treated with Dietary Fats] affects the expression of CCNT1 mRNA]; Berberine affects the reaction [[Streptozocin co-treated with Dietary Carbohydrates co-treated with Dietary Fats] affects the expression of CCNT1 protein] |
CTD |
PMID:20828602 |
|
NCBI chr 7:129,687,146...129,718,082
Ensembl chr 7:129,691,209...129,717,871
|
|
G |
Cd36 |
CD36 molecule |
increases expression multiple interactions |
ISO |
Berberine results in increased expression of CD36 mRNA Berberine results in increased expression of CD36 mRNA; Berberine results in increased expression of CD36 protein 15-deoxyprostaglandin J2 promotes the reaction [Berberine results in increased expression of CD36 mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Berberine results in increased expression of CD36 protein]; Berberine promotes the reaction [15-deoxyprostaglandin J2 results in increased expression of CD36 mRNA]; Berberine results in increased expression of and affects the localization of CD36 protein; CEBPB protein promotes the reaction [Berberine results in increased expression of CD36 mRNA] |
CTD |
PMID:28038998 PMID:29408570 |
|
NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Cdh2 |
cadherin 2 |
decreases expression |
ISO |
Berberine results in decreased expression of CDH2 mRNA |
CTD |
PMID:26478571 |
|
NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases expression |
ISO |
Berberine results in decreased expression of CDK2 protein |
CTD |
PMID:16505103 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
decreases expression |
ISO |
Berberine results in decreased expression of CDK4 protein |
CTD |
PMID:16505103 |
|
NCBI chr 7:62,885,647...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Cdk6 |
cyclin-dependent kinase 6 |
decreases expression |
ISO |
Berberine results in decreased expression of CDK6 protein |
CTD |
PMID:16505103 |
|
NCBI chr 4:30,637,650...30,829,688
Ensembl chr 4:30,646,460...30,829,634
|
|
G |
Cdk9 |
cyclin-dependent kinase 9 |
multiple interactions |
EXP |
Berberine affects the reaction [[Streptozocin co-treated with Dietary Carbohydrates co-treated with Dietary Fats] affects the expression of CDK9 mRNA]; Berberine affects the reaction [[Streptozocin co-treated with Dietary Carbohydrates co-treated with Dietary Fats] affects the expression of CDK9 protein] |
CTD |
PMID:20828602 |
|
NCBI chr 3:15,996,467...16,001,315
Ensembl chr 3:15,996,468...16,002,410
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
ISO |
Berberine results in increased expression of CDKN1A protein |
CTD |
PMID:16505103 PMID:23747414 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
increases expression |
ISO |
Berberine results in increased expression of CDKN1B protein |
CTD |
PMID:16505103 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cdkn1c |
cyclin-dependent kinase inhibitor 1C |
increases expression |
ISO |
Berberine results in increased expression of CDKN1C mRNA |
CTD |
PMID:26478571 |
|
NCBI chr 1:198,655,394...198,658,097
Ensembl chr 1:198,655,407...198,658,048
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
multiple interactions decreases expression |
ISO |
Berberine inhibits the reaction [Clozapine results in increased expression of CEBPA mRNA]; Berberine inhibits the reaction [Clozapine results in increased expression of CEBPA protein]; Berberine inhibits the reaction [Risperidone results in increased expression of CEBPA mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of CEBPA protein] Berberine results in decreased expression of CEBPA mRNA |
CTD |
PMID:20564506 PMID:26478571 |
|
NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
affects phosphorylation multiple interactions increases expression |
ISO |
Berberine affects the phosphorylation of CEBPB protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Berberine results in increased phosphorylation of CEBPB protein]; CEBPB protein promotes the reaction [Berberine results in increased expression of CD36 mRNA] Berberine results in increased expression of CEBPB mRNA |
CTD |
PMID:28038998 |
|
NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473
|
|
G |
Chek1 |
checkpoint kinase 1 |
increases expression |
ISO |
Berberine results in increased expression of CHEK1 protein modified form |
CTD |
PMID:23747414 |
|
NCBI chr 8:36,420,565...36,443,477
Ensembl chr 8:36,420,569...36,441,009
|
|
G |
Chek2 |
checkpoint kinase 2 |
increases expression |
ISO |
Berberine results in increased expression of CHEK2 protein modified form |
CTD |
PMID:23747414 |
|
NCBI chr12:45,788,823...45,821,382
Ensembl chr12:45,788,827...45,821,286
|
|
G |
Col10a1 |
collagen type X alpha 1 chain |
increases expression |
ISO |
Berberine results in increased expression of COL10A1 mRNA |
CTD |
PMID:26478571 |
|
NCBI chr20:38,183,103...38,189,488
Ensembl chr20:38,182,494...38,189,494
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
increases expression |
ISO |
Berberine results in increased expression of COL1A1 mRNA |
CTD |
PMID:26478571 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Col2a1 |
collagen type II alpha 1 chain |
decreases expression |
ISO |
Berberine results in decreased expression of COL2A1 mRNA |
CTD |
PMID:26478571 |
|
NCBI chr 7:129,098,489...129,127,620
Ensembl chr 7:129,098,786...129,127,546
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
multiple interactions |
ISO |
Berberine inhibits the reaction [Ethanol results in decreased expression of CPT1A mRNA] |
CTD |
PMID:25455889 |
|
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
EXP |
Berberine inhibits the reaction [Bortezomib results in decreased expression of CREB1 protein] |
CTD |
PMID:35121005 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Crebbp |
CREB binding protein |
increases expression |
ISO |
Berberine results in increased expression of CREBBP mRNA |
CTD |
PMID:27311644 |
|
NCBI chr10:11,335,551...11,461,888
Ensembl chr10:11,335,953...11,461,888
|
|
G |
Ctnnb1 |
catenin beta 1 |
increases expression multiple interactions |
ISO |
Berberine results in increased expression of CTNNB1 protein CTNNB1 mutant form inhibits the reaction [Berberine results in increased expression of BGLAP protein]; CTNNB1 mutant form inhibits the reaction [Berberine results in increased expression of RUNX2 mRNA]; CTNNB1 mutant form inhibits the reaction [Berberine results in increased expression of SPP1 protein]; DKK1 protein inhibits the reaction [Berberine results in increased expression of CTNNB1 protein] |
CTD |
PMID:26478571 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Ctsd |
cathepsin D |
multiple interactions decreases cleavage |
ISO |
GSK2795039 affects the reaction [Berberine results in decreased cleavage of CTSD protein] |
CTD |
PMID:36070022 |
|
NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488
|
|
G |
Ctsl |
cathepsin L |
decreases cleavage multiple interactions |
ISO |
Berberine results in decreased cleavage of CTSL protein Acetylcysteine inhibits the reaction [Berberine results in decreased cleavage of CTSL protein]; GSK2795039 affects the reaction [Berberine results in decreased cleavage of CTSL protein] |
CTD |
PMID:36070022 |
|
NCBI chr17:764,370...770,533
Ensembl chr17:764,309...770,548
|
|
G |
Cybb |
cytochrome b-245 beta chain |
multiple interactions |
ISO |
Berberine promotes the reaction [CYBB protein binds to NCF1 protein binds to NCF2 protein binds to RAC2 protein]; Berberine promotes the reaction [CYBB protein binds to NCF1 protein]; Berberine promotes the reaction [CYBB protein binds to NCF2 protein]; Berberine promotes the reaction [CYBB protein binds to RAC2 protein] |
CTD |
PMID:36070022 |
|
NCBI chr X:13,360,583...13,392,517
Ensembl chr X:13,359,430...13,392,586
|
|
G |
Cycs |
cytochrome c, somatic |
affects localization multiple interactions |
ISO |
Berberine affects the localization of CYCS protein [Berberine co-treated with Cisplatin] results in increased expression of CYCS protein |
CTD |
PMID:16505103 PMID:36070022 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
Berberine inhibits the reaction [Dexamethasone results in increased expression of CYP17A1 mRNA] |
CTD |
PMID:20462044 |
|
NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases activity increases expression multiple interactions |
ISO EXP |
Berberine results in decreased activity of CYP1A1 protein Berberine results in increased expression of CYP1A1 mRNA Berberine inhibits the reaction [beta-Naphthoflavone results in increased expression of CYP1A1 mRNA] |
CTD |
PMID:16046213 PMID:22342832 PMID:24583342 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
Berberine inhibits the reaction [beta-Naphthoflavone results in increased expression of CYP1A2 mRNA] |
CTD |
PMID:22342832 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
multiple interactions increases expression |
ISO |
Berberine inhibits the reaction [Streptozocin results in increased expression of CYP2B10 mRNA]; Berberine promotes the reaction [Phenobarbital results in increased expression of CYP2B10 mRNA] Berberine results in increased expression of CYP2B10 mRNA |
CTD |
PMID:22342832 |
|
NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
multiple interactions increases expression |
ISO |
Berberine promotes the reaction [Phenobarbital results in increased expression of CYP2B9 mRNA]; Berberine promotes the reaction [Streptozocin results in increased expression of CYP2B9 mRNA] Berberine results in increased expression of CYP2B9 mRNA |
CTD |
PMID:22342832 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
decreases expression multiple interactions |
ISO |
Berberine results in decreased expression of CYP2E1 mRNA Berberine inhibits the reaction [Ethanol results in increased expression of CYP2E1 protein]; Berberine inhibits the reaction [Isoniazid results in increased expression of CYP2E1 mRNA] |
CTD |
PMID:22342832 PMID:25455889 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
decreases expression multiple interactions decreases activity |
EXP ISO |
Berberine results in decreased expression of CYP3A4 mRNA; Berberine results in decreased expression of CYP3A4 protein [Berberine results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA Berberine results in decreased activity of CYP3A4 protein Atorvastatin promotes the reaction [Berberine results in decreased activity of CYP3A4 protein]; Berberine promotes the reaction [Atorvastatin results in decreased activity of CYP3A4 protein]; Berberine promotes the reaction [Atorvastatin results in decreased expression of CYP3A4 mRNA]; Berberine promotes the reaction [Atorvastatin results in decreased expression of CYP3A4 protein]; Berberine promotes the reaction [Simvastatin results in decreased activity of CYP3A4 protein]; Berberine promotes the reaction [Simvastatin results in decreased expression of CYP3A4 protein]; Simvastatin promotes the reaction [Berberine results in decreased activity of CYP3A4 protein] |
CTD |
PMID:21524698 PMID:30086269 |
|
NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Dkk1 |
dickkopf WNT signaling pathway inhibitor 1 |
multiple interactions |
ISO |
DKK1 protein inhibits the reaction [Berberine results in increased expression of BGLAP protein]; DKK1 protein inhibits the reaction [Berberine results in increased expression of CTNNB1 protein]; DKK1 protein inhibits the reaction [Berberine results in increased expression of RUNX2 mRNA]; DKK1 protein inhibits the reaction [Berberine results in increased expression of SPP1 protein] |
CTD |
PMID:26478571 |
|
NCBI chr 1:228,381,521...228,385,202
Ensembl chr 1:228,381,521...228,385,202
|
|
G |
Dnmt1 |
DNA methyltransferase 1 |
decreases expression |
ISO |
Berberine results in decreased expression of DNMT1 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659
|
|
G |
Dnmt3b |
DNA methyltransferase 3 beta |
decreases expression |
ISO |
Berberine results in decreased expression of DNMT3B mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 3:142,130,592...142,169,124
Ensembl chr 3:142,130,592...142,169,124
|
|
G |
Dzip3 |
DAZ interacting zinc finger protein 3 |
increases expression |
ISO |
Berberine results in increased expression of DZIP3 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr11:51,823,235...51,893,353
Ensembl chr11:51,823,231...51,893,353
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [EGF protein inhibits the reaction [Berberine results in decreased activity of MMP2 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [EGF protein inhibits the reaction [Berberine results in decreased activity of MMP9 protein]]; EGF protein inhibits the reaction [Berberine results in decreased activity of MMP2 protein]; EGF protein inhibits the reaction [Berberine results in decreased activity of MMP9 protein] |
CTD |
PMID:33325633 |
|
NCBI chr 2:218,219,408...218,302,370
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Egfr |
epidermal growth factor receptor |
decreases expression |
ISO |
Berberine results in decreased expression of EGFR protein |
CTD |
PMID:33325633 |
|
NCBI chr14:91,176,931...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
multiple interactions |
ISO |
Berberine results in decreased phosphorylation of and results in increased expression of EIF4EBP1 protein |
CTD |
PMID:23363784 |
|
NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
|
|
G |
Ep300 |
E1A binding protein p300 |
increases expression |
ISO |
Berberine results in increased expression of EP300 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 7:113,108,476...113,178,529
Ensembl chr 7:113,106,247...113,136,088 Ensembl chr 7:113,106,247...113,136,088
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
multiple interactions |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Berberine results in decreased expression of ERBB2 protein]; Berberine results in decreased expression of and results in increased ubiquitination of ERBB2 protein |
CTD |
PMID:33325633 |
|
NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
Berberine inhibits the reaction [Estradiol results in increased activity of ESR1 protein] |
CTD |
PMID:30818834 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esrra |
estrogen related receptor, alpha |
multiple interactions |
ISO |
Berberine inhibits the reaction [XCT790 results in decreased activity of ESRRA protein] |
CTD |
PMID:30818834 |
|
NCBI chr 1:204,104,100...204,114,182
Ensembl chr 1:204,104,101...204,114,268
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
decreases expression multiple interactions increases expression |
ISO |
Berberine results in decreased expression of FABP4 mRNA 15-deoxyprostaglandin J2 promotes the reaction [Berberine results in increased expression of FABP4 mRNA]; Berberine promotes the reaction [15-deoxyprostaglandin J2 results in increased expression of FABP4 mRNA] |
CTD |
PMID:26478571 PMID:29408570 |
|
NCBI chr 2:91,580,858...91,585,578
Ensembl chr 2:91,580,885...91,585,578
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions increases expression |
ISO |
[Clozapine co-treated with Berberine] results in decreased expression of FAS mRNA; Berberine inhibits the reaction [Risperidone results in increased expression of FAS mRNA] Berberine results in increased expression of FAS mRNA; Berberine results in increased expression of FAS protein |
CTD |
PMID:20564506 PMID:20656010 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Faslg |
Fas ligand |
increases expression |
ISO |
Berberine results in increased expression of FASLG mRNA; Berberine results in increased expression of FASLG protein |
CTD |
PMID:20656010 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fn1 |
fibronectin 1 |
multiple interactions |
EXP |
Berberine inhibits the reaction [Thioacetamide results in increased expression of FN1 mRNA] |
CTD |
PMID:30138605 |
|
NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
|
|
G |
Foxo1 |
forkhead box O1 |
multiple interactions |
ISO |
[Berberine co-treated with Niacinamide] results in increased expression of and results in increased acetylation of FOXO1 protein; Berberine results in increased expression of and results in increased acetylation of FOXO1 protein |
CTD |
PMID:26712469 |
|
NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790
|
|
G |
Foxo3 |
forkhead box O3 |
multiple interactions |
ISO |
[Berberine co-treated with Niacinamide] results in increased expression of and results in increased acetylation of FOXO3 protein; Berberine results in increased expression of and results in increased acetylation of FOXO3 protein |
CTD |
PMID:26712469 |
|
NCBI chr20:45,669,708...45,764,606
Ensembl chr20:45,672,995...45,764,561
|
|
G |
Fundc1 |
FUN14 domain containing 1 |
increases expression multiple interactions |
ISO |
Berberine results in increased expression of FUNDC1 protein [Cisplatin co-treated with Berberine] results in increased expression of FUNDC1 protein; FUNDC1 protein affects the reaction [[Berberine co-treated with Cisplatin] results in increased lipidation of MAP1LC3B protein] |
CTD |
PMID:36070022 |
|
NCBI chr X:5,083,635...5,100,293
Ensembl chr X:5,083,617...5,100,284
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions |
EXP |
Berberine inhibits the reaction [Bortezomib results in increased expression of GCLC mRNA] |
CTD |
PMID:35121005 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
multiple interactions |
EXP |
Berberine inhibits the reaction [Bortezomib results in increased expression of GCLM mRNA] |
CTD |
PMID:35121005 |
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Gdf5 |
growth differentiation factor 5 |
decreases expression |
ISO |
Berberine results in decreased expression of GDF5 mRNA |
CTD |
PMID:26478571 |
|
NCBI chr 3:144,454,306...144,458,757
Ensembl chr 3:144,454,338...144,458,612
|
|
G |
Gfap |
glial fibrillary acidic protein |
multiple interactions |
EXP |
Berberine inhibits the reaction [Bortezomib results in increased expression of GFAP mRNA] |
CTD |
PMID:35121005 |
|
NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
ISO EXP |
Berberine inhibits the reaction [Ethanol results in increased activity of GPT protein] Berberine inhibits the reaction [Mercuric Chloride results in increased activity of GPT protein]; Berberine inhibits the reaction [Thioacetamide results in increased activity of GPT protein] |
CTD |
PMID:24751971 PMID:25455889 PMID:30138605 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions |
EXP |
Berberine inhibits the reaction [Mercuric Chloride results in decreased expression of GPX1 mRNA] |
CTD |
PMID:24751971 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions increases phosphorylation |
ISO |
Berberine inhibits the reaction [Dexamethasone results in decreased expression of GSK3B mRNA] Berberine results in increased phosphorylation of GSK3B protein Berberine inhibits the reaction [Glucose results in decreased phosphorylation of GSK3B protein] |
CTD |
PMID:20462044 PMID:23954465 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
EXP |
Berberine inhibits the reaction [Mercuric Chloride results in decreased activity of GSR protein] |
CTD |
PMID:24751971 PMID:25600690 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
H2ac12 |
H2A clustered histone 12 |
decreases expression |
ISO |
Berberine results in decreased expression of H2AC12 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr17:42,486,315...42,486,880
Ensembl chr17:42,486,415...42,486,941
|
|
G |
H2ac18 |
H2A clustered histone 18 |
decreases expression |
ISO |
Berberine results in decreased expression of H2AC18 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 2:183,808,398...183,808,922
|
|
G |
H2ac25 |
H2A clustered histone 25 |
decreases expression |
ISO |
Berberine results in decreased expression of H2AC25 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr10:43,733,702...43,735,254
Ensembl chr10:43,733,668...43,744,874
|
|
G |
H2ac4 |
H2A clustered histone 4 |
decreases expression |
ISO |
Berberine results in decreased expression of H2AC4 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr17:42,799,953...42,800,345
Ensembl chr17:42,799,652...42,800,381
|
|
G |
H2ax |
H2A.X variant histone |
increases expression decreases expression multiple interactions |
ISO |
Berberine results in increased expression of H2AX protein modified form Berberine results in decreased expression of H2AX mRNA; Berberine results in decreased expression of H2AX protein TOP2A protein affects the reaction [Berberine results in increased expression of H2AX protein modified form] |
CTD |
PMID:23363784 PMID:23747414 PMID:27311644 |
|
NCBI chr 8:44,671,927...44,673,257
Ensembl chr 8:44,671,786...44,673,239
|
|
G |
H2bc12 |
H2B clustered histone 12 |
decreases expression |
ISO |
Berberine results in decreased expression of H2BC12 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr17:42,485,746...42,486,126
|
|
G |
H2bc6 |
H2B clustered histone 6 |
decreases expression |
ISO |
Berberine results in decreased expression of H2BC6 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr17:41,520,767...41,521,240
|
|
G |
H2bc8 |
H2B clustered histone 8 |
decreases expression |
ISO |
Berberine results in decreased expression of H2BC8 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr17:42,708,646...42,709,435
|
|
G |
H2bc9 |
H2B clustered histone 9 |
decreases expression |
ISO |
Berberine results in decreased expression of H2BC9 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr17:42,470,593...42,478,605
|
|
G |
H3c1 |
H3 clustered histone 1 |
decreases expression |
ISO |
Berberine results in decreased expression of H3C1 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr17:41,367,824...41,368,902
Ensembl chr17:41,368,386...41,368,856
|
|
G |
H3f3a |
H3.3 histone A |
decreases expression |
ISO |
Berberine results in decreased expression of H3-3A mRNA |
CTD |
PMID:27311644 |
|
NCBI chr13:92,533,294...92,544,903
Ensembl chr13:92,533,298...92,544,908
|
|
G |
H3f4 |
H3.4 histone, cluster member |
decreases expression |
ISO |
Berberine results in decreased expression of H3-4 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr10:43,740,797...43,741,207
|
|
G |
H4c3 |
H4 clustered histone 3 |
decreases expression |
ISO |
Berberine results in decreased expression of H4C3 mRNA |
CTD |
PMID:27311644 |
|
|
|
G |
Hat1 |
histone acetyltransferase 1 |
increases expression |
ISO |
Berberine results in increased expression of HAT1 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 3:56,217,344...56,265,021
Ensembl chr 3:56,217,342...56,275,517
|
|
G |
Hdac2 |
histone deacetylase 2 |
decreases expression |
ISO |
Berberine results in decreased expression of HDAC2 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr20:40,548,250...40,571,609
Ensembl chr20:40,548,250...40,571,609
|
|
G |
Hdac5 |
histone deacetylase 5 |
increases expression |
ISO |
Berberine results in increased expression of HDAC5 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr10:87,152,978...87,187,921
Ensembl chr10:87,152,978...87,188,235
|
|
G |
Hdac8 |
histone deacetylase 8 |
decreases expression |
ISO |
Berberine results in decreased expression of HDAC8 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr X:67,385,288...67,593,014
Ensembl chr X:67,385,289...67,592,923
|
|
G |
Hdac9 |
histone deacetylase 9 |
decreases expression increases expression |
ISO |
Berberine results in decreased expression of HDAC9 mRNA Berberine results in increased expression of HDAC9 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 6:50,762,074...51,624,311
Ensembl chr 6:50,763,590...51,625,333
|
|
G |
Hgf |
hepatocyte growth factor |
increases expression multiple interactions |
ISO |
Berberine results in increased expression of HGF mRNA; Berberine results in increased expression of HGF protein Berberine inhibits the reaction [Bleomycin results in decreased expression of HGF mRNA] 15-deoxyprostaglandin J2 promotes the reaction [Berberine results in increased expression of HGF mRNA]; 15-deoxyprostaglandin J2 promotes the reaction [Berberine results in increased expression of HGF protein]; 2-chloro-5-nitrobenzanilide inhibits the reaction [Berberine results in increased expression of HGF protein]; Berberine promotes the reaction [15-deoxyprostaglandin J2 results in increased expression of HGF mRNA]; Berberine promotes the reaction [15-deoxyprostaglandin J2 results in increased expression of HGF protein]; Dactinomycin inhibits the reaction [Berberine results in increased expression of HGF protein]; PPARG mRNA promotes the reaction [Berberine results in increased expression of HGF protein] |
CTD |
PMID:29408570 |
|
NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409
|
|
G |
Hist1h2af |
histone cluster 1 H2A family member F |
decreases expression |
ISO |
Berberine results in decreased expression of H2AC8 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr17:41,379,404...41,379,796
Ensembl chr17:41,379,404...41,379,796
|
|
G |
Hist1h2ah |
histone cluster 1 H2A family member H |
decreases expression |
ISO |
Berberine results in decreased expression of H2AC11 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr17:41,384,521...41,385,018
|
|
G |
Hist1h2bd |
histone cluster 1 H2B family member D |
decreases expression |
ISO |
Berberine results in decreased expression of H2BC5 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr17:42,792,887...42,793,268
|
|
G |
Hist1h2bq |
histone cluster 1 H2B family member Q |
decreases expression |
ISO |
Berberine results in decreased expression of H2BC7 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr17:41,432,100...41,441,487
Ensembl chr17:41,429,164...41,442,153
|
|
G |
Hist1h3b |
histone cluster 1, H3b |
decreases expression |
ISO |
Berberine results in decreased expression of H3C12 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr17:42,722,805...42,723,925
Ensembl chr17:42,723,450...42,723,911
|
|
G |
Hist1h4b |
histone cluster 1 H4 family member B |
decreases expression |
ISO |
Berberine results in decreased expression of H4C9 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr17:42,480,467...42,484,912
Ensembl chr17:42,480,313...42,485,370
|
|
G |
Hist2h2be |
histone cluster 2 H2B family member E |
decreases expression |
ISO |
Berberine results in decreased expression of H2BC11 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 2:183,780,449...183,783,030
|
|
G |
Hist2h4 |
histone cluster 2, H4 |
decreases expression |
ISO |
Berberine results in decreased expression of H4C2 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 2:183,831,601...183,831,996
Ensembl chr 2:183,825,994...183,832,048
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression multiple interactions |
ISO EXP |
Berberine results in increased expression of HMOX1 protein Berberine inhibits the reaction [Bortezomib results in increased expression of HMOX1 mRNA] Berberine promotes the reaction [Glucose results in increased expression of HMOX1 protein]; NFE2L2 mutant form inhibits the reaction [Berberine results in increased expression of HMOX1 protein] |
CTD |
PMID:23954465 PMID:35121005 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hnf4a |
hepatocyte nuclear factor 4, alpha |
multiple interactions |
EXP ISO |
Berberine inhibits the reaction [Fructose results in decreased expression of HNF4A mRNA]; Berberine inhibits the reaction [Fructose results in decreased expression of HNF4A protein] Berberine inhibits the reaction [Ethanol results in decreased expression of HNF4 protein] |
CTD |
PMID:18563319 PMID:25455889 |
|
NCBI chr 3:152,186,787...152,248,320
Ensembl chr 3:152,186,787...152,248,320
|
|
G |
Idh3a |
isocitrate dehydrogenase (NAD(+)) 3 catalytic subunit alpha |
decreases expression |
ISO |
Berberine results in decreased expression of IDH3A mRNA |
CTD |
PMID:30818834 |
|
NCBI chr 8:54,971,694...54,991,085
Ensembl chr 8:54,971,740...54,991,084
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
EXP |
Berberine inhibits the reaction [Thioacetamide results in increased expression of IFNG mRNA] |
CTD |
PMID:30138605 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Igf1r |
insulin-like growth factor 1 receptor |
multiple interactions increases expression |
ISO |
Berberine inhibits the reaction [Glucose results in decreased expression of IGF1R protein] Berberine results in increased expression of IGF1R protein |
CTD |
PMID:23954465 |
|
NCBI chr 1:121,549,839...121,838,545
Ensembl chr 1:121,550,743...121,831,777
|
|
G |
Il10 |
interleukin 10 |
multiple interactions increases expression |
ISO EXP |
Berberine affects the reaction [Lipopolysaccharides affects the expression of IL10 mRNA] [Berberine co-treated with Thioacetamide] results in increased expression of IL10 mRNA Berberine results in increased expression of IL10 mRNA |
CTD |
PMID:21867779 PMID:30138605 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO EXP |
Berberine inhibits the reaction [IL1B protein results in increased expression of CCL2 mRNA]; Berberine inhibits the reaction [IL1B protein results in increased expression of CXCL8 mRNA]; Berberine inhibits the reaction [IL1B protein results in increased secretion of CCL2 protein]; Berberine inhibits the reaction [IL1B protein results in increased secretion of CXCL8 protein] Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B mRNA]; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B protein] Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of IL1B protein]; Berberine inhibits the reaction [Bortezomib results in increased expression of IL1B mRNA]; Berberine inhibits the reaction [Thioacetamide results in increased expression of IL1B mRNA] |
CTD |
PMID:16391493 PMID:29170048 PMID:30138605 PMID:35121005 PMID:35691465 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il2 |
interleukin 2 |
increases expression |
ISO |
Berberine results in increased expression of IL2 mRNA |
CTD |
PMID:21867779 |
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Il23a |
interleukin 23 subunit alpha |
multiple interactions |
ISO |
Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of IL23A mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of IL23A protein] |
CTD |
PMID:30240693 |
|
NCBI chr 7:721,809...723,923
Ensembl chr 7:721,809...723,923
|
|
G |
Il4 |
interleukin 4 |
multiple interactions increases expression |
ISO |
Berberine inhibits the reaction [Lipopolysaccharides results in decreased expression of IL4 mRNA] Berberine results in increased expression of IL4 mRNA |
CTD |
PMID:21867779 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP ISO |
Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of IL6 protein]; Berberine inhibits the reaction [Bortezomib results in increased expression of IL6 mRNA]; Berberine inhibits the reaction [Thioacetamide results in increased expression of IL6 mRNA]; Berberine inhibits the reaction [Thioacetamide results in increased expression of IL6 protein] Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of IL6 mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of IL6 protein]; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 mRNA]; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein] Berberine inhibits the reaction [Mustard Gas results in increased secretion of IL6 protein] |
CTD |
PMID:28916288 PMID:29170048 PMID:30138605 PMID:30240693 PMID:35121005 PMID:35691465 More...
|
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Itga1 |
integrin subunit alpha 1 |
increases expression |
ISO |
Berberine results in increased expression of ITGA1 mRNA |
CTD |
PMID:26478571 |
|
NCBI chr 2:46,646,125...46,812,237
Ensembl chr 2:46,653,193...46,812,238
|
|
G |
Itgb4 |
integrin subunit beta 4 |
increases expression |
ISO |
berberine increases expression of ITGB4 protein in colon epithelial cells |
RGD |
PMID:29564000 |
RGD:152995489 |
NCBI chr10:101,206,657...101,243,012
Ensembl chr10:101,206,665...101,243,012
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
affects localization multiple interactions |
EXP |
Berberine affects the localization of JUN protein arsenic trioxide promotes the reaction [Berberine affects the localization of JUN protein] |
CTD |
PMID:18294404 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity multiple interactions |
EXP |
Berberine results in decreased activity of KCNH2 protein Berberine promotes the reaction [Atorvastatin results in decreased activity of KCNH2 protein]; Berberine promotes the reaction [Simvastatin results in decreased activity of KCNH2 protein] |
CTD |
PMID:30086269 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Kdm1a |
lysine demethylase 1A |
increases expression |
ISO |
Berberine results in increased expression of KDM1A mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 5:148,782,976...148,838,319
Ensembl chr 5:148,782,976...148,838,319
|
|
G |
Kdm4a |
lysine demethylase 4A |
increases expression |
ISO |
Berberine results in increased expression of KDM4A mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 5:131,672,754...131,719,534
Ensembl chr 5:131,672,754...131,719,501
|
|
G |
Kdm5b |
lysine demethylase 5B |
increases expression |
ISO |
Berberine results in increased expression of KDM5B mRNA |
CTD |
PMID:27311644 |
|
NCBI chr13:46,001,589...46,073,868
Ensembl chr13:46,002,542...46,073,872
|
|
G |
Kdm6a |
lysine demethylase 6A |
increases expression |
ISO |
Berberine results in increased expression of KDM6A mRNA |
CTD |
PMID:27311644 |
|
NCBI chr X:4,337,466...4,477,100
Ensembl chr X:4,337,750...4,477,062
|
|
G |
Kdm6b |
lysine demethylase 6B |
increases expression |
ISO |
Berberine results in increased expression of KDM6B mRNA |
CTD |
PMID:27311644 |
|
NCBI chr10:54,120,716...54,142,212
Ensembl chr10:54,121,848...54,130,794
|
|
G |
Kmt5a |
lysine methyltransferase 5A |
increases expression |
ISO |
Berberine results in increased expression of KMT5A mRNA |
CTD |
PMID:27311644 |
|
NCBI chr12:32,139,353...32,167,777
Ensembl chr12:32,139,178...32,162,711
|
|
G |
Ldlr |
low density lipoprotein receptor |
multiple interactions increases expression |
ISO EXP |
Berberine inhibits the reaction [Clozapine results in increased expression of LDLR mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of LDLR mRNA] Berberine results in increased expression of LDLR mRNA Berberine promotes the reaction [Simvastatin results in increased expression of LDLR mRNA]; Simvastatin promotes the reaction [Berberine results in increased expression of LDLR mRNA] |
CTD |
PMID:18640378 PMID:20564506 |
|
NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580
|
|
G |
LOC103690190 |
histone H2A type 1-E |
decreases expression |
ISO |
Berberine results in decreased expression of H2AC6 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr17:42,707,863...42,708,420
|
|
G |
LOC684841 |
similar to CG31613-PA |
decreases expression |
ISO |
Berberine results in decreased expression of H3C10 mRNA |
CTD |
PMID:27311644 |
|
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
multiple interactions |
ISO |
[Berberine co-treated with Cisplatin] results in increased lipidation of MAP1LC3B protein; Berberine results in increased expression of and results in increased lipidation of MAP1LC3B protein; BNIP3L protein affects the reaction [[Berberine co-treated with Cisplatin] results in increased lipidation of MAP1LC3B protein]; FUNDC1 protein affects the reaction [[Berberine co-treated with Cisplatin] results in increased lipidation of MAP1LC3B protein] |
CTD |
PMID:36070022 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
|
|
G |
Map3k5 |
mitogen-activated protein kinase kinase kinase 5 |
multiple interactions |
ISO |
Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in decreased expression of and results in increased phosphorylation of MAP3K5 protein] |
CTD |
PMID:30240693 |
|
NCBI chr 1:14,685,776...14,904,935
Ensembl chr 1:14,685,492...14,904,800
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
decreases phosphorylation |
EXP |
Berberine results in decreased phosphorylation of MAPK1 protein |
CTD |
PMID:18294404 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
decreases phosphorylation multiple interactions |
EXP ISO |
Berberine results in decreased phosphorylation of MAPK3 protein Berberine inhibits the reaction [Dexamethasone results in decreased expression of MAPK3 mRNA] |
CTD |
PMID:18294404 PMID:20462044 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
ISO |
[Berberine co-treated with Cisplatin] results in increased phosphorylation of MAPK8 protein; Acetylcysteine inhibits the reaction [[Berberine co-treated with Cisplatin] results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:36070022 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mapt |
microtubule-associated protein tau |
multiple interactions |
EXP |
Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of MAPT mRNA] |
CTD |
PMID:29170048 |
|
NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129
|
|
G |
Mcm2 |
minichromosome maintenance complex component 2 |
multiple interactions |
ISO |
Berberine inhibits the reaction [Dexamethasone results in increased expression of MCM2 mRNA] |
CTD |
PMID:20462044 |
|
NCBI chr 4:121,346,434...121,360,962
Ensembl chr 4:121,346,434...121,360,847
|
|
G |
Mir19a |
microRNA 19a |
decreases expression |
ISO |
Berberine results in decreased expression of MIR19A mRNA |
CTD |
PMID:29687521 |
|
NCBI chr15:92,180,912...92,180,993
Ensembl chr15:92,180,912...92,180,993
|
|
G |
Mir21 |
microRNA 21 |
decreases expression |
ISO |
berberine decreases expression of MIR21 RNA in colon epithelial cell |
RGD |
PMID:29564000 |
RGD:152995489 |
NCBI chr10:71,405,257...71,405,348
Ensembl chr10:71,405,257...71,405,348
|
|
G |
Mir92a1 |
microRNA 92a-1 |
decreases expression |
ISO |
Berberine results in decreased expression of MIR92A1 mRNA |
CTD |
PMID:29687521 |
|
NCBI chr15:92,181,336...92,181,413
Ensembl chr15:92,181,336...92,181,413
|
|
G |
Mmp13 |
matrix metallopeptidase 13 |
increases expression |
ISO |
Berberine results in increased expression of MMP13 mRNA |
CTD |
PMID:26478571 |
|
NCBI chr 8:4,497,960...4,508,239
Ensembl chr 8:4,497,960...4,508,239
|
|
G |
Mmp14 |
matrix metallopeptidase 14 |
multiple interactions decreases expression |
EXP |
arsenic trioxide promotes the reaction [Berberine results in decreased expression of MMP14 protein] |
CTD |
PMID:18294404 |
|
NCBI chr15:27,887,795...27,897,020
Ensembl chr15:27,887,727...27,899,864
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions decreases activity decreases expression |
ISO EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [EGF protein inhibits the reaction [Berberine results in decreased activity of MMP2 protein]]; Arsenic Trioxide promotes the reaction [Berberine results in decreased activity of MMP2 protein]; Berberine promotes the reaction [Arsenic Trioxide results in decreased activity of MMP2 protein]; EGF protein inhibits the reaction [Berberine results in decreased activity of MMP2 protein] Berberine results in decreased expression of MMP2 protein arsenic trioxide promotes the reaction [Berberine results in decreased activity of MMP2 protein]; arsenic trioxide promotes the reaction [Berberine results in decreased expression of MMP2 protein]; Berberine promotes the reaction [arsenic trioxide results in decreased activity of MMP2 protein] |
CTD |
PMID:18294404 PMID:33325633 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
decreases activity multiple interactions |
ISO |
Berberine results in decreased activity of MMP9 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [EGF protein inhibits the reaction [Berberine results in decreased activity of MMP9 protein]]; EGF protein inhibits the reaction [Berberine results in decreased activity of MMP9 protein] |
CTD |
PMID:33325633 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
Berberine inhibits the reaction [Lipopolysaccharides results in increased expression of MPO protein] |
CTD |
PMID:21963898 |
|
NCBI chr10:72,594,458...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Mttp |
microsomal triglyceride transfer protein |
multiple interactions |
ISO |
Berberine inhibits the reaction [Ethanol results in decreased expression of MTTP protein] |
CTD |
PMID:25455889 |
|
NCBI chr 2:226,613,090...226,654,239
Ensembl chr 2:226,613,090...226,654,239
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions affects localization |
EXP |
arsenic trioxide promotes the reaction [Berberine affects the localization of MYC protein] |
CTD |
PMID:18294404 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Nampt |
nicotinamide phosphoribosyltransferase |
multiple interactions decreases expression |
ISO |
[Berberine co-treated with Niacinamide] results in decreased expression of NAMPT protein; SRT1720 inhibits the reaction [Berberine results in decreased expression of NAMPT protein] |
CTD |
PMID:26712469 |
|
NCBI chr 6:49,425,316...49,462,109
Ensembl chr 6:49,424,332...49,462,100
|
|
G |
Ncf1 |
neutrophil cytosolic factor 1 |
multiple interactions |
ISO |
Berberine promotes the reaction [CYBB protein binds to NCF1 protein binds to NCF2 protein binds to RAC2 protein]; Berberine promotes the reaction [CYBB protein binds to NCF1 protein] |
CTD |
PMID:36070022 |
|
NCBI chr12:22,485,382...22,494,647
Ensembl chr12:22,485,451...22,494,646
|
|
G |
Ncf2 |
neutrophil cytosolic factor 2 |
multiple interactions |
ISO |
Berberine promotes the reaction [CYBB protein binds to NCF1 protein binds to NCF2 protein binds to RAC2 protein]; Berberine promotes the reaction [CYBB protein binds to NCF2 protein] |
CTD |
PMID:36070022 |
|
NCBI chr13:64,955,502...64,986,289
Ensembl chr13:64,955,503...64,986,277
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
increases expression increases activity multiple interactions |
ISO EXP |
Berberine results in increased expression of NFE2L2 protein Berberine results in increased activity of NFE2L2 protein Berberine inhibits the reaction [Bortezomib results in increased expression of NFE2L2 mRNA]; Berberine promotes the reaction [Bleomycin results in increased expression of NFE2L2 protein] NFE2L2 mutant form inhibits the reaction [Berberine inhibits the reaction [Glucose results in increased abundance of Reactive Oxygen Species]]; NFE2L2 mutant form inhibits the reaction [Berberine results in increased expression of HMOX1 protein]; NFE2L2 mutant form inhibits the reaction [Berberine results in increased expression of NGF protein] |
CTD |
PMID:23523906 PMID:23954465 PMID:30818834 PMID:35121005 |
|
NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
EXP |
Berberine inhibits the reaction [Bortezomib results in increased expression of NFKB1 mRNA] |
CTD |
PMID:35121005 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
Berberine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:21963898 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Ngf |
nerve growth factor |
multiple interactions |
ISO |
Berberine inhibits the reaction [Glucose results in decreased expression of NGF protein]; NFE2L2 mutant form inhibits the reaction [Berberine results in increased expression of NGF protein] |
CTD |
PMID:23954465 |
|
NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
EXP |
Berberine inhibits the reaction [Bortezomib results in increased expression of NLRP3 mRNA] |
CTD |
PMID:35121005 |
|
NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO EXP |
Berberine inhibits the reaction [Carbon Tetrachloride results in increased expression of NOS2 protein] Berberine inhibits the reaction [Bleomycin results in increased expression of NOS2 protein] |
CTD |
PMID:21095217 PMID:23523906 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
IEP EXP |
Berberine reverses reaction [Carbon tetrachloride decreases Nqo1 mRNA in liver] Berberine inhibits the reaction [Bortezomib results in increased expression of NQO1 mRNA] |
CTD RGD |
PMID:35121005 PMID:31432116 |
RGD:25823187 |
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases activity multiple interactions |
ISO |
Berberine results in increased activity of NR1I2 protein [Berberine results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA |
CTD |
PMID:21524698 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
increases activity |
ISO |
Berberine results in increased activity of NR1I3 protein |
CTD |
PMID:30818834 |
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Nsd2 |
nuclear receptor binding SET domain protein 2 |
decreases expression |
ISO |
Berberine results in decreased expression of NSD2 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr14:76,833,194...76,911,304
Ensembl chr14:76,835,637...76,913,641
|
|
G |
Odc1 |
ornithine decarboxylase 1 |
multiple interactions decreases expression |
EXP |
arsenic trioxide promotes the reaction [Berberine results in decreased expression of ODC1 protein] |
CTD |
PMID:18294404 |
|
NCBI chr 6:40,329,831...40,336,444
Ensembl chr 6:40,329,964...40,336,440
|
|
G |
Omd |
osteomodulin |
increases expression |
ISO |
Berberine results in increased expression of OMD mRNA |
CTD |
PMID:26478571 |
|
NCBI chr17:15,060,217...15,068,441
Ensembl chr17:15,060,217...15,068,441
|
|
G |
P2rx7 |
purinergic receptor P2X 7 |
multiple interactions |
ISO |
Berberine affects the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased activity of P2RX7 protein] |
CTD |
PMID:21320518 |
|
NCBI chr12:33,889,709...33,934,168
Ensembl chr12:33,879,745...33,934,619
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage multiple interactions |
ISO |
Berberine results in increased cleavage of PARP1 protein [Berberine co-treated with Cisplatin] results in increased cleavage of PARP1 protein; [Berberine co-treated with Niacinamide] results in increased cleavage of PARP1 protein; Acetylcysteine inhibits the reaction [[Berberine co-treated with Cisplatin] results in increased cleavage of PARP1 protein] |
CTD |
PMID:16505103 PMID:26712469 PMID:36070022 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pdcd4 |
programmed cell death 4 |
increases expression |
ISO |
Berberine increases expression of PDCD4 protein in colon epithelial cells |
RGD |
PMID:29564000 |
RGD:152995489 |
NCBI chr 1:252,921,342...252,944,278
Ensembl chr 1:252,921,392...252,944,275
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
Berberine inhibits the reaction [Ethanol results in decreased expression of PPARA mRNA] |
CTD |
PMID:25455889 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions increases response to substance increases expression decreases expression |
ISO |
Berberine inhibits the reaction [Clozapine results in increased expression of PPARG mRNA]; Berberine inhibits the reaction [Clozapine results in increased expression of PPARG protein]; Berberine inhibits the reaction [Risperidone results in increased expression of PPARG mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of PPARG protein] 15-deoxyprostaglandin J2 promotes the reaction [Berberine affects the localization of and results in increased activity of PPARG protein]; Berberine inhibits the reaction [Bleomycin binds to PPARG protein]; Berberine promotes the reaction [15-deoxyprostaglandin J2 affects the localization of and results in increased activity of PPARG protein]; Berberine results in increased activity of and affects the localization of PPARG protein; PPARG mRNA promotes the reaction [Berberine results in increased expression of HGF protein] PPARG mRNA results in increased susceptibility to Berberine Berberine results in increased expression of PPARG mRNA Berberine results in decreased expression of PPARG mRNA |
CTD |
PMID:20564506 PMID:26478571 PMID:29408570 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions |
ISO |
Berberine inhibits the reaction [Ethanol results in decreased expression of PPARGC1A mRNA] |
CTD |
PMID:25455889 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Prg4 |
proteoglycan 4 |
decreases expression |
ISO |
Berberine results in decreased expression of PRG4 mRNA |
CTD |
PMID:26478571 |
|
NCBI chr13:62,487,257...62,504,657
Ensembl chr13:62,487,257...62,504,119
|
|
G |
Prkaa1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
increases phosphorylation |
ISO |
Berberine results in increased phosphorylation of PRKAA1 protein |
CTD |
PMID:28298333 |
|
NCBI chr 2:54,240,298...54,275,978
Ensembl chr 2:54,240,137...54,275,978
|
|
G |
Prkca |
protein kinase C, alpha |
multiple interactions |
EXP |
arsenic trioxide promotes the reaction [Berberine results in decreased activity of PRKCA protein]; Berberine results in decreased activity of and affects the localization of PRKCA protein |
CTD |
PMID:18294404 |
|
NCBI chr10:92,889,390...93,288,013
Ensembl chr10:92,894,012...93,288,012
|
|
G |
Prkce |
protein kinase C, epsilon |
multiple interactions decreases activity |
EXP |
arsenic trioxide promotes the reaction [Berberine results in decreased activity of PRKCE protein]; Berberine results in decreased activity of and affects the localization of PRKCE protein |
CTD |
PMID:18294404 |
|
NCBI chr 6:7,965,048...8,451,966
Ensembl chr 6:7,965,048...8,451,719
|
|
G |
Prmt1 |
protein arginine methyltransferase 1 |
decreases expression |
ISO |
Berberine results in decreased expression of PRMT1 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 1:95,458,853...95,468,176
Ensembl chr 1:95,458,850...95,468,345
|
|
G |
Prmt2 |
protein arginine methyltransferase 2 |
increases expression |
ISO |
Berberine results in increased expression of PRMT2 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr20:12,394,748...12,420,643
Ensembl chr20:12,394,798...12,420,643
|
|
G |
Prmt5 |
protein arginine methyltransferase 5 |
increases expression |
ISO |
Berberine results in increased expression of PRMT5 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr15:27,968,893...27,978,291
Ensembl chr15:27,968,910...27,978,296
|
|
G |
Prmt6 |
protein arginine methyltransferase 6 |
increases expression |
ISO |
Berberine results in increased expression of PRMT6 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 2:197,927,750...197,932,980
Ensembl chr 2:197,927,220...197,933,648
|
|
G |
Prmt7 |
protein arginine methyltransferase 7 |
increases expression |
ISO |
Berberine results in increased expression of PRMT7 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr19:34,110,724...34,161,531
Ensembl chr19:34,110,747...34,162,577
|
|
G |
Prmt8 |
protein arginine methyltransferase 8 |
increases expression |
ISO |
Berberine results in increased expression of PRMT8 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 4:160,535,813...160,618,193
Ensembl chr 4:160,535,813...160,617,930
|
|
G |
Pten |
phosphatase and tensin homolog |
multiple interactions increases expression |
ISO |
((3Z)-N-(3-chlorophenyl)-3-((3,5-dimethyl-4-((4-methylpiperazin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-N-methyl-2-oxo-2,3-dihydro-1H-indole-5-sulfonamide) inhibits the reaction [Berberine inhibits the reaction [Bleomycin results in decreased expression of PTEN mRNA]]; Berberine inhibits the reaction [Bleomycin results in decreased expression of PTEN mRNA]; Berberine inhibits the reaction [Bleomycin results in decreased expression of PTEN protein] Berberine results in increased expression of PTEN protein |
CTD |
PMID:29408570 |
|
NCBI chr 1:230,631,303...230,696,754
Ensembl chr 1:230,630,338...230,696,838
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
Berberine inhibits the reaction [Carbon Tetrachloride results in increased expression of PTGS2 protein] |
CTD |
PMID:21095217 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rac2 |
Rac family small GTPase 2 |
multiple interactions |
ISO |
Berberine promotes the reaction [CYBB protein binds to NCF1 protein binds to NCF2 protein binds to RAC2 protein]; Berberine promotes the reaction [CYBB protein binds to RAC2 protein]; Berberine results in increased expression of and results in increased activity of RAC2 protein |
CTD |
PMID:36070022 |
|
NCBI chr 7:110,101,344...110,128,718
Ensembl chr 7:110,116,260...110,128,720
|
|
G |
Rbp4 |
retinol binding protein 4 |
multiple interactions |
EXP |
Berberine inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased secretion of RBP4 protein] |
CTD |
PMID:19080170 |
|
NCBI chr 1:235,893,917...235,901,315
Ensembl chr 1:235,893,917...235,901,399
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
Berberine inhibits the reaction [Bleomycin affects the localization of and results in increased expression of RELA protein] |
CTD |
PMID:23523906 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
RGD1562378 |
histone H4 variant H4-v.1 |
decreases expression |
ISO |
Berberine results in decreased expression of H4C14 mRNA |
CTD |
PMID:27311644 |
|
|
|
G |
Rln1 |
relaxin 1 |
affects binding increases expression multiple interactions |
EXP |
Berberine binds to RLN1 promoter Berberine results in increased expression of RLN1 mRNA [Berberine binds to RLN1 promoter] which results in increased expression of RLN1 mRNA |
CTD |
PMID:22363579 |
|
NCBI chr 1:227,079,960...227,082,960
Ensembl chr 1:227,079,966...227,082,882
|
|
G |
Rps6 |
ribosomal protein S6 |
decreases phosphorylation |
ISO |
Berberine results in decreased phosphorylation of RPS6 protein |
CTD |
PMID:23363784 |
|
NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602 Ensembl chr 5:101,371,136...101,374,602
|
|
G |
Runx2 |
RUNX family transcription factor 2 |
multiple interactions increases expression |
ISO |
CTNNB1 mutant form inhibits the reaction [Berberine results in increased expression of RUNX2 mRNA]; DKK1 protein inhibits the reaction [Berberine results in increased expression of RUNX2 mRNA] |
CTD |
PMID:26478571 |
|
NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167
|
|
G |
Setd1b |
SET domain containing 1B, histone lysine methyltransferase |
increases expression |
ISO |
Berberine results in increased expression of SETD1B mRNA |
CTD |
PMID:27311644 |
|
NCBI chr12:33,395,963...33,421,671
Ensembl chr12:33,396,120...33,426,934
|
|
G |
Setd2 |
SET domain containing 2, histone lysine methyltransferase |
increases expression |
ISO |
Berberine results in increased expression of SETD2 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 8:110,511,808...110,597,489
Ensembl chr 8:110,511,772...110,597,489
|
|
G |
Setd3 |
SET domain containing 3, actin histidine methyltransferase |
increases expression |
ISO |
Berberine results in increased expression of SETD3 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 6:127,023,058...127,090,020
Ensembl chr 6:127,023,058...127,090,008
|
|
G |
Setd5 |
SET domain containing 5 |
increases expression |
ISO |
Berberine results in increased expression of SETD5 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 4:146,217,172...146,294,896
Ensembl chr 4:146,217,180...146,294,894
|
|
G |
Setd6 |
SET domain containing 6, protein lysine methyltransferase |
increases expression |
ISO |
Berberine results in increased expression of SETD6 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr19:9,343,309...9,350,477
Ensembl chr19:9,347,458...9,350,453
|
|
G |
Setd7 |
SET domain containing 7, histone lysine methyltransferase |
increases expression |
ISO |
Berberine results in increased expression of SETD7 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 2:135,562,683...135,605,468
Ensembl chr 2:135,562,683...135,605,468
|
|
G |
Setdb1 |
SET domain bifurcated histone lysine methyltransferase 1 |
increases expression |
ISO |
Berberine results in increased expression of SETDB1 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr 2:182,898,738...182,930,283
Ensembl chr 2:182,898,738...182,930,506
|
|
G |
Setdb2 |
SET domain bifurcated histone lysine methyltransferase 2 |
increases expression |
ISO |
Berberine results in increased expression of SETDB2 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr15:33,553,657...33,606,586
Ensembl chr15:33,453,952...33,606,470
|
|
G |
Si |
sucrase-isomaltase |
decreases expression multiple interactions |
ISO EXP |
Berberine results in decreased expression of SI mRNA N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Berberine results in decreased expression of SI mRNA] |
CTD |
PMID:20229011 |
|
NCBI chr 2:157,505,893...157,586,228
Ensembl chr 2:157,506,342...157,585,260
|
|
G |
Sirt1 |
sirtuin 1 |
decreases expression multiple interactions |
ISO EXP |
Berberine results in decreased expression of SIRT1 mRNA; Berberine results in decreased expression of SIRT1 protein Berberine inhibits the reaction [Bortezomib results in decreased expression of SIRT1 protein] [Berberine co-treated with Niacinamide] results in decreased expression of SIRT1 protein; SRT1720 inhibits the reaction [Berberine results in decreased expression of SIRT1 protein] |
CTD |
PMID:26712469 PMID:35121005 |
|
NCBI chr20:25,307,143...25,329,260
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Sirt2 |
sirtuin 2 |
multiple interactions |
ISO |
[Berberine co-treated with Niacinamide] results in decreased expression of SIRT2 protein |
CTD |
PMID:26712469 |
|
NCBI chr 1:84,053,883...84,076,975
Ensembl chr 1:84,052,903...84,076,975
|
|
G |
Sirt3 |
sirtuin 3 |
multiple interactions increases expression decreases expression |
ISO |
[Berberine co-treated with Niacinamide] results in decreased expression of SIRT3 protein Berberine results in increased expression of SIRT3 mRNA Berberine results in decreased expression of SIRT3 mRNA; Berberine results in decreased expression of SIRT3 protein |
CTD |
PMID:26712469 PMID:27311644 |
|
NCBI chr 1:195,942,066...195,964,472
Ensembl chr 1:195,942,073...195,964,808
|
|
G |
Slc27a5 |
solute carrier family 27 member 5 |
decreases expression |
ISO |
Berberine results in decreased expression of SLC27A5 mRNA |
CTD |
PMID:28038998 |
|
NCBI chr 1:73,616,556...73,627,149
Ensembl chr 1:73,616,564...73,627,172
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
multiple interactions |
EXP |
Berberine inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in decreased expression of SLC2A4 protein] |
CTD |
PMID:19080170 |
|
NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565
|
|
G |
Slc6a19 |
solute carrier family 6 member 19 |
multiple interactions |
EXP |
Berberine affects the reaction [Lipopolysaccharides affects the expression of SLC6A19 mRNA]; Berberine affects the reaction [Lipopolysaccharides affects the expression of SLC6A19 protein] |
CTD |
PMID:21073932 |
|
NCBI chr 1:29,586,205...29,604,960
Ensembl chr 1:29,586,195...29,604,962
|
|
G |
Smyd3 |
SET and MYND domain containing 3 |
affects expression |
ISO |
Berberine affects the expression of SMYD3 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr13:90,709,263...91,266,209
Ensembl chr13:90,709,270...91,266,253
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
ISO |
Berberine inhibits the reaction [Carbon Tetrachloride results in decreased activity of SOD1 protein]; Berberine inhibits the reaction [Streptozocin affects the expression of SOD1 mRNA] |
CTD |
PMID:21095217 PMID:22775417 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
ISO EXP |
Berberine inhibits the reaction [Streptozocin affects the expression of SOD2 mRNA] Berberine inhibits the reaction [Mercuric Chloride results in decreased expression of SOD2 mRNA] |
CTD |
PMID:22775417 PMID:24751971 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sox9 |
SRY-box transcription factor 9 |
decreases expression |
ISO |
Berberine results in decreased expression of SOX9 mRNA |
CTD |
PMID:26478571 |
|
NCBI chr10:97,806,485...97,811,994
Ensembl chr10:97,806,485...97,811,994
|
|
G |
Sp7 |
Sp7 transcription factor |
increases expression |
ISO |
Berberine results in increased expression of SP7 mRNA |
CTD |
PMID:26478571 |
|
NCBI chr 7:133,484,609...133,494,788
Ensembl chr 7:133,484,609...133,494,847
|
|
G |
Sparc |
secreted protein acidic and cysteine rich |
increases expression |
ISO |
Berberine results in increased expression of SPARC mRNA |
CTD |
PMID:26478571 |
|
NCBI chr10:39,516,394...39,538,252
Ensembl chr10:39,516,406...39,538,396
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
increases expression multiple interactions |
ISO |
Berberine results in increased expression of SPP1 mRNA; Berberine results in increased expression of SPP1 protein CTNNB1 mutant form inhibits the reaction [Berberine results in increased expression of SPP1 protein]; DKK1 protein inhibits the reaction [Berberine results in increased expression of SPP1 protein] |
CTD |
PMID:26478571 |
|
NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
|
|
G |
Sqstm1 |
sequestosome 1 |
increases expression |
ISO |
Berberine results in increased expression of SQSTM1 protein |
CTD |
PMID:36070022 |
|
NCBI chr10:34,525,517...34,536,685
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions decreases expression |
ISO |
Berberine inhibits the reaction [Clozapine results in increased expression of SREBF1 mRNA]; Berberine inhibits the reaction [Clozapine results in increased expression of SREBF1 protein]; Berberine inhibits the reaction [Risperidone results in increased expression of SREBF1 mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of SREBF1 protein] Berberine results in decreased expression of SREBF1 mRNA |
CTD |
PMID:20564506 PMID:26478571 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
EXP |
Berberine inhibits the reaction [Bortezomib results in increased expression of STAT3 mRNA] |
CTD |
PMID:35121005 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Tert |
telomerase reverse transcriptase |
decreases activity |
ISO |
Berberine results in decreased activity of TERT protein |
CTD |
PMID:25265580 |
|
NCBI chr 1:29,637,213...29,659,509
Ensembl chr 1:29,637,506...29,659,561
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
decreases expression multiple interactions |
EXP |
Berberine results in decreased expression of TGFB1 protein Berberine inhibits the reaction [Bleomycin results in increased expression of TGFB1 protein]; Berberine inhibits the reaction [Thioacetamide results in increased expression of TGFB1 mRNA] |
CTD |
PMID:17973934 PMID:23523906 PMID:30138605 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
ISO EXP |
Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of TLR4 mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of TLR4 protein]; Berberine inhibits the reaction [Lipopolysaccharides results in increased expression of TLR4 mRNA] Berberine inhibits the reaction [Bortezomib results in increased expression of TLR4 protein] |
CTD |
PMID:21963898 PMID:30240693 PMID:35121005 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases secretion increases expression |
ISO EXP |
Berberine inhibits the reaction [TNF protein results in increased expression of CCL2 mRNA]; Berberine inhibits the reaction [TNF protein results in increased expression of CXCL8 mRNA]; Berberine inhibits the reaction [TNF protein results in increased secretion of CCL2 protein]; Berberine inhibits the reaction [TNF protein results in increased secretion of CXCL8 protein] Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of TNF mRNA]; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of TNF protein]; Berberine inhibits the reaction [Bleomycin results in increased expression of TNF protein]; Berberine inhibits the reaction [Bortezomib results in increased expression of TNF mRNA]; Berberine inhibits the reaction [Mercuric Chloride results in increased expression of TNF protein] Berberine results in increased secretion of TNF protein Berberine results in increased expression of TNF mRNA Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in decreased expression of and results in increased phosphorylation of MAP3K5 protein]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of IL23A mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of IL6 mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of TLR4 mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of TRAF2 mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of IL23A protein]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of IL6 protein]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of TLR4 protein]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of TRAF2 protein]; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF mRNA]; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]; Berberine inhibits the reaction [Benzo(a)pyrene results in increased expression of TNF mRNA]; Berberine inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF protein]; Berberine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA] |
CTD |
PMID:16391493 PMID:20656010 PMID:21095217 PMID:21867779 PMID:23523906 PMID:25600690 PMID:28533128 PMID:29170048 PMID:30240693 PMID:35121005 PMID:35691465 More...
|
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Top1 |
DNA topoisomerase I |
decreases activity |
ISO |
Berberine results in decreased activity of TOP1 protein |
CTD |
PMID:23747414 |
|
NCBI chr 3:149,293,658...149,375,405
Ensembl chr 3:149,293,403...149,376,623
|
|
G |
Top2a |
DNA topoisomerase II alpha |
multiple interactions affects response to substance |
ISO |
TOP2A protein affects the reaction [Berberine results in increased expression of H2AX protein modified form] TOP2A protein affects the susceptibility to Berberine |
CTD |
PMID:23747414 |
|
NCBI chr10:83,946,186...83,975,694
Ensembl chr10:83,945,735...83,976,874
|
|
G |
Tp53 |
tumor protein p53 |
increases expression multiple interactions |
ISO |
Berberine results in increased expression of TP53 mRNA; Berberine results in increased expression of TP53 protein [Berberine co-treated with Niacinamide] results in increased expression of and results in increased acetylation of TP53 protein; Berberine results in increased phosphorylation of and results in increased acetylation of TP53 protein |
CTD |
PMID:20656010 PMID:26712469 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Traf1 |
TNF receptor-associated factor 1 |
increases expression |
ISO |
Berberine results in increased expression of TRAF1 protein |
CTD |
PMID:20656010 |
|
NCBI chr 3:18,222,024...18,242,163
Ensembl chr 3:18,222,054...18,241,807
|
|
G |
Traf2 |
Tnf receptor-associated factor 2 |
multiple interactions |
ISO |
Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of TRAF2 mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of TRAF2 protein] |
CTD |
PMID:30240693 |
|
NCBI chr 3:8,341,950...8,366,609
Ensembl chr 3:8,341,951...8,366,538
|
|
G |
Tstd1 |
thiosulfate sulfurtransferase like domain containing 1 |
increases expression |
ISO |
Berberine results in increased expression of TSTD1 mRNA |
CTD |
PMID:27311644 |
|
NCBI chr13:83,853,421...83,854,875
Ensembl chr13:83,822,035...83,854,885
|
|
G |
Ube2a |
ubiquitin-conjugating enzyme E2A |
decreases expression |
ISO |
Berberine results in decreased expression of UBE2A mRNA |
CTD |
PMID:27311644 |
|
NCBI chr X:116,114,339...116,125,076
Ensembl chr X:116,113,875...116,125,070
|
|
G |
Ube2b |
ubiquitin-conjugating enzyme E2B |
decreases expression |
ISO |
Berberine results in decreased expression of UBE2B mRNA |
CTD |
PMID:27311644 |
|
NCBI chr10:36,248,434...36,263,379
Ensembl chr10:36,248,438...36,264,665
|
|
G |
Ucp2 |
uncoupling protein 2 |
multiple interactions |
ISO |
Berberine inhibits the reaction [Benzo(a)pyrene results in increased expression of UCP2 mRNA] |
CTD |
PMID:28533128 |
|
NCBI chr 1:154,839,242...154,845,612
Ensembl chr 1:154,839,209...154,845,611
|
|
G |
Vegfa |
vascular endothelial growth factor A |
decreases expression |
ISO |
Berberine results in decreased expression of VEGFA protein |
CTD |
PMID:33325633 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Vegfc |
vascular endothelial growth factor C |
increases expression |
ISO |
Berberine results in increased expression of VEGFC mRNA |
CTD |
PMID:26478571 |
|
NCBI chr16:37,712,408...37,827,657
Ensembl chr16:37,712,262...37,827,848
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases phosphorylation multiple interactions |
ISO |
butein results in decreased phosphorylation of AKT1 protein Acetylcysteine inhibits the reaction [butein results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:20696233 PMID:35130734 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
ISO |
butein results in increased expression of BAX protein |
CTD |
PMID:11055382 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression |
ISO |
butein results in decreased expression of BCL2 protein |
CTD |
PMID:11055382 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
decreases expression |
ISO |
butein results in decreased expression of BCL2L1 protein |
CTD |
PMID:11055382 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Casp3 |
caspase 3 |
increases activity multiple interactions |
ISO |
butein results in increased activity of CASP3 protein Acetylcysteine inhibits the reaction [butein results in increased activity of CASP3 protein] |
CTD |
PMID:24931875 PMID:35130734 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
increases activity |
ISO |
butein results in increased activity of CASP8 protein |
CTD |
PMID:35130734 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
increases activity |
ISO |
butein results in increased activity of CASP9 protein |
CTD |
PMID:35130734 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cdh1 |
cadherin 1 |
multiple interactions |
ISO |
butein affects the reaction [IL6 protein affects the expression of CDH1 protein] |
CTD |
PMID:35130734 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Dio2 |
iodothyronine deiodinase 2 |
decreases activity |
ISO |
butein results in decreased activity of DIO2 protein |
CTD |
PMID:17327447 |
|
NCBI chr 6:109,665,523...109,679,809
Ensembl chr 6:109,665,523...109,679,809
|
|
G |
Gpx4 |
glutathione peroxidase 4 |
decreases expression |
ISO |
butein results in decreased expression of GPX4 protein |
CTD |
PMID:35130734 |
|
NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
ISO |
[butein results in increased expression of HMOX1 protein] inhibits the reaction [Hydrogen Peroxide results in increased abundance of Reactive Oxygen Species]; [butein results in increased expression of HMOX1 protein] which results in decreased susceptibility to Hydrogen Peroxide; [tin protoporphyrin IX results in decreased expression of and results in decreased activity of HMOX1 protein] inhibits the reaction [butein inhibits the reaction [Hydrogen Peroxide results in increased abundance of Reactive Oxygen Species]]; butein results in increased expression of and results in increased activity of HMOX1 protein; pyrazolanthrone inhibits the reaction [butein results in increased expression of HMOX1 protein] |
CTD |
PMID:23318726 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
butein affects the reaction [IL6 protein affects the expression of CDH1 protein]; butein affects the reaction [IL6 protein affects the expression of MMP2 protein]; butein affects the reaction [IL6 protein affects the expression of MMP9 protein]; butein affects the reaction [IL6 protein affects the phosphorylation of STAT3 protein] |
CTD |
PMID:35130734 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
multiple interactions increases lipidation |
ISO |
Acetylcysteine inhibits the reaction [butein results in increased lipidation of MAP1LC3B protein]; MK 2206 promotes the reaction [butein results in increased lipidation of MAP1LC3B protein]; pyrazolanthrone inhibits the reaction [butein results in increased lipidation of MAP1LC3B protein] |
CTD |
PMID:35130734 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
increases phosphorylation multiple interactions |
ISO |
butein results in increased phosphorylation of MAPK8 protein Acetylcysteine inhibits the reaction [butein results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:35130734 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
ISO |
butein affects the reaction [IL6 protein affects the expression of MMP2 protein] |
CTD |
PMID:35130734 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions decreases expression |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [butein results in decreased expression of MMP9 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [butein results in decreased expression of MMP9 protein]; Bortezomib promotes the reaction [butein results in decreased expression of MMP9 protein]; butein affects the reaction [IL6 protein affects the expression of MMP9 protein]; butein inhibits the reaction [TNF protein results in increased expression of MMP9 protein]; prolinedithiocarbamate promotes the reaction [butein results in decreased expression of MMP9 protein] butein results in decreased expression of MMP9 mRNA; butein results in decreased expression of MMP9 protein |
CTD |
PMID:20696233 PMID:35130734 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
decreases phosphorylation multiple interactions |
ISO |
butein results in decreased phosphorylation of MTOR protein Acetylcysteine inhibits the reaction [butein results in decreased phosphorylation of MTOR protein] |
CTD |
PMID:35130734 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
affects localization |
ISO |
butein affects the localization of NFE2L2 protein |
CTD |
PMID:23318726 |
|
NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
affects localization |
ISO |
butein affects the localization of NFKB1 protein |
CTD |
PMID:20696233 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases activity |
ISO |
butein results in increased activity of NR1I2 protein |
CTD |
PMID:29933105 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage |
ISO |
butein results in increased cleavage of PARP1 protein |
CTD |
PMID:24931875 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pttg1 |
PTTG1 regulator of sister chromatid separation, securin |
decreases expression decreases response to substance |
ISO |
butein results in decreased expression of PTTG1 protein PTTG1 protein results in decreased susceptibility to butein |
CTD |
PMID:24931875 |
|
NCBI chr10:27,893,466...27,904,965
Ensembl chr10:27,893,689...27,904,837
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
affects localization |
ISO |
butein affects the localization of RELA protein |
CTD |
PMID:20696233 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Sirt1 |
sirtuin 1 |
increases activity |
ISO |
butein results in increased activity of SIRT1 protein |
CTD |
PMID:17327447 |
|
NCBI chr20:25,307,143...25,329,260
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
ISO |
butein affects the reaction [IL6 protein affects the phosphorylation of STAT3 protein] |
CTD |
PMID:35130734 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
butein inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of TNF protein]; butein inhibits the reaction [TNF protein results in increased expression of MMP9 protein] |
CTD |
PMID:20696233 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Vegfa |
vascular endothelial growth factor A |
decreases expression |
ISO |
butein results in decreased expression of VEGFA mRNA |
CTD |
PMID:20696233 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
|
G |
A4galt |
alpha 1,4-galactosyltransferase (P blood group) |
multiple interactions |
ISO |
Curcumin inhibits the reaction [IL1B protein results in increased expression of A4GALT mRNA]; Curcumin inhibits the reaction [TNF protein results in increased expression of A4GALT mRNA] |
CTD |
PMID:16819191 |
|
NCBI chr 7:114,368,525...114,392,872
Ensembl chr 7:114,368,276...114,396,071
|
|
G |
Aars1 |
alanyl-tRNA synthetase 1 |
decreases expression |
ISO |
Curcumin results in decreased expression of AARS1 mRNA |
CTD |
PMID:17198877 |
|
NCBI chr19:38,999,130...39,021,152
Ensembl chr19:38,999,163...39,021,147
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
multiple interactions |
ISO |
Curcumin inhibits the reaction [malondialdehyde-low density lipoprotein, human results in decreased expression of ABCA1 mRNA]; Curcumin inhibits the reaction [malondialdehyde-low density lipoprotein, human results in decreased expression of ABCA1 protein]; MIR125A mRNA inhibits the reaction [Curcumin inhibits the reaction [malondialdehyde-low density lipoprotein, human results in decreased expression of ABCA1 mRNA]]; MIR125A mRNA inhibits the reaction [Curcumin inhibits the reaction [malondialdehyde-low density lipoprotein, human results in decreased expression of ABCA1 protein]]; SIRT6 protein promotes the reaction [Curcumin inhibits the reaction [malondialdehyde-low density lipoprotein, human results in decreased expression of ABCA1 mRNA]]; SIRT6 protein promotes the reaction [Curcumin inhibits the reaction [malondialdehyde-low density lipoprotein, human results in decreased expression of ABCA1 protein]] |
CTD |
PMID:33952798 |
|
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
affects response to substance decreases response to substance decreases expression multiple interactions |
ISO |
ABCB1 affects the susceptibility to Curcumin ABCB1 protein results in decreased susceptibility to Curcumin Curcumin analog results in decreased expression of ABCB1 protein; Curcumin results in decreased expression of ABCB1 mRNA; Curcumin results in decreased expression of ABCB1B mRNA [Curcumin co-treated with Calcitriol] inhibits the reaction [Paclitaxel results in increased expression of ABCB1 protein]; Calcitriol promotes the reaction [Curcumin inhibits the reaction [Paclitaxel results in increased expression of ABCB1 protein]]; Curcumin inhibits the reaction [Paclitaxel results in increased expression of ABCB1 protein]; Curcumin inhibits the reaction [Trinitrobenzenesulfonic Acid results in decreased expression of ABCB1 mRNA] [Calcitriol co-treated with Curcumin] inhibits the reaction [Paclitaxel results in increased expression of ABCB1 protein]; [Curcumin co-treated with Calcitriol] inhibits the reaction [Paclitaxel results in increased expression of ABCB1 mRNA]; [Curcumin co-treated with Paclitaxel] results in increased expression of ABCB1 protein; [sulfinosine co-treated with Curcumin] results in decreased expression of ABCB1 mRNA; Calcitriol inhibits the reaction [[Curcumin co-treated with Paclitaxel] results in increased expression of ABCB1 protein]; Curcumin analog inhibits the reaction [ABCB1 protein results in decreased susceptibility to Paclitaxel]; Curcumin analog inhibits the reaction [ABCB1 protein results in decreased susceptibility to Vinblastine]; Curcumin inhibits the reaction [[Calcitriol co-treated with Paclitaxel] results in increased expression of ABCB1 mRNA]; Curcumin inhibits the reaction [[Calcitriol co-treated with Paclitaxel] results in increased expression of ABCB1 protein]; Curcumin inhibits the reaction [ABCB1 protein results in decreased susceptibility to Paclitaxel]; Curcumin inhibits the reaction [ABCB1 protein results in decreased susceptibility to Vinblastine]; Curcumin inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; Curcumin inhibits the reaction [Paclitaxel results in increased expression of ABCB1 mRNA]; Curcumin inhibits the reaction [Paclitaxel results in increased expression of ABCB1 protein]; Curcumin results in decreased expression of and results in decreased activity of ABCB1 protein |
CTD |
PMID:15476675 PMID:17121181 PMID:18200517 PMID:18385293 PMID:18414057 PMID:18439772 PMID:20816778 PMID:26689174 PMID:27318188 PMID:31628941 More...
|
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcb1b |
ATP-binding cassette, subfamily B (MDR/TAP), member 1B |
multiple interactions decreases expression |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Curcumin results in decreased expression of ABCB1B protein]; [Curcumin results in decreased expression of ABCB1B protein] which results in increased susceptibility to Doxorubicin; Curcumin inhibits the reaction [[NFKB1 protein binds to RELA protein] which results in increased expression of ABCB1B mRNA] Curcumin results in decreased expression of ABCB1B mRNA; Curcumin results in decreased expression of ABCB1B protein |
CTD |
PMID:18006147 |
|
NCBI chr 4:25,242,761...25,325,194
Ensembl chr 4:25,242,798...25,325,199
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
decreases activity decreases expression |
ISO |
Curcumin results in decreased activity of ABCC1 protein Curcumin analog results in decreased expression of ABCC1 mRNA |
CTD |
PMID:15885658 PMID:16021489 PMID:26409325 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
decreases activity multiple interactions |
ISO |
Curcumin results in decreased activity of ABCC2 protein [Curcumin co-treated with Acetaminophen] results in increased expression of ABCC2 mRNA; [Curcumin co-treated with Acetaminophen] results in increased expression of ABCC2 protein |
CTD |
PMID:15885658 PMID:35243748 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
multiple interactions |
ISO |
[Curcumin co-treated with Acetaminophen] results in increased expression of ABCC4 mRNA; [Curcumin co-treated with Acetaminophen] results in increased expression of ABCC4 protein |
CTD |
PMID:35243748 |
|
NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283
|
|
G |
Abcc5 |
ATP binding cassette subfamily C member 5 |
multiple interactions |
ISO |
[Curcumin analog binds to and results in decreased activity of ABCC5 protein] which results in decreased export of Hyaluronic Acid; [Curcumin binds to and results in decreased activity of ABCC5 protein] which results in decreased export of Hyaluronic Acid; Curcumin analog binds to and results in decreased activity of ABCC5 protein; Curcumin analog inhibits the reaction [ABCC5 protein results in increased export of Hyaluronic Acid]; Curcumin binds to and results in decreased activity of ABCC5 protein; Curcumin inhibits the reaction [ABCC5 protein results in increased export of Hyaluronic Acid] |
CTD |
PMID:23978416 |
|
NCBI chr11:80,473,809...80,567,257
Ensembl chr11:80,473,872...80,567,253
|
|
G |
Abcg1 |
ATP binding cassette subfamily G member 1 |
increases expression |
ISO |
Curcumin results in increased expression of ABCG1 mRNA |
CTD |
PMID:16713233 PMID:21594647 |
|
NCBI chr20:9,126,687...9,182,948
Ensembl chr20:9,126,687...9,182,948
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions decreases expression increases expression |
ISO |
AHR protein promotes the reaction [Curcumin results in increased expression of ABCG2 protein] Curcumin results in decreased expression of ABCG2 mRNA |
CTD |
PMID:17077187 PMID:33539684 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
increases phosphorylation decreases expression affects expression multiple interactions |
ISO EXP |
Curcumin results in increased phosphorylation of ACACA protein Curcumin results in decreased expression of ACACA mRNA Curcumin affects the expression of ACACA mRNA Curcumin inhibits the reaction [Dietary Fats results in decreased phosphorylation of ACACA protein] |
CTD |
PMID:18790744 PMID:19297423 PMID:27208389 |
|
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Ace |
angiotensin I converting enzyme |
multiple interactions |
EXP |
Curcumin inhibits the reaction [Paraquat affects the expression of ACE protein] |
CTD |
PMID:10666014 |
|
NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131
|
|
G |
Ace2 |
angiotensin I converting enzyme 2 |
multiple interactions |
EXP |
Curcumin inhibits the reaction [AGT protein results in increased expression of ACE2 protein] |
CTD |
PMID:26648693 |
|
NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions decreases activity |
ISO EXP |
[Curcumin co-treated with Niacin co-treated with ZM 241385] inhibits the reaction [Rotenone results in increased expression of ACHE protein]; Curcumin inhibits the reaction [Rotenone results in decreased activity of ACHE protein]; Curcumin inhibits the reaction [Rotenone results in increased expression of ACHE protein]; Curcumin inhibits the reaction [Streptozocin results in increased activity of ACHE protein] Curcumin results in decreased activity of ACHE protein Curcumin inhibits the reaction [Acrylamide results in increased activity of ACHE protein]; Curcumin inhibits the reaction [cadmium sulfate results in increased expression of ACHE mRNA]; Curcumin inhibits the reaction [cadmium sulfate results in increased expression of ACHE protein]; Curcumin inhibits the reaction [sodium arsenite results in decreased activity of ACHE protein]; pralidoxime promotes the reaction [[Atropine co-treated with Curcumin] inhibits the reaction [Dichlorvos results in decreased activity of ACHE protein]] |
CTD |
PMID:18809455 PMID:20369229 PMID:21839772 PMID:22783142 PMID:25199698 PMID:28527659 PMID:31714633 PMID:31820278 More...
|
|
NCBI chr12:19,407,359...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Ackr3 |
atypical chemokine receptor 3 |
increases expression |
ISO |
Curcumin results in increased expression of ACKR3 mRNA |
CTD |
PMID:21594647 |
|
NCBI chr 9:90,799,682...90,811,246
Ensembl chr 9:90,799,686...90,811,237
|
|
G |
Acly |
ATP citrate lyase |
affects expression decreases expression |
ISO EXP |
Curcumin affects the expression of ACLY mRNA Curcumin results in decreased expression of ACLY mRNA |
CTD |
PMID:27208389 |
|
NCBI chr10:85,412,045...85,464,253
Ensembl chr10:85,412,049...85,463,320
|
|
G |
Aco2 |
aconitase 2 |
multiple interactions |
EXP |
Curcumin inhibits the reaction [Potassium Dichromate results in decreased activity of ACO2 protein] |
CTD |
PMID:25130536 |
|
NCBI chr 7:113,385,677...113,428,794
Ensembl chr 7:113,385,646...113,428,261
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
decreases expression multiple interactions |
EXP ISO |
Curcumin results in decreased expression of ACTA2 mRNA; Curcumin results in decreased expression of ACTA2 protein Curcumin inhibits the reaction [Bleomycin results in increased expression of ACTA2 mRNA]; Curcumin inhibits the reaction [Thioacetamide results in increased expression of ACTA2 protein] [Arsenic Trioxide co-treated with Curcumin] inhibits the reaction [Cisplatin results in increased expression of ACTA2 mRNA]; Arsenic Trioxide promotes the reaction [Curcumin inhibits the reaction [Cisplatin results in increased expression of ACTA2 protein]]; Curcumin inhibits the reaction [Carbon Tetrachloride results in increased expression of ACTA2 mRNA]; Curcumin inhibits the reaction [Carbon Tetrachloride results in increased expression of ACTA2 protein]; Curcumin inhibits the reaction [Cisplatin results in increased expression of ACTA2 mRNA]; Curcumin inhibits the reaction [Cisplatin results in increased expression of ACTA2 protein]; Curcumin inhibits the reaction [Thioacetamide results in increased expression of ACTA2 protein]; Curcumin promotes the reaction [Arsenic Trioxide inhibits the reaction [Cisplatin results in increased expression of ACTA2 protein]] |
CTD |
PMID:17355460 PMID:17531121 PMID:18006644 PMID:22683883 PMID:27363783 PMID:31612257 PMID:35716765 More...
|
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Adam17 |
ADAM metallopeptidase domain 17 |
multiple interactions |
ISO |
Curcumin inhibits the reaction [TNF protein results in increased expression of ADAM17 mRNA] |
CTD |
PMID:17666914 |
|
NCBI chr 6:40,872,936...40,920,700
Ensembl chr 6:40,872,856...40,920,639
|
|
G |
Adamts4 |
ADAM metallopeptidase with thrombospondin type 1 motif, 4 |
increases expression |
ISO |
Curcumin results in increased expression of ADAMTS4 mRNA |
CTD |
PMID:18321735 |
|
NCBI chr13:83,670,556...83,680,045
Ensembl chr13:83,670,183...83,680,065
|
|
G |
Adcy9 |
adenylate cyclase 9 |
decreases expression |
ISO |
Curcumin results in decreased expression of ADCY9 mRNA |
CTD |
PMID:15713895 |
|
NCBI chr10:11,138,966...11,262,067
Ensembl chr10:11,139,446...11,262,066
|
|
G |
Adgre1 |
adhesion G protein-coupled receptor E1 |
decreases expression |
ISO |
Curcumin results in decreased expression of ADGRE1 mRNA |
CTD |
PMID:18403477 |
|
NCBI chr 9:2,242,476...2,398,000
Ensembl chr 9:2,242,474...2,398,000
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
increases expression multiple interactions affects expression |
ISO EXP |
Curcumin results in increased expression of ADIPOQ mRNA; Curcumin results in increased expression of ADIPOQ protein Curcumin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of ADIPOQ mRNA]; Curcumin inhibits the reaction [butylbenzyl phthalate promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of ADIPOQ mRNA]] Curcumin affects the expression of ADIPOQ mRNA Curcumin inhibits the reaction [Fructose results in decreased expression of ADIPOQ protein] |
CTD |
PMID:18403477 PMID:26713546 PMID:27208389 PMID:28595985 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Adora2a |
adenosine A2a receptor |
multiple interactions |
ISO |
[Curcumin co-treated with Niacin co-treated with ZM 241385] inhibits the reaction [Rotenone results in increased expression of ADORA2A mRNA]; Curcumin inhibits the reaction [Rotenone results in increased expression of ADORA2A mRNA] |
CTD |
PMID:31820278 |
|
NCBI chr20:13,315,848...13,333,386
Ensembl chr20:13,315,853...13,333,386
|
|
G |
Ager |
advanced glycosylation end product-specific receptor |
multiple interactions |
EXP |
2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [Curcumin inhibits the reaction [Lipopolysaccharides results in increased expression of AGER protein]]; Curcumin inhibits the reaction [Lipopolysaccharides results in increased expression of AGER protein] |
CTD |
PMID:29480285 |
|
NCBI chr20:4,148,150...4,151,361
Ensembl chr20:4,147,890...4,151,078
|
|
G |
Agr2 |
anterior gradient 2, protein disulphide isomerase family member |
decreases expression |
ISO |
Curcumin results in decreased expression of AGR2 mRNA |
CTD |
PMID:17198877 |
|
NCBI chr 6:52,708,602...52,729,378
Ensembl chr 6:52,708,602...52,729,371
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
EXP ISO |
[Curcumin binds to carboxymethyl-chitosan analog] inhibits the reaction [AGT protein modified form results in decreased degradation of TP53 protein]; [Curcumin binds to carboxymethyl-chitosan analog] inhibits the reaction [AGT protein modified form results in increased expression of and results in increased phosphorylation of RELA protein]; [Curcumin binds to carboxymethyl-chitosan analog] inhibits the reaction [AGT protein modified form results in increased expression of KIT protein]; [Curcumin binds to carboxymethyl-chitosan analog] inhibits the reaction [AGT protein modified form results in increased expression of PCNA protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Curcumin binds to carboxymethyl-chitosan analog] inhibits the reaction [AGT protein modified form results in decreased degradation of TP53 protein]]; carboxymethyl-chitosan analog promotes the reaction [Curcumin inhibits the reaction [AGT protein modified form results in increased acetylation of TP53 protein]]; carboxymethyl-chitosan analog promotes the reaction [Curcumin inhibits the reaction [AGT protein modified form results in increased expression of BAX protein]]; carboxymethyl-chitosan analog promotes the reaction [Curcumin promotes the reaction [AGT protein modified form results in increased expression of BCL2 protein]]; Curcumin inhibits the reaction [AGT protein modified form promotes the reaction [TP53 protein binds to EP300 protein]]; Curcumin inhibits the reaction [AGT protein modified form results in increased cleavage of and results in increased activity of CASP3 protein]; Curcumin inhibits the reaction [AGT protein modified form results in increased cleavage of PARP1 protein]; Curcumin inhibits the reaction [AGT protein modified form results in increased expression of and results in increased phosphorylation of and results in increased acetylation of TP53 protein]; Curcumin inhibits the reaction [AGT protein modified form results in increased expression of BAX protein]; Curcumin inhibits the reaction [AGT protein results in decreased expression of AGTR2 protein]; Curcumin inhibits the reaction [AGT protein results in increased expression of ACE2 protein]; Curcumin inhibits the reaction [AGT protein results in increased expression of TGFB1 protein]; Curcumin inhibits the reaction [AGT protein results in increased phosphorylation of SMAD2 protein]; Curcumin inhibits the reaction [AGT protein results in increased phosphorylation of SMAD3 protein]; Curcumin promotes the reaction [AGT protein modified form results in increased expression of BCL2 protein] [Curcumin co-treated with Niacin co-treated with ZM 241385] inhibits the reaction [Rotenone results in increased expression of AGT protein]; Curcumin inhibits the reaction [Rotenone results in increased expression of AGT protein] |
CTD |
PMID:26612707 PMID:26648693 PMID:31820278 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Agtr2 |
angiotensin II receptor, type 2 |
multiple interactions |
EXP |
Curcumin inhibits the reaction [AGT protein results in decreased expression of AGTR2 protein] |
CTD |
PMID:26648693 |
|
NCBI chr X:112,119,673...112,124,060
Ensembl chr X:112,120,228...112,124,057
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions affects binding increases degradation |
ISO |
AHR protein promotes the reaction [Curcumin results in increased expression of ABCG2 protein] Curcumin binds to AHR protein Curcumin results in increased degradation of AHR protein [Curcumin co-treated with resveratrol] inhibits the reaction [Benzo(a)pyrene results in increased activity of AHR protein]; Curcumin inhibits the reaction [Benzo(a)pyrene affects the localization of AHR protein]; Curcumin inhibits the reaction [Benzo(a)pyrene results in increased phosphorylation of and results in increased activity of AHR protein]; Curcumin inhibits the reaction [Methylcholanthrene binds to AHR protein]; Curcumin inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to ARNT protein]]; Curcumin inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of [AHR protein co-treated with ARNT protein]]; Curcumin inhibits the reaction [Tetrachlorodibenzodioxin results in increased phosphorylation of AHR protein]; Curcumin promotes the reaction [Tetrachlorodibenzodioxin results in increased localization of AHR protein] |
CTD |
PMID:17077187 PMID:17880909 PMID:18321868 PMID:19018768 PMID:25632966 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Ak1 |
adenylate kinase 1 |
multiple interactions |
ISO |
[ERBB2 protein results in increased susceptibility to Curcumin analog] which results in decreased phosphorylation of AK1 protein |
CTD |
PMID:25866362 |
|
NCBI chr 3:15,912,431...15,923,045
Ensembl chr 3:15,912,485...15,923,041
|
|
G |
Akap6 |
A-kinase anchoring protein 6 |
increases expression multiple interactions |
ISO |
Curcumin results in increased expression of AKAP6 mRNA Curcumin inhibits the reaction [Trinitrobenzenesulfonic Acid results in decreased expression of AKAP6 mRNA] |
CTD |
PMID:18200517 PMID:18421014 |
|
NCBI chr 6:70,184,101...70,624,369
Ensembl chr 6:70,184,175...70,619,738
|
|
G |
Akr1b1 |
aldo-keto reductase family 1 member B1 |
increases expression multiple interactions increases activity |
ISO EXP |
Curcumin results in increased expression of AKR1B1 mRNA 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Curcumin results in increased expression of AKR1B1 mRNA]; 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [Curcumin results in increased expression of AKR1B1 mRNA]; 3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [Curcumin results in increased expression of AKR1B1 protein]; AKT1 protein affects the reaction [Curcumin results in increased expression of AKR1B1 mRNA]; NFE2L2 protein promotes the reaction [Curcumin results in increased expression of AKR1B1 mRNA]; NFE2L2 protein promotes the reaction [Curcumin results in increased expression of AKR1B1 protein]; pyrazolanthrone inhibits the reaction [Curcumin results in increased expression of AKR1B1 mRNA]; SB 203580 inhibits the reaction [Curcumin results in increased expression of AKR1B1 mRNA] Curcumin results in increased expression of AKR1B1 mRNA; Curcumin results in increased expression of AKR1B1 protein Curcumin results in increased activity of AKR1B1 protein |
CTD |
PMID:17640564 PMID:18200517 PMID:18299980 PMID:18588981 |
|
NCBI chr 4:62,932,033...62,946,126
Ensembl chr 4:62,932,031...62,946,157
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions affects phosphorylation decreases expression decreases phosphorylation increases expression increases phosphorylation decreases activity |
ISO EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Curcumin results in increased phosphorylation of AKT1 protein]; [bisdemethoxycurcumin co-treated with Curcumin co-treated with demethoxycurcumin] inhibits the reaction [VEGF protein results in increased phosphorylation of AKT1 protein]; Arsenic Trioxide promotes the reaction [Curcumin results in decreased phosphorylation of AKT1 protein]; calyculin A inhibits the reaction [Curcumin results in decreased phosphorylation of AKT1 protein]; Curcumin inhibits the reaction [bisphenol A results in increased phosphorylation of AKT1 protein]; Curcumin inhibits the reaction [CXCL12 protein results in increased phosphorylation of AKT1 protein]; Curcumin inhibits the reaction [EGF protein results in increased phosphorylation of AKT1 protein]; Curcumin inhibits the reaction [IL1B protein results in increased phosphorylation of and results in increased activity of AKT1 protein]; Curcumin inhibits the reaction [Nicotine results in increased expression of AKT1 protein modified form]; Curcumin inhibits the reaction [Oxygen deficiency results in increased expression of AKT1 mRNA]; Curcumin inhibits the reaction [TNF protein results in increased phosphorylation of and results in increased activity of AKT1 protein]; Curcumin promotes the reaction [Folfox protocol results in decreased expression of and results in decreased phosphorylation of and results in decreased activity of AKT1 protein]; Curcumin results in decreased expression of and results in decreased phosphorylation of and results in decreased activity of AKT1 protein; Glutathione inhibits the reaction [Curcumin inhibits the reaction [TNF protein results in increased phosphorylation of and results in increased activity of AKT1 protein]]; lonidamine promotes the reaction [Curcumin results in decreased phosphorylation of AKT1 protein] Curcumin affects the phosphorylation of AKT1 protein Curcumin analog results in decreased expression of AKT1 mRNA; Curcumin results in decreased expression of AKT1 protein Curcumin results in increased expression of AKT1 protein AKT1 protein affects the reaction [Curcumin results in increased expression of AKR1B1 mRNA]; Curcumin inhibits the reaction [sodium arsenite results in decreased phosphorylation of AKT1 protein]; Curcumin inhibits the reaction [Streptozocin results in decreased phosphorylation of AKT1 protein]; Curcumin results in decreased phosphorylation of and results in decreased activity of AKT1 protein AKT1 protein affects the reaction [Curcumin results in increased expression of HMOX1 mRNA] Curcumin results in decreased activity of AKT1 protein |
CTD |
PMID:16023083 PMID:16219905 PMID:17289836 PMID:17291458 PMID:17332930 PMID:17372590 PMID:17535857 PMID:17596214 PMID:17640564 PMID:17640567 PMID:17918158 PMID:18006147 PMID:18214481 PMID:18660423 PMID:18790744 PMID:19372569 PMID:20605902 PMID:20727180 PMID:20938987 PMID:23222814 PMID:23452621 PMID:23555722 PMID:24211270 PMID:24365254 PMID:24831732 PMID:25541178 PMID:26409325 PMID:27208389 PMID:27966075 PMID:34634291 PMID:35752269 More...
|
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Akt2 |
AKT serine/threonine kinase 2 |
multiple interactions decreases expression |
ISO |
Curcumin inhibits the reaction [Oxygen deficiency results in increased expression of AKT2 protein modified form]; Curcumin inhibits the reaction [Oxygen deficiency results in increased expression of AKT2 protein] Curcumin analog results in decreased expression of AKT2 mRNA |
CTD |
PMID:23452621 PMID:26409325 |
|
NCBI chr 1:82,877,228...82,933,828
Ensembl chr 1:82,883,547...82,933,817
|
|
G |
Alad |
aminolevulinate dehydratase |
multiple interactions |
EXP ISO |
[Curcumin co-treated with Chitosan analog] inhibits the reaction [Arsenic results in decreased activity of ALAD protein]; Curcumin inhibits the reaction [Arsenic results in decreased activity of ALAD protein] Curcumin inhibits the reaction [lead acetate results in decreased activity of ALAD protein] |
CTD |
PMID:22704994 PMID:23292317 |
|
NCBI chr 5:75,961,993...75,972,334
Ensembl chr 5:75,961,993...75,972,474
|
|
G |
Alas1 |
5'-aminolevulinate synthase 1 |
increases expression |
EXP |
Curcumin results in increased expression of ALAS1 mRNA |
CTD |
PMID:18299980 |
|
NCBI chr 8:106,876,514...106,889,852
Ensembl chr 8:106,876,514...106,889,917
|
|
G |
Alb |
albumin |
multiple interactions |
EXP |
[Curcumin analog co-treated with Hydrogels] inhibits the reaction [Aflatoxin B1 results in decreased expression of ALB protein]; [Curcumin analog co-treated with Hydrogels] results in increased expression of ALB protein; Curcumin inhibits the reaction [Acetaminophen results in decreased expression of ALB protein]; Curcumin inhibits the reaction [sodium arsenite results in decreased expression of ALB protein]; Curcumin inhibits the reaction [Streptozocin results in decreased expression of ALB protein]; Curcumin inhibits the reaction [Thioacetamide results in increased expression of ALB protein] |
CTD |
PMID:18204486 PMID:18809455 PMID:20804811 PMID:24704557 PMID:27288928 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Alcam |
activated leukocyte cell adhesion molecule |
decreases expression |
ISO |
Curcumin results in decreased expression of ALCAM mRNA |
CTD |
PMID:33539684 |
|
NCBI chr11:48,336,123...48,536,296
Ensembl chr11:48,336,169...48,537,954
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
multiple interactions decreases expression |
ISO |
[Calcitriol co-treated with Curcumin] promotes the reaction [Paclitaxel results in decreased expression of ALDH1A1 mRNA]; [Calcitriol co-treated with Paclitaxel] promotes the reaction [Curcumin results in decreased expression of ALDH1A1 mRNA]; [Curcumin co-treated with Calcitriol] inhibits the reaction [Paclitaxel results in decreased expression of ALDH1A1 protein]; [Curcumin co-treated with Paclitaxel] promotes the reaction [Calcitriol results in decreased expression of ALDH1A1 mRNA]; Curcumin promotes the reaction [Paclitaxel results in decreased expression of ALDH1A1 protein]; Paclitaxel promotes the reaction [Curcumin results in decreased expression of ALDH1A1 mRNA] [Calcitriol co-treated with Curcumin] inhibits the reaction [Paclitaxel results in decreased expression of ALDH1A1 protein] Curcumin results in decreased expression of ALDH1A1 mRNA; Curcumin results in decreased expression of ALDH1A1 protein |
CTD |
PMID:31628941 |
|
NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961
|
|
G |
Aldoa |
aldolase, fructose-bisphosphate A |
decreases expression |
ISO |
Curcumin results in decreased expression of ALDOA mRNA |
CTD |
PMID:16880289 |
|
NCBI chr 1:181,402,275...181,407,476
Ensembl chr 1:181,402,275...181,406,182
|
|
G |
Aldoc |
aldolase, fructose-bisphosphate C |
decreases expression |
ISO |
Curcumin results in decreased expression of ALDOC mRNA |
CTD |
PMID:17198877 |
|
NCBI chr10:63,217,477...63,221,066
Ensembl chr10:63,217,451...63,221,066
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
multiple interactions decreases activity |
EXP |
[Capsaicin co-treated with Curcumin] results in decreased activity of ALOX5 protein Curcumin results in decreased activity of ALOX5 protein |
CTD |
PMID:16956363 |
|
NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743
|
|
G |
Ampd3 |
adenosine monophosphate deaminase 3 |
increases expression |
EXP |
Curcumin results in increased expression of AMPD3 mRNA |
CTD |
PMID:18299980 |
|
NCBI chr 1:164,884,823...164,929,899
Ensembl chr 1:164,885,320...164,929,887
|
|
G |
Ankrd37 |
ankyrin repeat domain 37 |
decreases expression |
ISO |
Curcumin results in decreased expression of ANKRD37 mRNA |
CTD |
PMID:17198877 |
|
NCBI chr16:46,269,025...46,271,971
Ensembl chr16:46,268,443...46,271,963
|
|
G |
Ankrd50 |
ankyrin repeat domain containing 50 |
decreases expression |
ISO |
Curcumin results in decreased expression of ANKRD50 mRNA |
CTD |
PMID:17999991 |
|
NCBI chr 2:121,466,275...121,500,758
Ensembl chr 2:121,468,573...121,500,752
|
|
G |
Ankzf1 |
ankyrin repeat and zinc finger peptidyl tRNA hydrolase 1 |
decreases expression |
ISO |
Curcumin results in decreased expression of ANKZF1 mRNA |
CTD |
PMID:17198877 |
|
NCBI chr 9:76,688,223...76,695,141
Ensembl chr 9:76,688,194...76,696,469
|
|
G |
Aoc1 |
amine oxidase, copper containing 1 |
multiple interactions |
EXP ISO |
Curcumin inhibits the reaction [Methotrexate results in increased activity of AOC1 protein] Curcumin inhibits the reaction [deoxynivalenol results in increased activity of AOC1 protein] |
CTD |
PMID:20885979 PMID:35817260 |
|
NCBI chr 4:77,812,260...77,831,846
Ensembl chr 4:77,812,260...77,831,840
|
|
G |
Apaf1 |
apoptotic peptidase activating factor 1 |
increases expression multiple interactions |
ISO EXP |
Curcumin results in increased expression of APAF1 protein Curcumin inhibits the reaction [Peroxynitrous Acid results in increased expression of APAF1 mRNA] |
CTD |
PMID:17277231 PMID:20869986 |
|
NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540
|
|
G |
Apc |
APC regulator of WNT signaling pathway |
decreases expression |
ISO |
Curcumin results in decreased expression of APC mRNA |
CTD |
PMID:15713895 |
|
NCBI chr18:25,828,558...25,925,511
Ensembl chr18:25,864,222...25,922,696
|
|
G |
Apoe |
apolipoprotein E |
affects expression |
ISO |
Curcumin affects the expression of APOE mRNA |
CTD |
PMID:27208389 |
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions increases expression |
ISO EXP |
Curcumin affects the reaction [APP protein binds to APP protein]; Curcumin inhibits the reaction [Copper results in increased expression of APP mRNA]; Curcumin inhibits the reaction [Hydrogen Peroxide results in increased expression of APP mRNA]; Curcumin inhibits the reaction [Paraquat results in increased expression of APP mRNA]; Curcumin inhibits the reaction [Paraquat results in increased expression of APP protein] Curcumin results in increased expression of APP mRNA [Curcumin analog co-treated with APP protein modified form] results in increased expression of NFE2L2 protein; [Curcumin co-treated with APP protein modified form] results in increased expression of NFE2L2 protein; Curcumin analog inhibits the reaction [APP protein modified form results in decreased activity of CAT protein]; Curcumin analog promotes the reaction [APP protein modified form results in decreased expression of KEAP1 protein]; Curcumin inhibits the reaction [APP protein modified form results in decreased activity of CAT protein]; Curcumin promotes the reaction [APP protein modified form results in decreased expression of KEAP1 protein] |
CTD |
PMID:18537544 PMID:18583042 PMID:27793699 PMID:30946834 PMID:31521693 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Aqp3 |
aquaporin 3 (Gill blood group) |
decreases expression multiple interactions |
ISO |
Curcumin results in decreased expression of AQP3 protein Curcumin inhibits the reaction [EGF protein results in increased expression of AQP3 protein] |
CTD |
PMID:18214481 |
|
NCBI chr 5:56,239,200...56,244,718
Ensembl chr 5:56,239,201...56,244,720
|
|
G |
Ar |
androgen receptor |
multiple interactions increases expression decreases activity decreases expression |
ISO |
[[Quercetin co-treated with Curcumin] results in decreased methylation of AR promoter] which results in increased expression of AR mRNA; [[Quercetin co-treated with Curcumin] results in decreased methylation of AR promoter] which results in increased expression of AR protein; [Quercetin co-treated with Curcumin] results in decreased methylation of AR promoter; AR protein affects the reaction [[Curcumin co-treated with Quercetin] results in increased expression of BAX protein]; AR protein affects the reaction [[Curcumin co-treated with Quercetin] results in increased expression of CASP3 protein]; AR protein affects the reaction [[Curcumin co-treated with Quercetin] results in increased expression of CDKN1A protein]; AR protein affects the reaction [[Curcumin co-treated with Quercetin] results in increased expression of CDKN1B protein]; Curcumin inhibits the reaction [AR protein results in increased expression of KLK3 mRNA]; Curcumin inhibits the reaction [Dihydrotestosterone promotes the reaction [AR protein binds to KLK3 enhancer]]; Curcumin inhibits the reaction [Dihydrotestosterone promotes the reaction [AR protein binds to TMPRSS2 enhancer]]; Curcumin inhibits the reaction [IL6 protein results in increased expression of AR mRNA]; Curcumin inhibits the reaction [IL6 protein results in increased expression of AR protein]; Curcumin promotes the reaction [Quercetin results in increased expression of AR mRNA]; Curcumin promotes the reaction [Quercetin results in increased expression of AR protein]; Quercetin promotes the reaction [Curcumin results in increased expression of AR mRNA]; Quercetin promotes the reaction [Curcumin results in increased expression of AR protein] Curcumin results in increased expression of AR mRNA; Curcumin results in increased expression of AR protein Curcumin results in decreased activity of AR protein Curcumin results in decreased expression of AR mRNA; Curcumin results in decreased expression of AR protein |
CTD |
PMID:12497104 PMID:18676361 PMID:18719366 PMID:22258452 PMID:27132804 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Arhgap24 |
Rho GTPase activating protein 24 |
multiple interactions |
ISO |
Curcumin inhibits the reaction [Trinitrobenzenesulfonic Acid results in decreased expression of ARHGAP24 mRNA] |
CTD |
PMID:18200517 |
|
NCBI chr14:6,800,631...7,184,001
Ensembl chr14:6,800,631...7,183,823
|
|
G |
Arhgap30 |
Rho GTPase activating protein 30 |
decreases expression |
ISO |
Curcumin results in decreased expression of ARHGAP30 mRNA |
CTD |
PMID:18421014 |
|
NCBI chr13:83,822,290...83,843,634
Ensembl chr13:83,822,283...83,854,885
|
|
G |
Arhgdib |
Rho GDP dissociation inhibitor beta |
multiple interactions |
ISO |
Curcumin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of ARHGDIB mRNA] |
CTD |
PMID:18200517 |
|
NCBI chr 4:169,822,951...169,841,884
Ensembl chr 4:169,822,952...169,841,658
|
|
G |
Arnt |
aryl hydrocarbon receptor nuclear translocator |
multiple interactions increases degradation decreases expression |
ISO |
Acetylcysteine inhibits the reaction [Curcumin results in increased degradation of ARNT protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Curcumin results in increased degradation of ARNT protein]; Curcumin results in increased ubiquitination of and results in increased degradation of ARNT protein Curcumin inhibits the reaction [Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to ARNT protein]]; Curcumin inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of [AHR protein co-treated with ARNT protein]]; Curcumin inhibits the reaction [Tetrachlorodibenzodioxin results in increased phosphorylation of ARNT protein] Curcumin results in decreased expression of ARNT protein |
CTD |
PMID:16880289 PMID:17880909 PMID:18682687 PMID:19018768 |
|
NCBI chr 2:182,997,731...183,056,584
Ensembl chr 2:182,997,736...183,056,580
|
|
G |
Atf1 |
activating transcription factor 1 |
multiple interactions |
ISO |
Curcumin inhibits the reaction [Oxygen deficiency results in increased expression of ATF1 mRNA] |
CTD |
PMID:23452621 |
|
NCBI chr 7:131,361,962...131,404,677
Ensembl chr 7:131,362,450...131,404,670
|
|
G |
Atf2 |
activating transcription factor 2 |
decreases expression |
ISO |
Curcumin analog results in decreased expression of ATF2 mRNA |
CTD |
PMID:26409325 |
|
NCBI chr 3:58,718,323...58,795,280
Ensembl chr 3:58,718,332...58,795,236
|
|
G |
Atf3 |
activating transcription factor 3 |
increases expression |
ISO |
Curcumin results in increased expression of ATF3 mRNA; Curcumin results in increased expression of ATF3 protein |
CTD |
PMID:15713895 PMID:18555241 PMID:18719366 |
|
NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
|
|
G |
Atf6 |
activating transcription factor 6 |
increases expression |
ISO |
Curcumin results in increased expression of ATF6 protein Curcumin results in increased expression of ATF6 mRNA |
CTD |
PMID:21793155 PMID:29723631 |
|
NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177
|
|
G |
Atm |
ATM serine/threonine kinase |
multiple interactions increases phosphorylation |
ISO |
[Isoflavones co-treated with Curcumin] results in increased phosphorylation of ATM protein Curcumin results in increased phosphorylation of ATM protein |
CTD |
PMID:19401701 PMID:21134073 |
|
NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437
|
|
G |
Aurka |
aurora kinase A |
decreases expression |
ISO |
Curcumin analog results in decreased expression of AURKA mRNA |
CTD |
PMID:26409325 |
|
NCBI chr 3:161,128,309...161,144,524
Ensembl chr 3:161,128,313...161,144,390
|
|
G |
Aurkb |
aurora kinase B |
decreases expression |
ISO |
Curcumin analog results in decreased expression of AURKB mRNA |
CTD |
PMID:26409325 |
|
NCBI chr10:53,744,290...53,750,831
Ensembl chr10:53,745,142...53,750,837
|
|
G |
Axin1 |
axin 1 |
multiple interactions increases expression |
EXP |
Curcumin inhibits the reaction [bisphenol A results in decreased expression of AXIN1 mRNA] Curcumin results in increased expression of AXIN1 mRNA |
CTD |
PMID:25963729 |
|
NCBI chr10:15,163,684...15,215,615
Ensembl chr10:15,163,684...15,215,615
|
|
G |
B3galt6 |
Beta-1,3-galactosyltransferase 6 |
increases expression |
ISO |
Curcumin results in increased expression of B3GALT6 mRNA |
CTD |
PMID:17198877 |
|
NCBI chr 5:166,584,202...166,586,338
Ensembl chr 5:166,584,202...166,586,338
|
|
G |
Bace1 |
beta-secretase 1 |
multiple interactions increases expression |
ISO |
Curcumin inhibits the reaction [Copper results in increased expression of BACE1 mRNA]; Curcumin inhibits the reaction [Hydrogen Peroxide results in increased expression of BACE1 mRNA] Curcumin results in increased expression of BACE1 mRNA |
CTD |
PMID:18583042 PMID:31521693 |
|
NCBI chr 8:46,142,060...46,166,268
Ensembl chr 8:46,142,116...46,165,876
|
|
G |
Bad |
BCL2-associated agonist of cell death |
increases expression multiple interactions |
ISO EXP |
Curcumin results in increased expression of BAD mRNA; Curcumin results in increased expression of BAD protein [arsenic trioxide co-treated with Curcumin] results in increased expression of BAD protein Curcumin inhibits the reaction [tert-Butylhydroperoxide results in increased expression of BAD protein] |
CTD |
PMID:15569404 PMID:19235267 PMID:27430728 |
|
NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
|
|
G |
Bak1 |
BCL2-antagonist/killer 1 |
multiple interactions decreases expression increases expression increases response to substance |
ISO |
TNFSF10 protein promotes the reaction [Curcumin results in increased expression of BAK1 protein] Curcumin results in decreased expression of BAK1 mRNA Curcumin results in increased expression of BAK1 mRNA; Curcumin results in increased expression of BAK1 protein BAK1 protein results in increased susceptibility to Curcumin |
CTD |
PMID:17277231 PMID:17332930 PMID:18226269 PMID:33582110 |
|
NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions decreases expression increases expression affects localization increases response to substance |
ISO EXP |
[Arsenic Trioxide co-treated with Curcumin] results in increased expression of BAX protein; [bicalutamide co-treated with Curcumin co-treated with Quercetin] results in increased expression of BAX protein; [Curcumin co-treated with Quercetin] results in increased expression of BAX protein; [Curcumin co-treated with Sirolimus] results in increased expression of BAX; [Doxorubicin co-treated with Curcumin] results in increased expression of BAX mRNA; AR protein affects the reaction [[Curcumin co-treated with Quercetin] results in increased expression of BAX protein]; Arsenic Trioxide promotes the reaction [Curcumin affects the localization of BAX protein]; Curcumin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of BAX protein]; Curcumin inhibits the reaction [bisphenol A results in decreased expression of BAX protein]; Curcumin inhibits the reaction [Paraquat results in increased expression of BAX protein]; Curcumin promotes the reaction [Arsenic Trioxide affects the localization of BAX protein]; Curcumin promotes the reaction [lonidamine affects the localization of BAX protein]; Curcumin promotes the reaction [Paclitaxel promotes the reaction [Calcitriol results in increased expression of BAX protein]]; Curcumin promotes the reaction [Paclitaxel results in increased expression of BAX protein]; Dihydrotestosterone inhibits the reaction [[Curcumin co-treated with Quercetin] results in increased expression of BAX protein]; lonidamine promotes the reaction [Curcumin affects the localization of BAX protein]; Paclitaxel promotes the reaction [Curcumin results in increased expression of BAX protein]; piperine inhibits the reaction [Curcumin results in decreased expression of BAX protein]; TNFSF10 protein promotes the reaction [Curcumin results in increased expression of BAX protein]; Vitamin E inhibits the reaction [Curcumin results in decreased expression of BAX protein] Curcumin results in decreased expression of BAX mRNA; Curcumin results in decreased expression of BAX protein Curcumin results in increased expression of BAX mRNA; Curcumin results in increased expression of BAX protein 2-chloro-5-nitrobenzanilide inhibits the reaction [Curcumin results in increased expression of BAX mRNA]; 2-chloro-5-nitrobenzanilide inhibits the reaction [Curcumin results in increased expression of BAX protein]; [Curcumin analog co-treated with Hydrogels] inhibits the reaction [Aflatoxin B1 results in increased expression of BAX mRNA]; carboxymethyl-chitosan analog promotes the reaction [Curcumin inhibits the reaction [AGT protein modified form results in increased expression of BAX protein]]; carboxymethyl-chitosan analog promotes the reaction [Curcumin results in decreased expression of BAX protein]; Curcumin inhibits the reaction [AGT protein modified form results in increased expression of BAX protein]; Curcumin inhibits the reaction [aristolochic acid I results in increased expression of BAX mRNA]; Curcumin inhibits the reaction [bisphenol A results in increased expression of BAX mRNA]; Curcumin inhibits the reaction [Peroxynitrous Acid results in increased expression of BAX mRNA]; Curcumin inhibits the reaction [Peroxynitrous Acid results in increased expression of BAX protein]; Curcumin inhibits the reaction [sodium arsenite results in increased expression of BAX protein]; Curcumin inhibits the reaction [Streptozocin affects the expression of BAX protein]; Curcumin inhibits the reaction [Streptozocin results in increased expression of BAX mRNA]; Curcumin inhibits the reaction [tert-Butylhydroperoxide results in increased expression of BAX protein] BAX protein results in increased susceptibility to Curcumin [Curcumin co-treated with Quercetin] inhibits the reaction [Benzo(a)pyrene results in decreased expression of BAX protein]; Curcumin affects the localization of and results in increased expression of and results in increased activity of BAX protein; Curcumin inhibits the reaction [Benzo(a)pyrene results in decreased expression of BAX protein]; Curcumin inhibits the reaction [deoxynivalenol results in increased expression of BAX mRNA]; Curcumin inhibits the reaction [deoxynivalenol results in increased expression of BAX protein] |
CTD |
PMID:15569404 PMID:17096185 PMID:17277231 PMID:17332930 PMID:17531121 PMID:17671742 PMID:18226269 PMID:19235267 PMID:19373661 PMID:20605902 PMID:20869986 PMID:21594647 PMID:23222814 PMID:23267840 PMID:24952339 PMID:25541178 PMID:25963729 PMID:26612707 PMID:27132804 PMID:27288928 PMID:27430728 PMID:27793699 PMID:27966075 PMID:28681665 PMID:30463061 PMID:30935902 PMID:31628941 PMID:32128952 PMID:33582110 PMID:35817260 PMID:36037877 More...
|
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bbc3 |
Bcl-2 binding component 3 |
increases expression multiple interactions decreases expression |
ISO EXP |
Curcumin results in increased expression of BBC3 mRNA Curcumin inhibits the reaction [Doxorubicin results in increased expression of BBC3 protein] Curcumin results in decreased expression of BBC3 mRNA |
CTD |
PMID:17332930 PMID:22714040 PMID:34047412 |
|
NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509
|
|
G |
Bcl10 |
BCL10, immune signaling adaptor |
multiple interactions |
ISO |
Curcumin inhibits the reaction [Oxygen deficiency results in increased expression of BCL10 mRNA] |
CTD |
PMID:23452621 |
|
NCBI chr 2:234,840,880...234,850,520
Ensembl chr 2:234,840,858...234,850,523
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions increases expression decreases expression |
ISO EXP |
[Arsenic Trioxide co-treated with Curcumin] affects the expression of BCL2 protein; [Curcumin binds to 4-bis(2-chloroethyl)aminobenzaldehyde] which results in decreased expression of BCL2 protein; [Curcumin co-treated with Calcitriol] promotes the reaction [Paclitaxel results in decreased expression of BCL2 protein]; [Curcumin co-treated with Isoflavones] results in decreased expression of BCL2 protein; [Curcumin co-treated with Sirolimus] results in decreased expression of BCL2; [Curcumin results in increased expression of SERPINB5] which results in decreased expression of BCL2 protein; [Dihydrotestosterone co-treated with Curcumin co-treated with Quercetin] results in increased expression of BCL2 protein; [Doxorubicin co-treated with Curcumin] results in decreased expression of BCL2 mRNA; [piperine co-treated with Curcumin] results in decreased expression of BCL2 protein; [Vitamin E co-treated with Curcumin] results in decreased expression of BCL2 protein; Curcumin inhibits the reaction [Docetaxel results in increased phosphorylation of BCL2 protein]; Curcumin inhibits the reaction [Nicotine results in increased expression of BCL2 protein]; Curcumin inhibits the reaction [Oxygen deficiency results in increased expression of BCL2 mRNA]; Curcumin inhibits the reaction [Paclitaxel results in increased expression of BCL2 protein]; Curcumin inhibits the reaction [TNF protein results in increased expression of BCL2 mRNA]; Curcumin inhibits the reaction [TNF protein results in increased expression of BCL2 protein]; Curcumin promotes the reaction [Calcitriol promotes the reaction [Paclitaxel results in decreased expression of BCL2 protein]]; Curcumin promotes the reaction [Paclitaxel results in decreased expression of BCL2 protein]; Curcumin results in increased ubiquitination of and results in increased degradation of BCL2 protein; Glutathione inhibits the reaction [Curcumin inhibits the reaction [TNF protein results in increased expression of BCL2 protein]]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [Curcumin results in increased ubiquitination of and results in increased degradation of BCL2 protein]; TNFSF10 protein promotes the reaction [Curcumin results in decreased expression of BCL2 protein] Curcumin results in increased expression of BCL2 mRNA; Curcumin results in increased expression of BCL2 protein Curcumin results in decreased expression of BCL2 mRNA; Curcumin results in decreased expression of BCL2 protein Curcumin analog results in decreased expression of BCL2 mRNA; Curcumin results in decreased expression of BCL2 mRNA; Curcumin results in decreased expression of BCL2 protein [Curcumin co-treated with Gemcitabine] results in decreased expression of BCL2 protein; [Quercetin co-treated with Curcumin] inhibits the reaction [Benzo(a)pyrene results in increased expression of BCL2 protein]; Curcumin inhibits the reaction [Benzo(a)pyrene results in increased expression of BCL2 protein]; Curcumin inhibits the reaction [deoxynivalenol results in decreased expression of BCL2 mRNA]; Curcumin inhibits the reaction [deoxynivalenol results in decreased expression of BCL2 protein]; NFE2L2 gene mutant form inhibits the reaction [Curcumin results in increased expression of BCL2 protein] 2-chloro-5-nitrobenzanilide inhibits the reaction [Curcumin results in decreased expression of BCL2 mRNA]; 2-chloro-5-nitrobenzanilide inhibits the reaction [Curcumin results in decreased expression of BCL2 protein]; [Curcumin analog co-treated with Hydrogels] inhibits the reaction [Aflatoxin B1 results in decreased expression of BCL2 mRNA]; carboxymethyl-chitosan analog promotes the reaction [Curcumin promotes the reaction [AGT protein modified form results in increased expression of BCL2 protein]]; carboxymethyl-chitosan analog promotes the reaction [Curcumin results in increased expression of BCL2 protein]; Curcumin analog inhibits the reaction [Copper Sulfate results in decreased expression of BCL2 mRNA]; Curcumin inhibits the reaction [aristolochic acid I results in decreased expression of BCL2 mRNA]; Curcumin inhibits the reaction [aristolochic acid I results in decreased expression of BCL2 protein]; Curcumin inhibits the reaction [bisphenol A results in decreased expression of BCL2 mRNA]; Curcumin inhibits the reaction [Colistin results in decreased expression of BCL2 protein]; Curcumin inhibits the reaction [Copper Sulfate results in decreased expression of BCL2 mRNA]; Curcumin inhibits the reaction [Cyclosporine results in decreased expression of BCL2 protein]; Curcumin inhibits the reaction [Peroxynitrous Acid results in decreased expression of BCL2 mRNA]; Curcumin inhibits the reaction [Peroxynitrous Acid results in decreased expression of BCL2 protein]; Curcumin inhibits the reaction [sodium arsenite results in decreased expression of BCL2 protein]; Curcumin inhibits the reaction [Streptozocin affects the expression of BCL2 protein]; Curcumin inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of BCL2 protein]; Curcumin promotes the reaction [AGT protein modified form results in increased expression of BCL2 protein] |
CTD |
PMID:12497104 PMID:14724571 PMID:15569404 PMID:16023083 PMID:16219905 PMID:16243823 PMID:17096185 PMID:17332930 PMID:17440100 PMID:17531121 PMID:17596214 PMID:17640567 PMID:17671737 PMID:17671742 PMID:18226269 PMID:18593936 PMID:18640131 PMID:18829502 PMID:19235267 PMID:19250217 PMID:19372569 PMID:19373661 PMID:19944674 PMID:20127174 PMID:20727180 PMID:20869986 PMID:21397623 PMID:21594647 PMID:21595920 PMID:21793155 PMID:22714040 PMID:23452621 PMID:24952339 PMID:25256401 PMID:25541178 PMID:25963729 PMID:26409325 PMID:26612707 PMID:27132804 PMID:27288928 PMID:27430728 PMID:28681665 PMID:29571711 PMID:30138604 PMID:30431687 PMID:30935902 PMID:31628941 PMID:32128952 PMID:32569592 PMID:33582110 PMID:33617879 PMID:35817260 PMID:36037877 More...
|
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2a1 |
BCL2-related protein A1 |
multiple interactions decreases expression |
ISO |
Curcumin inhibits the reaction [TNF protein results in increased expression of BCL2A1 mRNA] Curcumin results in decreased expression of BCL2A1 mRNA |
CTD |
PMID:16219905 PMID:17596214 |
|
NCBI chr 8:89,716,914...89,724,998
Ensembl chr 8:89,716,914...89,724,998
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions decreases expression increases expression |
ISO EXP |
[Curcumin co-treated with Doxorubicin] affects the expression of BCL2L1 mRNA; [Curcumin co-treated with Isoflavones] results in decreased expression of BCL2L1 protein; Curcumin inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of BCL2L1 protein]; Curcumin inhibits the reaction [Oxygen deficiency results in increased expression of BCL2L1 mRNA]; Curcumin inhibits the reaction [Paclitaxel results in increased expression of BCL2L1 protein]; Curcumin inhibits the reaction [TNF protein results in increased expression of BCL2L1 mRNA]; Curcumin inhibits the reaction [TNF protein results in increased expression of BCL2L1 protein]; Glutathione inhibits the reaction [Curcumin inhibits the reaction [TNF protein results in increased expression of BCL2L1 protein]]; TNFSF10 protein promotes the reaction [Curcumin results in decreased expression of BCL2L1 protein] Curcumin analog results in decreased expression of BCL2L1 mRNA; Curcumin results in decreased expression of BCL2L1 mRNA; Curcumin results in decreased expression of BCL2L1 protein Curcumin inhibits the reaction [tert-Butylhydroperoxide results in decreased expression of BCL2L1 protein] [Curcumin co-treated with Gemcitabine] results in decreased expression of BCL2L1 protein Curcumin results in increased expression of BCL2L1 mRNA |
CTD |
PMID:12497104 PMID:15569404 PMID:15911101 PMID:16023083 PMID:16173963 PMID:16219905 PMID:16243823 PMID:17148446 PMID:17332930 PMID:17440100 PMID:17596214 PMID:17640567 PMID:17671737 PMID:18226269 PMID:18640131 PMID:18829502 PMID:19235267 PMID:19250217 PMID:19372569 PMID:23452621 PMID:30463061 More...
|
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Bcl2l11 |
Bcl2-like 11 |
increases expression multiple interactions |
ISO |
Curcumin results in increased expression of BCL2L11 mRNA [arsenic trioxide co-treated with Curcumin] results in increased expression of BCL2L11 protein |
CTD |
PMID:17332930 PMID:27430728 |
|
NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068
|
|
G |
Bcl2l2 |
Bcl2-like 2 |
increases expression multiple interactions |
ISO |
Curcumin results in increased expression of BCL2L2 mRNA [arsenic trioxide co-treated with Curcumin] affects the expression of BCL2L2 protein |
CTD |
PMID:16101141 PMID:27430728 |
|
NCBI chr15:28,346,449...28,361,627
Ensembl chr15:28,356,807...28,361,624
|
|
G |
Bcl3 |
BCL3, transcription coactivator |
multiple interactions |
ISO |
Curcumin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of BCL3 mRNA] Curcumin inhibits the reaction [Oxygen deficiency results in increased expression of BCL3 mRNA] |
CTD |
PMID:18200517 PMID:23452621 |
|
NCBI chr 1:79,471,368...79,485,908
Ensembl chr 1:79,471,369...79,485,607
|
|
G |
Bcor |
BCL6 co-repressor |
increases expression |
ISO |
Curcumin results in increased expression of BCOR mRNA |
CTD |
PMID:17198877 |
|
NCBI chr X:10,609,756...10,729,613
Ensembl chr X:10,687,732...10,729,613
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
multiple interactions increases expression affects expression |
EXP ISO |
[Curcumin co-treated with Manganese] inhibits the reaction [Kainic Acid results in increased expression of BDNF mRNA]; Curcumin inhibits the reaction [sodium arsenite results in decreased expression of BDNF protein] Curcumin results in increased expression of BDNF protein Curcumin affects the expression of BDNF protein [Docosahexaenoic Acids co-treated with Curcumin] results in increased expression of BDNF mRNA; Curcumin inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of BDNF protein]; Curcumin inhibits the reaction [Morphine results in increased expression of BDNF mRNA] |
CTD |
PMID:17022948 PMID:17617388 PMID:17827730 PMID:19033880 PMID:22911773 PMID:27966075 PMID:29723552 PMID:32735850 More...
|
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Becn1 |
beclin 1 |
increases expression |
ISO |
Curcumin results in increased expression of BECN1 protein |
CTD |
PMID:34634291 |
|
NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742
|
|
G |
Bgn |
biglycan |
multiple interactions |
ISO |
Curcumin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of BGN mRNA] |
CTD |
PMID:18200517 |
|
NCBI chr X:151,197,296...151,209,458
Ensembl chr X:151,197,273...151,209,461
|
|
G |
Bid |
BH3 interacting domain death agonist |
multiple interactions |
ISO |
[arsenic trioxide co-treated with Curcumin] results in decreased expression of BID protein; [arsenic trioxide co-treated with Curcumin] results in increased expression of BID protein; Curcumin promotes the reaction [arsenic trioxide results in increased activity of BID protein] |
CTD |
PMID:20605902 PMID:27430728 |
|
NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
|
|
G |
Birc2 |
baculoviral IAP repeat-containing 2 |
decreases expression multiple interactions |
ISO |
Curcumin analog results in decreased expression of BIRC2 mRNA; Curcumin results in decreased expression of BIRC2 mRNA; Curcumin results in decreased expression of BIRC2 protein Curcumin inhibits the reaction [Nicotine results in increased expression of BIRC2 protein]; Curcumin inhibits the reaction [Oxygen deficiency results in increased expression of BIRC2 protein]; Curcumin inhibits the reaction [Paclitaxel results in increased expression of BIRC2 protein]; Curcumin inhibits the reaction [TNF protein results in increased expression of BIRC2 mRNA]; Curcumin inhibits the reaction [TNF protein results in increased expression of BIRC2 protein]; Glutathione inhibits the reaction [Curcumin inhibits the reaction [TNF protein results in increased expression of BIRC2 protein]] |
CTD |
PMID:16023083 PMID:16219905 PMID:16243823 PMID:17596214 PMID:17640567 PMID:17671737 PMID:20727180 PMID:23452621 More...
|
|
NCBI chr 8:4,968,856...4,989,325
Ensembl chr 8:4,968,842...4,988,732
|
|
G |
Birc3 |
baculoviral IAP repeat-containing 3 |
multiple interactions increases expression decreases expression |
ISO |
[arsenic trioxide co-treated with Curcumin] results in decreased expression of BIRC3 protein; [Curcumin co-treated with Doxorubicin] affects the expression of BIRC3 mRNA; Curcumin inhibits the reaction [Paclitaxel results in increased expression of BIRC3 protein]; Curcumin inhibits the reaction [TNF protein results in increased expression of BIRC3 mRNA] [Curcumin co-treated with Gemcitabine] results in decreased expression of BIRC3 protein Curcumin results in increased expression of BIRC3 mRNA Curcumin results in decreased expression of BIRC3 mRNA; Curcumin results in decreased expression of BIRC3 protein |
CTD |
PMID:15911101 PMID:16101141 PMID:16219905 PMID:16243823 PMID:17440100 PMID:17596214 PMID:19372569 PMID:27430728 More...
|
|
NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
multiple interactions decreases expression |
ISO EXP |
[arsenic trioxide co-treated with Curcumin] results in decreased expression of BIRC5 protein; Curcumin inhibits the reaction [Benzo(a)pyrene results in decreased expression of BIRC5 protein]; Curcumin inhibits the reaction [Nicotine results in increased expression of BIRC5 protein]; Curcumin inhibits the reaction [Oxygen deficiency results in increased expression of BIRC5 protein] Curcumin inhibits the reaction [Doxorubicin results in decreased expression of BIRC5 protein] Curcumin analog results in decreased expression of BIRC5 mRNA; Curcumin results in decreased expression of BIRC5 mRNA; Curcumin results in decreased expression of BIRC5 protein [Curcumin co-treated with Gemcitabine] results in decreased expression of BIRC5 protein |
CTD |
PMID:16023083 PMID:17440100 PMID:17596214 PMID:17671737 PMID:18593936 PMID:19235267 PMID:19372569 PMID:20727180 PMID:23452621 PMID:24664296 PMID:26409325 PMID:27430728 PMID:34047412 More...
|
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Birc7 |
baculoviral IAP repeat-containing 7 |
increases expression multiple interactions |
ISO |
Curcumin results in increased expression of BIRC7 mRNA [arsenic trioxide co-treated with Curcumin] results in increased expression of BIRC7 protein |
CTD |
PMID:15911101 PMID:27430728 |
|
NCBI chr 3:168,047,824...168,052,606
Ensembl chr 3:168,047,824...168,052,606
|
|
G |
Bmp2 |
bone morphogenetic protein 2 |
decreases expression |
ISO |
Curcumin results in decreased expression of BMP2 mRNA |
CTD |
PMID:27237783 |
|
NCBI chr 3:120,812,660...120,822,579
Ensembl chr 3:120,812,882...120,821,397
|
|
G |
Bsg |
basigin (Ok blood group) |
decreases response to substance |
ISO |
BSG protein results in decreased susceptibility to Curcumin |
CTD |
PMID:18379992 |
|
NCBI chr 7:9,993,170...10,000,387
Ensembl chr 7:9,993,170...10,000,387
|
|
G |
C1qa |
complement C1q A chain |
decreases expression |
ISO |
Curcumin results in decreased expression of C1QA mRNA |
CTD |
PMID:19555370 |
|
NCBI chr 5:149,133,635...149,136,482
Ensembl chr 5:149,133,636...149,136,534
|
|
G |
C1qb |
complement C1q B chain |
multiple interactions |
ISO |
Curcumin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of C1QB mRNA] |
CTD |
PMID:18200517 |
|
NCBI chr 5:149,118,843...149,124,394
Ensembl chr 5:149,118,846...149,124,407
|
|
G |
C3 |
complement C3 |
multiple interactions |
ISO |
Curcumin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of C3 mRNA] |
CTD |
PMID:18200517 |
|
NCBI chr 9:2,087,437...2,114,366
Ensembl chr 9:2,087,437...2,114,429
|
|
G |
C4b |
complement C4B (Chido blood group) |
multiple interactions |
ISO |
Curcumin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of C4B mRNA] |
CTD |
PMID:18200517 |
|
NCBI chr20:4,197,371...4,211,684
Ensembl chr20:4,197,366...4,211,681
|
|
G |
Camk2a |
calcium/calmodulin-dependent protein kinase II alpha |
multiple interactions |
ISO EXP |
[Docosahexaenoic Acids co-treated with Curcumin] results in increased expression of CAMK2A mRNA Curcumin inhibits the reaction [sodium arsenite results in decreased phosphorylation of CAMK2A protein] |
CTD |
PMID:22911773 PMID:29723552 |
|
NCBI chr18:54,378,642...54,441,120
Ensembl chr18:54,378,784...54,438,994
|
|
G |
Capg |
capping actin protein, gelsolin like |
multiple interactions |
ISO |
Curcumin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of CAPG mRNA] |
CTD |
PMID:18200517 |
|
NCBI chr 4:104,594,743...104,611,856
Ensembl chr 4:104,594,753...104,611,856
|
|
G |
Car9 |
carbonic anhydrase 9 |
decreases expression |
EXP |
Curcumin results in decreased expression of CAR9 mRNA |
CTD |
PMID:18299980 |
|
NCBI chr 5:57,763,234...57,769,838
Ensembl chr 5:57,763,206...57,769,838
|
|
G |
Casp1 |
caspase 1 |
increases expression multiple interactions |
ISO |
Curcumin results in increased expression of CASP1 mRNA [Dexamethasone co-treated with Curcumin] inhibits the reaction [[Ovalbumin co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased cleavage of CASP1 protein]; [Dexamethasone co-treated with Curcumin] inhibits the reaction [[Ovalbumin co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of CASP1 mRNA]; Curcumin inhibits the reaction [[Ovalbumin co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased cleavage of CASP1 protein]; Curcumin inhibits the reaction [[Ovalbumin co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of CASP1 mRNA]; Curcumin inhibits the reaction [Aflatoxin B1 results in increased expression of CASP1 mRNA]; Curcumin inhibits the reaction [Aflatoxin B1 results in increased expression of CASP1 protein] Curcumin inhibits the reaction [Oxygen deficiency results in increased expression of CASP1 mRNA] |
CTD |
PMID:16101141 PMID:23452621 PMID:34998855 PMID:35063475 |
|
NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Casp12 |
caspase 12 |
increases expression multiple interactions |
ISO EXP |
Curcumin results in increased expression of CASP12 protein Curcumin inhibits the reaction [Streptozocin results in increased cleavage of CASP12 protein] |
CTD |
PMID:21793155 PMID:25541178 |
|
NCBI chr 8:2,642,296...2,669,549
Ensembl chr 8:2,642,434...2,674,037
|
|
G |
Casp2 |
caspase 2 |
increases expression |
ISO |
Curcumin results in increased expression of CASP2 mRNA |
CTD |
PMID:16101141 |
|
NCBI chr 4:71,149,632...71,167,388
Ensembl chr 4:71,149,669...71,167,379
|
|
G |
Casp3 |
caspase 3 |
multiple interactions decreases expression increases cleavage increases activity decreases activity increases expression |
ISO EXP |
[Arsenic Trioxide co-treated with Curcumin] results in increased expression of CASP3 protein; [bicalutamide co-treated with Curcumin co-treated with Quercetin] results in increased expression of CASP3 protein; [Curcumin binds to 4-bis(2-chloroethyl)aminobenzaldehyde] which results in increased cleavage of CASP3 protein; [Curcumin co-treated with Arsenic Trioxide] results in increased cleavage of CASP3 protein; [Curcumin co-treated with lonidamine] results in increased cleavage of CASP3 protein; [Curcumin co-treated with Quercetin] results in increased expression of CASP3 protein; [Curcumin co-treated with Sirolimus] results in increased activity of CASP3 protein; Acetylcysteine inhibits the reaction [Curcumin results in increased activity of CASP3 protein]; AR protein affects the reaction [[Curcumin co-treated with Quercetin] results in increased expression of CASP3 protein]; Arsenic Trioxide promotes the reaction [Curcumin results in increased expression of CASP3 protein modified form]; Curcumin inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of CASP3 protein modified form]; Curcumin inhibits the reaction [quinocetone results in increased activity of CASP3 protein]; Curcumin inhibits the reaction [sodium arsenite results in increased cleavage of CASP3 protein]; Curcumin promotes the reaction [Arsenic Trioxide results in increased expression of CASP3 protein modified form]; Curcumin results in increased cleavage of and results in increased activity of CASP3 protein; Dihydrotestosterone inhibits the reaction [[Curcumin co-treated with Quercetin] results in increased expression of CASP3 protein]; Glutathione inhibits the reaction [Curcumin results in increased activity of CASP3 protein]; piperine inhibits the reaction [Curcumin results in decreased expression of CASP3 protein]; Vitamin E inhibits the reaction [Curcumin results in decreased expression of CASP3 protein]; zinc protoporphyrin inhibits the reaction [Curcumin inhibits the reaction [quinocetone results in increased activity of CASP3 protein]] Curcumin results in decreased expression of CASP3 protein modified form Curcumin results in increased cleavage of CASP3 protein Curcumin results in decreased activity of CASP3 protein [Curcumin analog co-treated with Hydrogels] inhibits the reaction [Aflatoxin B1 results in increased expression of CASP3 mRNA]; Curcumin analog inhibits the reaction [Copper Sulfate results in increased secretion of CASP3 protein]; Curcumin analog inhibits the reaction [Rotenone results in increased expression of CASP3 protein modified form]; Curcumin inhibits the reaction [AGT protein modified form results in increased cleavage of and results in increased activity of CASP3 protein]; Curcumin inhibits the reaction [aristolochic acid I results in increased expression of and results in increased cleavage of CASP3 protein]; Curcumin inhibits the reaction [aristolochic acid I results in increased expression of CASP3 mRNA]; Curcumin inhibits the reaction [Atrazine results in increased expression of CASP3 protein]; Curcumin inhibits the reaction [bisphenol A results in increased cleavage of CASP3 protein]; Curcumin inhibits the reaction [Colistin results in increased expression of CASP3 protein]; Curcumin inhibits the reaction [Copper Sulfate results in increased secretion of CASP3 protein]; Curcumin inhibits the reaction [Cyclosporine results in increased cleavage of CASP3 protein]; Curcumin inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; Curcumin inhibits the reaction [Peroxynitrous Acid results in increased cleavage of and results in increased activity of CASP3 protein]; Curcumin inhibits the reaction [Peroxynitrous Acid results in increased expression of CASP3 mRNA]; Curcumin inhibits the reaction [sodium arsenite results in increased cleavage of CASP3 protein]; Curcumin inhibits the reaction [sodium arsenite results in increased expression of CASP3 protein]; Curcumin inhibits the reaction [Streptozocin results in increased cleavage of CASP3 protein]; Curcumin inhibits the reaction [Streptozocin results in increased expression of CASP3 protein]; Curcumin inhibits the reaction [tert-Butylhydroperoxide results in increased cleavage of CASP3 protein]; Curcumin results in decreased cleavage of and results in decreased activity of CASP3 protein [Curcumin co-treated with Gemcitabine] results in decreased expression of CASP3 protein; [Curcumin co-treated with Niacin co-treated with ZM 241385] inhibits the reaction [Rotenone results in increased activity of CASP3 protein]; [Quercetin co-treated with Curcumin] inhibits the reaction [Benzo(a)pyrene results in decreased activity of CASP3 protein]; Curcumin inhibits the reaction [Benzo(a)pyrene results in decreased activity of CASP3 protein]; Curcumin inhibits the reaction [deoxynivalenol results in increased activity of CASP3 protein]; Curcumin inhibits the reaction [Dibutyl Phthalate results in increased expression of CASP3 protein]; Curcumin inhibits the reaction [Rotenone results in increased activity of CASP3 protein]; Curcumin results in increased cleavage of and results in increased activity of CASP3 protein; NFE2L2 gene mutant form inhibits the reaction [Curcumin results in decreased expression of CASP3 protein modified form] Curcumin results in increased expression of CASP3 mRNA; Curcumin results in increased expression of CASP3 protein; Curcumin results in increased expression of CASP3 protein modified form Curcumin analog results in increased activity of CASP3 protein; Curcumin results in increased activity of CASP3; Curcumin results in increased activity of CASP3 protein Curcumin results in decreased expression of CASP3 mRNA; Curcumin results in decreased expression of CASP3 protein |
CTD |
PMID:15095415 PMID:15569404 PMID:16023083 PMID:16101141 PMID:17041101 PMID:17096185 PMID:17148446 PMID:17277231 PMID:17332930 PMID:17351913 PMID:17363495 PMID:17440100 PMID:17640567 PMID:17671742 PMID:17885582 PMID:18555241 PMID:19235267 PMID:19294764 PMID:19373661 PMID:19401701 PMID:20127174 PMID:20605902 PMID:20869986 PMID:21397623 PMID:21450334 PMID:21594647 PMID:21595920 PMID:22523229 PMID:23267840 PMID:23555722 PMID:23710286 PMID:24863870 PMID:24952339 PMID:25541178 PMID:25963729 PMID:26409325 PMID:26612707 PMID:27132804 PMID:27288928 PMID:27375190 PMID:27430728 PMID:27535828 PMID:27966075 PMID:28681665 PMID:29315967 PMID:29571711 PMID:30138604 PMID:30431687 PMID:30463061 PMID:30935902 PMID:31712109 PMID:31820278 PMID:32569592 PMID:33582110 PMID:33617879 PMID:34994998 PMID:35817260 PMID:36037877 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp4 |
caspase 4 |
increases expression |
ISO |
Curcumin results in increased expression of CASP4 mRNA |
CTD |
PMID:16101141 |
|
NCBI chr 8:2,599,017...2,635,097
Ensembl chr 8:2,598,876...2,635,092
|
|
G |
Casp7 |
caspase 7 |
multiple interactions increases expression decreases expression |
ISO |
[Calcitriol co-treated with Curcumin] promotes the reaction [Paclitaxel results in increased expression of CASP7 protein]; [Curcumin co-treated with Sirolimus] results in increased activity of CASP7 protein; Calcitriol inhibits the reaction [Curcumin inhibits the reaction [Paclitaxel results in increased expression of CASP7 protein]]; Curcumin inhibits the reaction [Calcitriol inhibits the reaction [Paclitaxel results in increased expression of CASP7 protein]]; Curcumin inhibits the reaction [Paclitaxel results in increased expression of CASP7 protein]; Curcumin results in increased cleavage of and results in increased activity of CASP7 protein Curcumin results in increased expression of CASP7 protein Curcumin results in decreased expression of CASP7 mRNA |
CTD |
PMID:16023083 PMID:16101141 PMID:19373661 PMID:31628941 |
|
NCBI chr 1:255,437,195...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp8 |
caspase 8 |
increases activity multiple interactions increases cleavage decreases expression |
ISO EXP |
Curcumin results in increased activity of CASP8 protein Curcumin inhibits the reaction [Streptozocin results in increased cleavage of CASP8 protein]; Curcumin inhibits the reaction [Streptozocin results in increased expression of CASP8 mRNA] Curcumin results in increased cleavage of CASP8 protein Curcumin results in decreased expression of CASP8 mRNA; Curcumin results in decreased expression of CASP8 protein [Arsenic Trioxide co-treated with Curcumin] results in increased expression of CASP8 protein; Curcumin inhibits the reaction [Oxygen deficiency results in increased expression of CASP8 mRNA]; Curcumin results in increased cleavage of and results in increased activity of CASP8 protein; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride promotes the reaction [Curcumin results in increased cleavage of CASP8 protein] |
CTD |
PMID:14555224 PMID:16173963 PMID:17096185 PMID:17148446 PMID:22523229 PMID:23267840 PMID:23452621 PMID:25541178 PMID:27430728 PMID:33582110 More...
|
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
decreases expression multiple interactions increases activity increases expression increases cleavage |
ISO EXP |
Curcumin results in decreased expression of CASP9 mRNA; Curcumin results in decreased expression of CASP9 protein Curcumin inhibits the reaction [aristolochic acid I results in increased expression of and results in increased cleavage of CASP9 protein]; Curcumin inhibits the reaction [aristolochic acid I results in increased expression of CASP9 mRNA]; Curcumin inhibits the reaction [Peroxynitrous Acid results in increased cleavage of and results in increased activity of CASP9 protein]; Curcumin inhibits the reaction [Peroxynitrous Acid results in increased expression of CASP9 mRNA] Curcumin results in increased activity of CASP9 protein Curcumin results in increased expression of CASP9 mRNA; Curcumin results in increased expression of CASP9 protein [Curcumin co-treated with Gemcitabine] results in decreased expression of CASP9 protein; [Quercetin co-treated with Curcumin] inhibits the reaction [Benzo(a)pyrene results in decreased activity of CASP9 protein]; Curcumin inhibits the reaction [Benzo(a)pyrene results in decreased activity of CASP9 protein]; Curcumin inhibits the reaction [Dibutyl Phthalate results in increased expression of CASP9 protein]; Curcumin results in increased cleavage of and results in increased activity of CASP9 protein Curcumin results in increased cleavage of CASP9 protein [Curcumin co-treated with Arsenic Trioxide] results in increased cleavage of CASP9 protein; [Curcumin co-treated with Calcitriol] promotes the reaction [Paclitaxel results in increased expression of CASP9 protein]; [Curcumin co-treated with lonidamine] results in increased cleavage of CASP9 protein; [Curcumin co-treated with Sirolimus] results in increased activity of CASP9 protein; [Doxorubicin co-treated with Curcumin] results in increased expression of CASP9 mRNA; [Paclitaxel co-treated with Calcitriol] promotes the reaction [Curcumin results in increased expression of CASP9 protein]; [Paclitaxel co-treated with Curcumin] promotes the reaction [Calcitriol results in increased expression of CASP9 protein]; Curcumin inhibits the reaction [quinocetone results in increased activity of CASP9 protein]; Curcumin promotes the reaction [[Calcitriol co-treated with Paclitaxel] results in increased expression of CASP9 protein]; Curcumin results in increased cleavage of and results in increased activity of CASP9 protein; Paclitaxel promotes the reaction [Curcumin results in increased expression of CASP9 protein]; zinc protoporphyrin inhibits the reaction [Curcumin inhibits the reaction [quinocetone results in increased activity of CASP9 protein]] |
CTD |
PMID:14555224 PMID:16023083 PMID:16101141 PMID:17148446 PMID:17277231 PMID:17440100 PMID:17671742 PMID:18555241 PMID:19095035 PMID:19373661 PMID:20605902 PMID:20869986 PMID:21594647 PMID:27375190 PMID:28681665 PMID:31628941 PMID:31712109 PMID:32128952 PMID:33582110 PMID:34994998 PMID:36037877 More...
|
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions increases activity increases expression |
ISO EXP |
[arsenite co-treated with Curcumin] results in increased expression of CAT protein; Curcumin inhibits the reaction [Cisplatin results in decreased activity of CAT protein]; Curcumin inhibits the reaction [Hydrogen Peroxide results in decreased expression of CAT mRNA]; Curcumin inhibits the reaction [Oxaliplatin results in decreased activity of CAT protein]; Curcumin inhibits the reaction [quinocetone results in decreased activity of CAT protein]; Curcumin inhibits the reaction [Vehicle Emissions promotes the reaction [Cisplatin results in decreased activity of CAT protein]]; Curcumin inhibits the reaction [Vehicle Emissions results in decreased activity of CAT protein] Curcumin results in increased activity of CAT protein Curcumin inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in decreased activity of CAT protein]; Curcumin inhibits the reaction [Acetaminophen results in decreased expression of CAT protein]; Curcumin inhibits the reaction [Acrylamide results in decreased activity of CAT protein]; Curcumin inhibits the reaction [Aflatoxin B1 results in decreased activity of CAT protein]; Curcumin inhibits the reaction [Aflatoxin B1 results in decreased expression of CAT mRNA]; Curcumin inhibits the reaction [Chloranil results in decreased activity of CAT protein]; Curcumin inhibits the reaction [deoxynivalenol results in decreased expression of CAT mRNA]; Curcumin inhibits the reaction [Paraquat results in decreased activity of CAT protein]; Curcumin inhibits the reaction [Rotenone results in decreased activity of CAT protein]; Curcumin inhibits the reaction [sodium arsenite results in decreased activity of CAT protein]; Curcumin inhibits the reaction [sodium arsenite results in decreased expression of CAT mRNA]; Curcumin inhibits the reaction [sodium arsenite results in decreased expression of CAT]; Curcumin metabolite inhibits the reaction [Acetaminophen results in decreased expression of CAT protein]; sodium arsenite inhibits the reaction [Curcumin results in increased activity of CAT protein] Curcumin results in increased expression of CAT mRNA [Curcumin co-treated with Chitosan analog] inhibits the reaction [Arsenic results in decreased activity of CAT protein]; [Curcumin co-treated with Vitamin E] inhibits the reaction [Thyroxine results in decreased expression of CAT mRNA]; [Vitamin E co-treated with Curcumin] inhibits the reaction [Thyroxine results in decreased activity of CAT protein]; Curcumin analog inhibits the reaction [APP protein modified form results in decreased activity of CAT protein]; Curcumin analog inhibits the reaction [Monocrotaline results in increased activity of CAT protein]; Curcumin analog inhibits the reaction [sodium arsenite results in decreased activity of CAT protein]; Curcumin inhibits the reaction [[Lipopolysaccharides co-treated with Tobacco Smoke Pollution] results in decreased activity of CAT protein]; Curcumin inhibits the reaction [Acetaminophen results in decreased activity of CAT protein]; Curcumin inhibits the reaction [Acrylonitrile results in decreased activity of CAT protein]; Curcumin inhibits the reaction [Aflatoxin B1 results in decreased activity of CAT protein]; Curcumin inhibits the reaction [APP protein modified form results in decreased activity of CAT protein]; Curcumin inhibits the reaction [Arsenic results in decreased activity of CAT protein]; Curcumin inhibits the reaction [Chloroquine results in decreased activity of CAT protein]; Curcumin inhibits the reaction [Colistin results in decreased expression of CAT protein]; Curcumin inhibits the reaction [Doxorubicin results in decreased activity of CAT protein]; Curcumin inhibits the reaction [Hexachlorocyclohexane results in decreased activity of CAT protein]; Curcumin inhibits the reaction [Indomethacin results in decreased activity of CAT protein]; Curcumin inhibits the reaction [methylmercuric chloride results in decreased activity of CAT protein]; Curcumin inhibits the reaction [Oxygen deficiency results in decreased activity of CAT protein]; Curcumin inhibits the reaction [Paraquat results in decreased activity of CAT protein]; Curcumin inhibits the reaction [sodium arsenite results in decreased activity of CAT protein]; Curcumin inhibits the reaction [Sodium Selenite results in decreased activity of CAT protein]; Curcumin inhibits the reaction [Streptozocin results in decreased expression of CAT protein]; Curcumin inhibits the reaction [Thyroxine results in decreased expression of CAT mRNA]; Curcumin inhibits the reaction [Thyroxine results in decreased expression of CAT protein] |
CTD |
PMID:16770732 PMID:17076682 PMID:17351913 PMID:17461496 PMID:18299980 PMID:18392098 PMID:19481068 PMID:19631675 PMID:19913070 PMID:19914224 PMID:20112103 PMID:20593964 PMID:21574897 PMID:21976817 PMID:22704994 PMID:24113306 PMID:24347089 PMID:24760747 PMID:25123790 PMID:25169090 PMID:25461551 PMID:27375190 PMID:28951138 PMID:29205955 PMID:29315967 PMID:30138604 PMID:30423402 PMID:30934151 PMID:30946834 PMID:31081568 PMID:31199764 PMID:31330227 PMID:31407471 PMID:31521693 PMID:31714633 PMID:32735850 PMID:33350580 PMID:35063475 PMID:35817260 More...
|
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cbr1 |
carbonyl reductase 1 |
multiple interactions |
ISO |
[[Curcumin binds to and results in decreased activity of CBR1 protein] which results in decreased reduction of Daunorubicin] which results in decreased chemical synthesis of daunorubicinol; [Curcumin binds to and results in decreased activity of CBR1 protein] which results in decreased reduction of Daunorubicin; Curcumin binds to and results in decreased activity of CBR1 protein; Curcumin inhibits the reaction [CBR1 protein results in increased reduction of 2,3-hexanedione]; Curcumin inhibits the reaction [NADP metabolite binds to and results in increased activity of CBR1 protein] |
CTD |
PMID:25541467 |
|
NCBI chr11:32,860,618...32,862,981
Ensembl chr11:32,908,950...32,911,393 Ensembl chr11:32,908,950...32,911,393
|
|
G |
Ccar1 |
cell division cycle and apoptosis regulator 1 |
increases expression |
ISO |
Curcumin results in increased expression of CCAR1 protein |
CTD |
PMID:21594647 |
|
NCBI chr20:30,685,916...30,728,531
Ensembl chr20:30,685,916...30,728,526
|
|
G |
Ccdc116 |
coiled-coil domain containing 116 |
increases expression |
ISO |
Curcumin results in increased expression of CCDC116 mRNA |
CTD |
PMID:18200517 |
|
NCBI chr11:83,842,707...83,850,607
Ensembl chr11:83,845,557...83,850,607
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions decreases expression increases expression |
ISO EXP |
Curcumin inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of CCL2 protein]; Curcumin inhibits the reaction [Oxygen deficiency results in increased expression of CCL2 mRNA]; Curcumin inhibits the reaction [TNF protein results in increased expression of CCL2 mRNA]; Curcumin inhibits the reaction [TNF protein results in increased expression of CCL2 protein]; MIR125A mRNA inhibits the reaction [Curcumin inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of CCL2 protein]]; SIRT6 protein promotes the reaction [Curcumin inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of CCL2 protein]] Curcumin results in decreased expression of CCL2 mRNA; Curcumin results in decreased expression of CCL2 protein Curcumin inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA] Curcumin inhibits the reaction [Carbon Tetrachloride results in increased expression of CCL2 mRNA] Curcumin results in increased expression of CCL2 mRNA |
CTD |
PMID:10925121 PMID:11053056 PMID:17198877 PMID:17666914 PMID:18403477 PMID:19152916 PMID:20712904 PMID:22683883 PMID:23452621 PMID:33952798 More...
|
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccn2 |
cellular communication network factor 2 |
decreases expression multiple interactions |
ISO EXP |
Curcumin results in decreased expression of CCN2 mRNA; Curcumin results in decreased expression of CCN2 protein IKBKB protein inhibits the reaction [Curcumin results in decreased expression of CCN2 mRNA]; Lipopolysaccharides inhibits the reaction [Curcumin results in decreased expression of CCN2 mRNA]; NFKBIA protein inhibits the reaction [Curcumin results in decreased expression of CCN2 mRNA]; PPARG protein promotes the reaction [Curcumin results in decreased expression of CCN2 mRNA] |
CTD |
PMID:17965732 PMID:19764552 |
|
NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
|
|
G |
Ccna2 |
cyclin A2 |
multiple interactions decreases expression |
ISO |
Curcumin inhibits the reaction [bisphenol A results in increased expression of CCNA2 protein] Curcumin results in decreased expression of CCNA2 protein |
CTD |
PMID:23222814 |
|
NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
|
|
G |
Ccnb1 |
cyclin B1 |
decreases expression |
ISO |
Curcumin results in decreased expression of CCNB1 mRNA; Curcumin results in decreased expression of CCNB1 protein |
CTD |
PMID:17148446 PMID:18719366 PMID:19401701 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions increases expression decreases expression increases degradation |
ISO EXP |
[Curcumin co-treated with Isoflavones] results in decreased expression of CCND1 protein; calyculin A inhibits the reaction [Curcumin results in decreased expression of CCND1 protein]; Curcumin inhibits the reaction [Acrylamide results in increased expression of CCND1 protein]; Curcumin inhibits the reaction [Nicotine results in increased expression of CCND1 protein]; Curcumin inhibits the reaction [Paclitaxel results in increased expression of CCND1 protein]; Curcumin inhibits the reaction [TNF protein results in increased expression of CCND1 mRNA]; Curcumin inhibits the reaction [TNF protein results in increased expression of CCND1 protein]; Curcumin inhibits the reaction [VIP protein results in increased expression of CCND1 protein]; Glutathione inhibits the reaction [Curcumin inhibits the reaction [TNF protein results in increased expression of CCND1 protein]]; lactacystin inhibits the reaction [Curcumin results in increased degradation of CCND1 protein]; piperine inhibits the reaction [Curcumin results in decreased expression of CCND1 protein]; TNFSF10 protein promotes the reaction [Curcumin results in decreased expression of CCND1 protein]; Vitamin E inhibits the reaction [Curcumin results in decreased expression of CCND1 protein] Curcumin results in increased expression of CCND1 mRNA Curcumin results in decreased expression of CCND1 mRNA; Curcumin results in decreased expression of CCND1 protein 2-chloro-5-nitrobenzanilide inhibits the reaction [Curcumin results in decreased expression of CCND1 mRNA]; Buthionine Sulfoximine inhibits the reaction [Curcumin results in decreased expression of CCND1 protein]; Curcumin inhibits the reaction [bisphenol A results in decreased expression of CCND1 mRNA] Curcumin results in decreased expression of CCND1; Curcumin results in decreased expression of CCND1 protein [Curcumin co-treated with Gemcitabine] results in decreased expression of CCND1 protein Curcumin analog results in decreased expression of CCND1 protein; Curcumin results in decreased expression of CCND1 mRNA; Curcumin results in decreased expression of CCND1 protein |
CTD |
PMID:15486348 PMID:15489888 PMID:15738001 PMID:16023083 PMID:16219905 PMID:16243823 PMID:16959222 PMID:17041101 PMID:17148446 PMID:17440100 PMID:17531121 PMID:17602960 PMID:17640567 PMID:17885582 PMID:18156803 PMID:18226269 PMID:18316600 PMID:18593936 PMID:18640131 PMID:18790744 PMID:18829502 PMID:19189304 PMID:19372569 PMID:19501152 PMID:19573523 PMID:20727180 PMID:24211270 PMID:24508477 PMID:25822711 PMID:25963729 PMID:30935902 More...
|
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccnd3 |
cyclin D3 |
multiple interactions decreases expression |
ISO |
Curcumin inhibits the reaction [bisphenol A results in increased expression of CCND3 protein] Curcumin results in decreased expression of CCND3 protein |
CTD |
PMID:23222814 |
|
NCBI chr 9:13,394,161...13,400,341
Ensembl chr 9:13,394,169...13,489,371
|
|
G |
Ccne1 |
cyclin E1 |
decreases expression multiple interactions increases degradation |
ISO EXP |
Curcumin results in decreased expression of CCNE1 protein Curcumin results in decreased expression of CCNE1 mRNA lactacystin inhibits the reaction [Curcumin results in increased degradation of CCNE1 protein] |
CTD |
PMID:17148446 PMID:18156803 PMID:18299980 |
|
NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
|
|
G |
Ccpg1 |
cell cycle progression 1 |
increases expression |
ISO |
Curcumin results in increased expression of CCPG1 mRNA |
CTD |
PMID:17198877 |
|
NCBI chr 8:73,719,960...73,752,437
Ensembl chr 8:73,719,955...73,752,430
|
|
G |
Ccr2 |
C-C motif chemokine receptor 2 |
decreases expression |
ISO |
Curcumin results in decreased expression of CCR2 mRNA |
CTD |
PMID:18403477 |
|
NCBI chr 8:123,734,465...123,742,483
Ensembl chr 8:123,734,430...123,742,100
|
|
G |
Cd14 |
CD14 molecule |
multiple interactions |
ISO |
Curcumin inhibits the reaction [Glucose promotes the reaction [Lipopolysaccharides results in increased expression of CD14 protein]]; Curcumin inhibits the reaction [Lipopolysaccharides results in increased expression of CD14 protein] |
CTD |
PMID:18180316 |
|
NCBI chr18:28,335,522...28,337,383
Ensembl chr18:28,335,340...28,337,261
|
|
G |
Cd36 |
CD36 molecule |
decreases expression increases expression multiple interactions |
ISO |
Curcumin results in decreased expression of CD36 mRNA Curcumin results in increased expression of CD36 mRNA Curcumin inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of CD36 mRNA]; Curcumin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of CD36 mRNA]; Curcumin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of CD36 protein] Curcumin results in decreased expression of CD36 mRNA; Curcumin results in decreased expression of CD36 protein |
CTD |
PMID:16713233 PMID:23386263 PMID:23603106 |
|
NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Cd40 |
CD40 molecule |
decreases expression multiple interactions |
ISO EXP |
Curcumin results in decreased expression of CD40 mRNA CD40 protein affects the reaction [Curcumin affects the reaction [Lipopolysaccharides affects the expression of IL10 protein]]; CD40 protein affects the reaction [Curcumin affects the reaction [Lipopolysaccharides affects the expression of IL6 protein]]; CD40 protein affects the reaction [Curcumin affects the reaction [Lipopolysaccharides affects the expression of TNF protein]]; CD40 protein affects the reaction [Curcumin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein]]; CD40 protein affects the reaction [Curcumin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of RELA protein]]; Curcumin inhibits the reaction [Lipopolysaccharides results in increased expression of CD40 protein] [arsenic trioxide co-treated with Curcumin] results in increased expression of CD40 protein |
CTD |
PMID:16101141 PMID:27430728 PMID:35549587 |
|
NCBI chr 3:153,790,372...153,805,279
Ensembl chr 3:153,790,449...153,805,534
|
|
G |
Cd40lg |
CD40 ligand |
multiple interactions |
ISO |
[arsenic trioxide co-treated with Curcumin] results in increased expression of CD40LG protein |
CTD |
PMID:27430728 |
|
NCBI chr X:135,127,119...135,138,302
Ensembl chr X:135,126,969...135,138,306
|
|
G |
Cd44 |
CD44 molecule (Indian blood group) |
increases expression |
ISO |
Curcumin results in increased expression of CD44 mRNA |
CTD |
PMID:15713895 |
|
NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620
|
|
G |
Cd47 |
Cd47 molecule |
multiple interactions |
ISO |
Curcumin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of CD47 mRNA] |
CTD |
PMID:18200517 |
|
NCBI chr11:50,906,052...50,970,000
Ensembl chr11:50,906,177...50,969,425
|
|
G |
Cd55 |
CD55 molecule (Cromer blood group) |
decreases expression |
ISO |
Curcumin results in decreased expression of CD55 mRNA |
CTD |
PMID:17999991 |
|
NCBI chr13:41,857,242...41,885,966
Ensembl chr13:41,857,395...41,885,831
|
|
G |
Cdc14b |
cell division cycle 14B |
increases expression |
ISO |
Curcumin results in increased expression of CDC14B mRNA |
CTD |
PMID:17198877 |
|
NCBI chr17:844,731...934,787
Ensembl chr17:844,685...933,235
|
|
G |
Cdc20 |
cell division cycle 20 |
decreases expression |
ISO |
Curcumin results in decreased expression of CDC20 mRNA |
CTD |
PMID:22258452 |
|
NCBI chr 5:131,966,203...131,970,406
Ensembl chr 5:131,966,215...131,970,512
|
|
G |
Cdc25c |
cell division cycle 25C |
increases phosphorylation |
ISO |
Curcumin results in increased phosphorylation of CDC25C protein |
CTD |
PMID:19401701 |
|
NCBI chr18:26,335,156...26,356,199
Ensembl chr18:26,335,834...26,356,185
|
|
G |
Cdh1 |
cadherin 1 |
increases expression multiple interactions |
ISO |
Curcumin results in increased expression of CDH1 protein Curcumin inhibits the reaction [Tobacco Smoke Pollution results in decreased expression of CDH1 mRNA]; Curcumin inhibits the reaction [Tobacco Smoke Pollution results in decreased expression of CDH1 protein] Curcumin inhibits the reaction [Tetradecanoylphorbol Acetate results in decreased expression of CDH1 protein] |
CTD |
PMID:19573523 PMID:25656647 PMID:26191140 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdh11 |
cadherin 11 |
decreases expression |
ISO |
Curcumin results in decreased expression of CDH11 protein |
CTD |
PMID:18025290 |
|
NCBI chr19:2,148,447...2,305,754
Ensembl chr19:2,148,458...2,304,272
|
|
G |
Cdh17 |
cadherin 17 |
decreases expression |
ISO |
Curcumin results in decreased expression of CDH17 mRNA |
CTD |
PMID:17198877 |
|
NCBI chr 5:25,262,820...25,314,884
Ensembl chr 5:25,262,758...25,314,884
|
|
G |
Cdh2 |
cadherin 2 |
multiple interactions |
ISO EXP |
Curcumin inhibits the reaction [Tobacco Smoke Pollution results in increased expression of CDH2 mRNA]; Curcumin inhibits the reaction [Tobacco Smoke Pollution results in increased expression of CDH2 protein] Curcumin inhibits the reaction [Lipopolysaccharides results in increased expression of CDH2 protein]; ICAM1 protein affects the reaction [Curcumin inhibits the reaction [Lipopolysaccharides results in increased expression of CDH2 protein]] |
CTD |
PMID:26191140 PMID:35549587 |
|
NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
decreases expression |
EXP ISO |
Curcumin results in decreased expression of CDK1 mRNA Curcumin results in decreased expression of CDK1 mRNA; Curcumin results in decreased expression of CDK1 protein |
CTD |
PMID:17148446 PMID:18299980 PMID:19401701 PMID:22258452 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
multiple interactions decreases expression |
ISO |
Curcumin inhibits the reaction [bisphenol A results in increased expression of CDK2 protein] Curcumin results in decreased expression of CDK2 protein Curcumin analog results in decreased expression of CDK2 mRNA; Curcumin results in decreased expression of CDK2 protein |
CTD |
PMID:19501152 PMID:23222814 PMID:26409325 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
decreases expression |
ISO |
Curcumin analog results in decreased expression of CDK4 mRNA; Curcumin results in decreased expression of CDK4 protein |
CTD |
PMID:18156803 PMID:24211270 PMID:26409325 |
|
NCBI chr 7:62,885,647...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Cdk5 |
cyclin-dependent kinase 5 |
decreases expression |
ISO |
Curcumin analog results in decreased expression of CDK5 mRNA |
CTD |
PMID:26409325 |
|
NCBI chr 4:10,754,682...10,760,110
Ensembl chr 4:10,754,687...10,760,112
|
|
G |
Cdk6 |
cyclin-dependent kinase 6 |
decreases expression |
ISO |
Curcumin results in decreased expression of CDK6 protein |
CTD |
PMID:18156803 |
|
NCBI chr 4:30,637,650...30,829,688
Ensembl chr 4:30,646,460...30,829,634
|
|
G |
Cdk7 |
cyclin-dependent kinase 7 |
decreases expression |
ISO |
Curcumin analog results in decreased expression of CDK7 mRNA |
CTD |
PMID:26409325 |
|
NCBI chr 2:31,840,545...31,865,447
Ensembl chr 2:31,840,558...31,865,383
|
|
G |
Cdk9 |
cyclin-dependent kinase 9 |
decreases expression |
ISO |
Curcumin analog results in decreased expression of CDK9 mRNA |
CTD |
PMID:26409325 |
|
NCBI chr 3:15,996,467...16,001,315
Ensembl chr 3:15,996,468...16,002,410
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions increases expression decreases expression |
ISO EXP |
[Arsenic Trioxide co-treated with Curcumin] results in increased expression of CDKN1A protein; [bicalutamide co-treated with Curcumin co-treated with Quercetin] results in increased expression of CDKN1A protein; [Curcumin binds to and results in increased activity of VDR protein] which results in increased expression of CDKN1A mRNA; [Curcumin co-treated with Quercetin] results in increased expression of CDKN1A protein; [piperine co-treated with Curcumin] results in decreased expression of CDKN1A protein; AR protein affects the reaction [[Curcumin co-treated with Quercetin] results in increased expression of CDKN1A protein]; Curcumin inhibits the reaction [bisphenol A results in decreased expression of CDKN1A protein]; Dihydrotestosterone inhibits the reaction [[Curcumin co-treated with Quercetin] results in increased expression of CDKN1A protein]; EGR1 protein affects the reaction [Curcumin results in increased expression of CDKN1A protein]; EGR1 protein promotes the reaction [Curcumin results in increased expression of CDKN1A mRNA]; MAPK1 protein affects the reaction [Curcumin results in increased expression of CDKN1A mRNA]; MAPK8 protein affects the reaction [Curcumin results in increased expression of CDKN1A mRNA]; TNFSF10 protein promotes the reaction [Curcumin results in increased expression of CDKN1A protein]; Vitamin E inhibits the reaction [Curcumin results in decreased expression of CDKN1A protein] [Curcumin co-treated with Quercetin] inhibits the reaction [Benzo(a)pyrene results in decreased expression of CDKN1A protein]; Curcumin inhibits the reaction [Benzo(a)pyrene results in decreased expression of CDKN1A protein] Curcumin results in increased expression of CDKN1A; Curcumin results in increased expression of CDKN1A mRNA; Curcumin results in increased expression of CDKN1A protein [Curcumin results in decreased expression of MDM2 protein] which results in decreased expression of CDKN1A mRNA; Curcumin results in decreased expression of CDKN1A protein Buthionine Sulfoximine inhibits the reaction [Curcumin results in increased expression of CDKN1A protein] |
CTD |
PMID:15713895 PMID:15738001 PMID:17148446 PMID:17332326 PMID:17602960 PMID:18156803 PMID:18161303 PMID:18226269 PMID:18316600 PMID:18593936 PMID:20153625 PMID:23222814 PMID:25644192 PMID:25822711 PMID:27132804 PMID:27430728 PMID:28681665 PMID:30935902 PMID:33582110 More...
|
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
increases expression multiple interactions decreases expression |
ISO EXP |
Curcumin results in increased expression of CDKN1B mRNA; Curcumin results in increased expression of CDKN1B protein Buthionine Sulfoximine inhibits the reaction [Curcumin results in increased expression of CDKN1B protein] [arsenic trioxide co-treated with Curcumin] results in increased expression of CDKN1B protein; [Curcumin co-treated with Quercetin] results in increased expression of CDKN1B protein; AR protein affects the reaction [[Curcumin co-treated with Quercetin] results in increased expression of CDKN1B protein]; Dihydrotestosterone inhibits the reaction [[Curcumin co-treated with Quercetin] results in increased expression of CDKN1B protein]; TNFSF10 protein promotes the reaction [Curcumin results in increased expression of CDKN1B protein] Curcumin results in decreased expression of CDKN1B protein |
CTD |
PMID:15713895 PMID:17602960 PMID:18156803 PMID:18226269 PMID:18593936 PMID:21594647 PMID:25822711 PMID:27132804 PMID:27430728 More...
|
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
decreases expression increases expression |
ISO |
Curcumin results in decreased expression of CDKN2A protein Curcumin results in increased expression of CDKN2A protein |
CTD |
PMID:17148446 PMID:18156803 |
|
NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
|
|
G |
Cdkn2d |
cyclin dependent kinase inhibitor 2D |
decreases expression |
EXP |
Curcumin results in decreased expression of CDKN2D mRNA |
CTD |
PMID:18299980 |
|
NCBI chr 8:19,831,874...19,834,640
Ensembl chr 8:19,831,866...19,834,674
|
|
G |
Cdx2 |
caudal type homeo box 2 |
increases expression |
EXP ISO |
Curcumin results in increased expression of CDX2 mRNA |
CTD |
PMID:18299980 PMID:27237783 |
|
NCBI chr12:7,726,798...7,733,142
Ensembl chr12:7,726,798...7,733,142
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
multiple interactions |
ISO |
Curcumin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CEBPA mRNA]; Curcumin inhibits the reaction [butylbenzyl phthalate promotes the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of CEBPA mRNA]]; Curcumin inhibits the reaction [Dietary Fats results in increased expression of CEBPA mRNA] |
CTD |
PMID:19297423 PMID:28595985 |
|
NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
multiple interactions |
ISO |
Curcumin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of CEBPB mRNA] |
CTD |
PMID:18200517 |
|
NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473
|
|
G |
Ces1d |
carboxylesterase 1D |
multiple interactions |
ISO |
Curcumin inhibits the reaction [Trinitrobenzenesulfonic Acid results in decreased expression of CES1 mRNA] |
CTD |
PMID:18200517 |
|
NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035
|
|
G |
Ces3a |
carboxylesterase 3a |
multiple interactions |
ISO |
Curcumin inhibits the reaction [Trinitrobenzenesulfonic Acid results in decreased expression of CES3 mRNA] |
CTD |
PMID:18200517 |
|
NCBI chr19:32,992,386...33,000,562
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
multiple interactions decreases expression |
ISO |
Curcumin inhibits the reaction [Oxygen deficiency results in increased expression of CFLAR mRNA]; Curcumin inhibits the reaction [TNF protein results in increased expression of CFLAR mRNA] Curcumin results in decreased expression of CFLAR protein |
CTD |
PMID:16173963 PMID:16219905 PMID:23452621 |
|
NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034
|
|
G |
Cftr |
CF transmembrane conductance regulator |
multiple interactions increases activity affects localization |
ISO |
[PRKCA protein results in increased phosphorylation of CFTR protein] promotes the reaction [Curcumin results in increased activity of CFTR protein]; Adenosine Triphosphate affects the reaction [Curcumin results in increased activity of CFTR protein mutant form]; Curcumin analog inhibits the reaction [CFTR protein results in increased export of Hyaluronic Acid] Curcumin results in increased activity of CFTR protein; Curcumin results in increased activity of CFTR protein mutant form Curcumin affects the localization of CFTR protein mutant form Curcumin affects the folding of and affects the localization of CFTR protein mutant form |
CTD |
PMID:15105504 PMID:15280357 PMID:15582996 PMID:17178710 PMID:23978416 |
|
NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756
|
|
G |
Chat |
choline O-acetyltransferase |
multiple interactions |
EXP |
Curcumin inhibits the reaction [sodium arsenite results in decreased expression of CHAT protein] |
CTD |
PMID:21839772 |
|
NCBI chr16:7,657,362...7,717,093
Ensembl chr16:7,657,362...7,717,093
|
|
G |
Chek1 |
checkpoint kinase 1 |
decreases response to substance increases activity increases phosphorylation |
ISO |
CHEK1 protein results in decreased susceptibility to Curcumin Curcumin results in increased activity of CHEK1 protein Curcumin results in increased phosphorylation of CHEK1 protein |
CTD |
PMID:18602917 PMID:19401701 |
|
NCBI chr 8:36,420,565...36,443,477
Ensembl chr 8:36,420,569...36,441,009
|
|
G |
Chek2 |
checkpoint kinase 2 |
multiple interactions increases phosphorylation |
ISO |
[Curcumin co-treated with Dihydrotestosterone] results in increased phosphorylation of CHEK2 protein; [Curcumin co-treated with Metribolone] results in increased phosphorylation of CHEK2 protein; [Isoflavones co-treated with Curcumin] results in increased phosphorylation of CHEK2 protein; Flutamide inhibits the reaction [[Dihydrotestosterone co-treated with Curcumin] results in increased phosphorylation of CHEK2 protein] Curcumin results in increased phosphorylation of CHEK2 protein |
CTD |
PMID:21134073 |
|
NCBI chr12:45,788,823...45,821,382
Ensembl chr12:45,788,827...45,821,286
|
|
G |
Chrm2 |
cholinergic receptor, muscarinic 2 |
multiple interactions |
EXP |
Curcumin inhibits the reaction [sodium arsenite results in decreased expression of CHRM2 mRNA] |
CTD |
PMID:24952339 |
|
NCBI chr 4:65,015,408...65,149,104
Ensembl chr 4:65,014,144...65,149,103
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
multiple interactions decreases activity |
ISO |
Curcumin inhibits the reaction [TNF protein results in increased activity of CHUK protein]; Curcumin inhibits the reaction [TNFSF11 protein results in increased activity of CHUK protein] Curcumin results in decreased activity of CHUK protein |
CTD |
PMID:15129424 PMID:15489888 PMID:16023083 PMID:16219905 |
|
NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065
|
|
G |
Ckb |
creatine kinase B |
multiple interactions |
EXP |
Curcumin inhibits the reaction [Doxorubicin results in increased expression of [CKM protein binds to CKB protein]]; Curcumin inhibits the reaction [lead acetate results in increased secretion of [CKM protein binds to CKB protein]] |
CTD |
PMID:21378372 PMID:29315967 |
|
NCBI chr 6:130,729,420...130,732,301
Ensembl chr 6:130,729,423...130,732,315
|
|
G |
Ckm |
creatine kinase, M-type |
multiple interactions |
EXP |
Curcumin inhibits the reaction [Doxorubicin results in increased expression of [CKM protein binds to CKB protein]]; Curcumin inhibits the reaction [lead acetate results in increased secretion of [CKM protein binds to CKB protein]] |
CTD |
PMID:21378372 PMID:29315967 |
|
NCBI chr 1:79,061,390...79,071,721
Ensembl chr 1:79,061,456...79,071,720
|
|
G |
Clca4 |
chloride channel accessory 4 |
multiple interactions |
ISO |
Curcumin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of CLCA4A mRNA] |
CTD |
PMID:18200517 |
|
NCBI chr 2:233,883,625...233,904,993
Ensembl chr 2:233,883,851...233,903,089
|
|
G |
Clcn6 |
chloride voltage-gated channel 6 |
decreases expression |
ISO |
Curcumin results in decreased expression of CLCN6 mRNA |
CTD |
PMID:17198877 |
|
NCBI chr 5:158,434,299...158,465,174
Ensembl chr 5:158,434,299...158,465,059
|
|
G |
Cldn1 |
claudin 1 |
multiple interactions |
ISO |
Curcumin inhibits the reaction [deoxynivalenol results in decreased expression of CLDN1 mRNA]; Curcumin inhibits the reaction [deoxynivalenol results in decreased expression of CLDN1 protein] |
CTD |
PMID:35817260 |
|
NCBI chr11:74,421,569...74,436,728
Ensembl chr11:74,421,569...74,436,724
|
|
G |
Cldn2 |
claudin 2 |
multiple interactions |
EXP |
Curcumin inhibits the reaction [maleic acid results in decreased expression of CLDN2] |
CTD |
PMID:25119790 |
|
NCBI chr X:103,459,870...103,473,794
Ensembl chr X:103,459,780...103,474,838
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions decreases expression |
EXP ISO |
Buthionine Sulfoximine inhibits the reaction [Curcumin results in decreased expression of COL1A1 mRNA]; Buthionine Sulfoximine inhibits the reaction [Curcumin results in decreased expression of COL1A1 protein]; Curcumin analog inhibits the reaction [Glucose results in increased expression of COL1A1 mRNA]; Curcumin inhibits the reaction [Bleomycin results in increased expression of COL1A1 mRNA]; Curcumin inhibits the reaction [Bleomycin results in increased expression of COL1A1 protein]; Curcumin inhibits the reaction [Carbon Tetrachloride results in increased expression of COL1A1 mRNA]; Curcumin inhibits the reaction [Glucose results in increased expression of COL1A1 mRNA]; Curcumin inhibits the reaction [Thioacetamide results in increased expression of COL1A1 mRNA] Curcumin analog inhibits the reaction [Streptozocin results in increased expression of COL1A1 mRNA]; Curcumin inhibits the reaction [Streptozocin results in increased expression of COL1A1 mRNA] Curcumin results in decreased expression of COL1A1 mRNA; Curcumin results in decreased expression of COL1A1 protein |
CTD |
PMID:17355460 PMID:17434272 PMID:17531121 PMID:17602960 PMID:17965732 PMID:18006644 PMID:28700904 More...
|
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Col1a2 |
collagen type I alpha 2 chain |
multiple interactions |
ISO |
Curcumin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of COL1A2 mRNA] |
CTD |
PMID:18200517 |
|
NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867
|
|
G |
Col27a1 |
collagen type XXVII alpha 1 chain |
increases expression |
EXP |
Curcumin results in increased expression of COL27A1 mRNA |
CTD |
PMID:18299980 |
|
NCBI chr 5:76,647,302...76,765,987
Ensembl chr 5:76,647,429...76,765,174
|
|
G |
Col2a1 |
collagen type II alpha 1 chain |
increases expression multiple interactions |
ISO |
Curcumin results in increased expression of COL2A1 mRNA; Curcumin results in increased expression of COL2A1 protein [resveratrol co-treated with Curcumin] results in increased expression of COL2A1 protein |
CTD |
PMID:18321735 PMID:19889203 |
|
NCBI chr 7:129,098,489...129,127,620
Ensembl chr 7:129,098,786...129,127,546
|
|
G |
Col3a1 |
collagen type III alpha 1 chain |
multiple interactions |
EXP |
Curcumin inhibits the reaction [Carbon Tetrachloride results in increased expression of COL3A1 mRNA] |
CTD |
PMID:22683883 |
|
NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547
|
|
G |
Col4a1 |
collagen type IV alpha 1 chain |
increases expression multiple interactions |
ISO EXP |
Curcumin results in increased expression of COL4A1 mRNA Curcumin analog inhibits the reaction [Glucose results in increased expression of COL4A1 mRNA]; Curcumin inhibits the reaction [Glucose results in increased expression of COL4A1 mRNA] Curcumin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of COL4A1 mRNA] |
CTD |
PMID:18200517 PMID:21594647 PMID:28700904 |
|
NCBI chr16:78,183,533...78,294,412
Ensembl chr16:78,183,533...78,294,412
|
|
G |
Col4a2 |
collagen type IV alpha 2 chain |
multiple interactions |
ISO |
Curcumin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of COL4A2 mRNA] |
CTD |
PMID:18200517 |
|
NCBI chr16:78,047,591...78,183,360
Ensembl chr16:78,047,602...78,183,839
|
|
G |
Col4a5 |
collagen type IV alpha 5 chain |
decreases expression |
ISO |
Curcumin results in decreased expression of COL4A5 mRNA |
CTD |
PMID:15713895 |
|
NCBI chr X:105,118,762...105,322,699
Ensembl chr X:105,118,820...105,322,692
|
|
G |
Col5a1 |
collagen type V alpha 1 chain |
multiple interactions |
ISO |
Curcumin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of COL5A1 mRNA] |
CTD |
PMID:18200517 |
|
NCBI chr 3:11,208,429...11,356,715
Ensembl chr 3:11,208,512...11,354,588
|
|
G |
Col5a2 |
collagen type V alpha 2 chain |
multiple interactions |
ISO |
Curcumin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of COL5A2 mRNA] |
CTD |
PMID:18200517 |
|
NCBI chr 9:47,448,736...47,598,396
Ensembl chr 9:47,448,736...47,598,154
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
increases expression |
ISO |
Curcumin results in increased expression of CPT1A mRNA |
CTD |
PMID:19297423 |
|
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
increases expression multiple interactions increases phosphorylation |
EXP ISO |
Curcumin results in increased expression of CREB1 mRNA 1,3-dihydro-1-(1-((4-(6-phenyl-1H-imidazo(4,5-g)quinoxalin-7-yl)phenyl)methyl)-4-piperidinyl)-2H-benzimidazol-2-one inhibits the reaction [Curcumin inhibits the reaction [sodium arsenite results in decreased phosphorylation of CREB1 protein]]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Curcumin inhibits the reaction [sodium arsenite results in decreased phosphorylation of CREB1 protein]]; Curcumin inhibits the reaction [sodium arsenite results in decreased phosphorylation of CREB1 protein] [Docosahexaenoic Acids co-treated with Curcumin] results in increased expression of CREB1 mRNA; Curcumin inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of CREB1 protein] Curcumin results in increased phosphorylation of CREB1 protein |
CTD |
PMID:17022948 PMID:18299980 PMID:22911773 PMID:27966075 PMID:29723552 PMID:32735850 More...
|
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Creb3 |
cAMP responsive element binding protein 3 |
increases expression |
EXP |
Curcumin results in increased expression of CREB3 mRNA |
CTD |
PMID:18299980 |
|
NCBI chr 5:57,817,835...57,823,171
Ensembl chr 5:57,817,832...57,824,390
|
|
G |
Crebbp |
CREB binding protein |
multiple interactions |
ISO |
Curcumin inhibits the reaction [Dihydrotestosterone promotes the reaction [CREBBP protein binds to KLK3 enhancer]] |
CTD |
PMID:22258452 |
|
NCBI chr10:11,335,551...11,461,888
Ensembl chr10:11,335,953...11,461,888
|
|
G |
Crp |
C-reactive protein |
multiple interactions |
EXP ISO |
Curcumin analog inhibits the reaction [Copper Sulfate results in increased secretion of CRP protein]; Curcumin inhibits the reaction [Copper Sulfate results in increased secretion of CRP protein]; Curcumin inhibits the reaction [Fructose results in increased expression of CRP protein]; Curcumin inhibits the reaction [lead acetate results in increased secretion of CRP protein] [Curcumin co-treated with Niacin co-treated with ZM 241385] inhibits the reaction [Rotenone results in increased expression of CRP protein]; Curcumin inhibits the reaction [Rotenone results in increased expression of CRP protein] |
CTD |
PMID:21378372 PMID:26713546 PMID:30431687 PMID:31820278 |
|
NCBI chr13:85,131,635...85,175,179
Ensembl chr13:85,124,977...85,175,178
|
|
G |
Cryab |
crystallin, alpha B |
multiple interactions |
ISO EXP |
Curcumin promotes the reaction [arsenite results in increased expression of CRYAB protein] [Curcumin co-treated with arsenite] results in increased expression of CRYAB mRNA; [Curcumin co-treated with Cadmium Chloride] results in increased expression of CRYAB protein; Curcumin promotes the reaction [arsenite results in increased expression of CRYAB protein] |
CTD |
PMID:9764755 |
|
NCBI chr 8:51,093,441...51,099,161
Ensembl chr 8:51,093,441...51,099,157
|
|
G |
Cs |
citrate synthase |
affects expression |
EXP |
Curcumin affects the expression of CS mRNA |
CTD |
PMID:18539377 |
|
NCBI chr 7:758,074...791,421
Ensembl chr 7:758,345...791,421
|
|
G |
Csf1 |
colony stimulating factor 1 |
multiple interactions |
ISO |
Curcumin inhibits the reaction [CSF1 protein results in increased phosphorylation of CSF1R protein] |
CTD |
PMID:15129424 |
|
NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704
|
|
G |
Csf1r |
colony stimulating factor 1 receptor |
multiple interactions increases expression |
ISO |
Curcumin inhibits the reaction [CSF1 protein results in increased phosphorylation of CSF1R protein] Curcumin results in increased expression of CSF1R mRNA |
CTD |
PMID:15129424 PMID:22714040 |
|
NCBI chr18:54,546,673...54,590,418
Ensembl chr18:54,546,659...54,590,415
|
|
G |
Csf2ra |
colony stimulating factor 2 receptor subunit alpha |
increases expression |
ISO |
Curcumin results in increased expression of CSF2RA mRNA |
CTD |
PMID:22714040 |
|
NCBI chr14:98,089...103,261
Ensembl chr14:89,172...103,128
|
|
G |
Csf2rb |
colony stimulating factor 2 receptor subunit beta |
multiple interactions |
ISO |
Curcumin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of CSF2RB mRNA] |
CTD |
PMID:18200517 |
|
NCBI chr 7:109,876,919...109,901,589
Ensembl chr 7:109,886,425...109,904,157
|
|
G |
Ctnnb1 |
catenin beta 1 |
decreases expression increases expression multiple interactions decreases phosphorylation increases degradation |
ISO EXP |
Curcumin analog results in decreased expression of CTNNB1 mRNA; Curcumin results in decreased expression of CTNNB1 mRNA; Curcumin results in decreased expression of CTNNB1 protein Curcumin results in increased expression of CTNNB1 mRNA Curcumin inhibits the reaction [bisphenol A results in decreased expression of CTNNB1 mRNA]; Curcumin results in decreased phosphorylation of and affects the localization of CTNNB1 protein Curcumin results in decreased phosphorylation of CTNNB1 protein [piperine co-treated with Curcumin] results in decreased expression of CTNNB1 protein; Curcumin inhibits the reaction [CTNNB1 protein binds to TCF7L2 protein]; Curcumin inhibits the reaction [IL1B protein results in increased expression of CTNNB1 protein]; Curcumin results in decreased activity of [CTNNB1 protein binds to TCF7L2 protein]; Vitamin E inhibits the reaction [Curcumin results in decreased expression of CTNNB1 protein] Curcumin analog results in increased degradation of CTNNB1 protein; Curcumin results in increased degradation of CTNNB1 protein |
CTD |
PMID:10783313 PMID:17041101 PMID:19294764 PMID:19573523 PMID:25963729 PMID:27645308 PMID:30935902 More...
|
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Ctsb |
cathepsin B |
multiple interactions decreases expression |
EXP ISO |
Curcumin inhibits the reaction [Isoproterenol results in increased activity of CTSB protein] Curcumin analog results in decreased expression of CTSB mRNA |
CTD |
PMID:8534267 PMID:26409325 |
|
NCBI chr15:37,389,636...37,410,508
Ensembl chr15:37,389,629...37,410,500
|
|
G |
Ctsd |
cathepsin D |
multiple interactions decreases expression |
EXP ISO |
Curcumin inhibits the reaction [Isoproterenol results in decreased activity of CTSD protein]; Curcumin inhibits the reaction [Isoproterenol results in increased activity of CTSD protein] Curcumin analog results in decreased expression of CTSD mRNA |
CTD |
PMID:8534267 PMID:26409325 |
|
NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488
|
|
G |
Ctss |
cathepsin S |
decreases expression |
ISO |
Curcumin results in decreased expression of CTSS mRNA |
CTD |
PMID:19555370 |
|
NCBI chr 2:183,089,192...183,114,483
Ensembl chr 2:183,086,437...183,114,483
|
|
G |
Cxcl1 |
C-X-C motif chemokine ligand 1 |
multiple interactions decreases expression |
ISO |
NFKBIA protein affects the reaction [Curcumin results in decreased expression of CXCL1 mRNA] Curcumin results in decreased expression of CXCL1 mRNA; Curcumin results in decreased expression of CXCL1 protein |
CTD |
PMID:17999991 |
|
NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
multiple interactions |
ISO |
Curcumin inhibits the reaction [CXCL12 protein results in increased expression of CXCR4 mRNA]; Curcumin inhibits the reaction [CXCL12 protein results in increased phosphorylation of AKT1 protein]; Curcumin inhibits the reaction [CXCL12 protein results in increased phosphorylation of NOS3 protein] |
CTD |
PMID:18660423 |
|
NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168
|
|
G |
Cxcl14 |
C-X-C motif chemokine ligand 14 |
decreases expression |
ISO |
Curcumin results in decreased expression of CXCL14 mRNA |
CTD |
PMID:19555370 |
|
NCBI chr17:8,317,933...8,325,956
Ensembl chr17:8,317,933...8,324,839
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
decreases expression multiple interactions |
ISO EXP |
Curcumin results in decreased expression of CXCL2 mRNA; Curcumin results in decreased expression of CXCL2 protein Curcumin inhibits the reaction [Fluorouracil results in increased expression of CXCL2 mRNA]; Curcumin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of CXCL2 mRNA] Curcumin inhibits the reaction [[TNF protein co-treated with IL1B protein] results in increased secretion of CXCL2 protein] NFKBIA protein affects the reaction [Curcumin results in decreased expression of CXCL2 mRNA] |
CTD |
PMID:17999991 PMID:18001810 PMID:18200517 PMID:27194111 |
|
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
decreases expression multiple interactions |
ISO |
Curcumin results in decreased expression of CXCL1 mRNA; Curcumin results in decreased expression of CXCL1 protein Curcumin inhibits the reaction [Fluorouracil results in increased expression of CXCL1 mRNA]; Curcumin inhibits the reaction [Fluorouracil results in increased expression of CXCL1 protein] NFKBIA protein affects the reaction [Curcumin results in decreased expression of CXCL1 mRNA] |
CTD |
PMID:17999991 PMID:27194111 |
|
NCBI chr14:17,270,146...17,289,458
Ensembl chr14:17,270,146...17,289,511
|
|
G |
Cxcr1 |
C-X-C motif chemokine receptor 1 |
increases expression |
ISO |
Curcumin results in increased expression of CXCR1 protein |
CTD |
PMID:12216086 |
|
NCBI chr 9:75,768,124...75,771,122
Ensembl chr 9:75,766,770...75,771,084
|
|
G |
Cxcr2 |
C-X-C motif chemokine receptor 2 |
increases expression |
ISO |
Curcumin results in increased expression of CXCR2 protein |
CTD |
PMID:12216086 |
|
NCBI chr 9:75,729,493...75,735,868
Ensembl chr 9:75,729,115...75,739,425
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
decreases expression multiple interactions |
ISO |
Curcumin results in decreased expression of CXCR4 mRNA Curcumin inhibits the reaction [CXCL12 protein results in increased expression of CXCR4 mRNA] |
CTD |
PMID:17198877 PMID:18660423 |
|
NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883
|
|
G |
Cycs |
cytochrome c, somatic |
affects localization multiple interactions |
ISO |
Curcumin affects the localization of CYCS protein [Arsenic Trioxide co-treated with Curcumin] results in increased expression of CYCS protein; [Curcumin binds to 4-bis(2-chloroethyl)aminobenzaldehyde] which results in increased expression of CYCS protein |
CTD |
PMID:19235267 PMID:27430728 PMID:33617879 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions increases activity increases expression decreases activity decreases expression |
ISO EXP |
Acetylcysteine affects the reaction [Curcumin affects the reaction [6-formylindolo(3,2-b)carbazole results in increased activity of CYP1A1 protein]]; Buthionine Sulfoximine affects the reaction [Curcumin affects the reaction [6-formylindolo(3,2-b)carbazole results in increased activity of CYP1A1 protein]]; Curcumin affects the reaction [6-formylindolo(3,2-b)carbazole results in increased activity of CYP1A1 protein]; Curcumin affects the reaction [6-formylindolo(3,2-b)carbazole results in increased expression of CYP1A1 mRNA]; Curcumin inhibits the reaction [6-formylindolo(3,2-b)carbazole results in increased activity of CYP1A1 protein]; Curcumin inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; Curcumin inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 protein]; Curcumin promotes the reaction [6-formylindolo(3,2-b)carbazole results in increased expression of CYP1A1 mRNA]; decitabine affects the reaction [Curcumin affects the reaction [6-formylindolo(3,2-b)carbazole results in increased expression of CYP1A1 mRNA]]; trichostatin A affects the reaction [Curcumin affects the reaction [6-formylindolo(3,2-b)carbazole results in increased expression of CYP1A1 mRNA]] Curcumin inhibits the reaction [Aflatoxin B1 results in increased activity of CYP1A1 protein]; Curcumin inhibits the reaction [beta-Naphthoflavone results in increased activity of CYP1A1 protein]; Curcumin inhibits the reaction [Carbon Tetrachloride results in decreased activity of CYP1A1 protein] Curcumin results in increased activity of CYP1A1 protein Curcumin results in increased expression of CYP1A1 mRNA Curcumin results in decreased activity of CYP1A1 protein Curcumin results in decreased expression of CYP1A1 mRNA Curcumin inhibits the reaction [Benzo(a)pyrene results in increased activity of CYP1A1 protein]; Curcumin inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]; Curcumin inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 protein]; Curcumin inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA] |
CTD |
PMID:11454723 PMID:12628514 PMID:15841493 PMID:16288784 PMID:17012224 PMID:17880909 PMID:18321868 PMID:19018768 PMID:20015472 PMID:20816778 PMID:22867086 PMID:27041069 More...
|
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
decreases activity multiple interactions |
ISO EXP |
Curcumin results in decreased activity of CYP1A2 protein Curcumin inhibits the reaction [Carbon Tetrachloride results in decreased activity of CYP1A2 protein] Curcumin inhibits the reaction [Aflatoxin B1 results in decreased expression of CYP1A2 mRNA]; Curcumin inhibits the reaction [Benzo(a)pyrene results in increased activity of CYP1A2 protein]; Curcumin inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A2 mRNA]; Curcumin inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A2 protein] |
CTD |
PMID:15841493 PMID:16288784 PMID:18321868 PMID:35063475 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
multiple interactions decreases expression |
ISO |
Curcumin inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1B1 mRNA]; Curcumin inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1B1 protein] Curcumin results in decreased expression of CYP1B1 mRNA |
CTD |
PMID:17637178 PMID:19018768 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp24a1 |
cytochrome P450, family 24, subfamily a, polypeptide 1 |
multiple interactions increases expression |
ISO |
[Curcumin binds to and results in increased activity of VDR protein] which results in increased expression of CYP24A1 mRNA Curcumin results in increased expression of CYP24A1 protein |
CTD |
PMID:20153625 |
|
NCBI chr 3:159,275,947...159,290,383
Ensembl chr 3:159,275,947...159,290,383
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
affects expression multiple interactions |
EXP |
Curcumin affects the expression of CYP2B1 protein Curcumin inhibits the reaction [CYP2B1 protein results in increased metabolism of nitrosobenzylmethylamine] |
CTD |
PMID:16805852 |
|
NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
multiple interactions |
EXP |
Curcumin inhibits the reaction [Carbon Tetrachloride results in decreased activity of CYP2C9 protein] |
CTD |
PMID:16288784 |
|
NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
decreases expression |
ISO |
Curcumin results in decreased expression of CYP2D6 mRNA |
CTD |
PMID:33582110 |
|
NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
affects expression multiple interactions increases expression |
EXP ISO |
Curcumin affects the expression of CYP2E1 protein Curcumin inhibits the reaction [Acetaminophen results in increased expression of CYP2E1 mRNA] Curcumin inhibits the reaction [Acetaminophen results in increased expression of CYP2E1 mRNA]; Curcumin inhibits the reaction [Acetaminophen results in increased expression of CYP2E1 protein]; Curcumin metabolite inhibits the reaction [Acetaminophen results in increased expression of CYP2E1 mRNA]; Curcumin metabolite inhibits the reaction [Acetaminophen results in increased expression of CYP2E1 protein]; Curcumin metabolite promotes the reaction [Acetaminophen results in decreased activity of CYP2E1 protein] Curcumin inhibits the reaction [Acrylamide results in increased expression of CYP2E1 protein] Curcumin results in increased expression of CYP2E1 mRNA |
CTD |
PMID:16805852 PMID:18539377 PMID:24508477 PMID:30423402 PMID:33350580 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
decreases expression multiple interactions increases expression |
ISO |
Curcumin results in decreased expression of CYP3A4 mRNA [Curcumin binds to and results in increased activity of VDR protein] which results in increased expression of CYP3A4 mRNA; Curcumin inhibits the reaction [Calcitriol results in increased expression of and results in increased activity of CYP3A4 protein]; Curcumin inhibits the reaction [Calcitriol results in increased expression of CYP3A4 mRNA]; Curcumin inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam] Curcumin results in increased expression of CYP3A4 mRNA |
CTD |
PMID:17210444 PMID:17270371 PMID:17965521 PMID:18385293 PMID:20153625 PMID:20816778 More...
|
|
NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp4a3 |
cytochrome P450, family 4, subfamily a, polypeptide 3 |
increases expression |
EXP |
Curcumin results in increased expression of CYP4A3 mRNA |
CTD |
PMID:18539377 |
|
NCBI chr 5:129,097,571...129,115,488
Ensembl chr 5:129,097,926...129,115,463
|
|
G |
Cyth4 |
cytohesin 4 |
increases expression |
ISO |
Curcumin results in increased expression of CYTH4 mRNA |
CTD |
PMID:17198877 |
|
NCBI chr 7:110,152,232...110,176,741
Ensembl chr 7:110,152,272...110,176,741
|
|
G |
Daxx |
death-domain associated protein |
increases expression |
ISO |
Curcumin results in increased expression of DAXX mRNA |
CTD |
PMID:16101141 |
|
NCBI chr20:4,970,090...4,976,145
Ensembl chr20:4,970,092...4,975,843
|
|
G |
Dbn1 |
drebrin 1 |
multiple interactions |
EXP |
Curcumin inhibits the reaction [Glucose results in decreased expression of DBN1 mRNA] |
CTD |
PMID:23333261 |
|
NCBI chr17:9,150,608...9,164,982
Ensembl chr17:9,150,659...9,164,984
|
|
G |
Dcn |
decorin |
increases expression |
ISO |
Curcumin results in increased expression of DCN mRNA |
CTD |
PMID:21594647 |
|
NCBI chr 7:32,281,252...32,321,291
Ensembl chr 7:32,281,252...32,321,270
|
|
G |
Dcx |
doublecortin |
multiple interactions increases expression |
EXP ISO |
Curcumin inhibits the reaction [bisphenol A results in decreased expression of DCX mRNA] Curcumin inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of DCX protein] Curcumin results in increased expression of DCX mRNA |
CTD |
PMID:25963729 PMID:32735850 |
|
NCBI chr X:107,430,767...107,573,612
Ensembl chr X:107,430,767...107,507,476
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions increases expression |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Curcumin results in increased expression of DDIT3 mRNA]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Curcumin results in increased expression of DDIT3 protein]; Acetylcysteine inhibits the reaction [Curcumin results in increased expression of DDIT3 mRNA]; Buthionine Sulfoximine promotes the reaction [Curcumin results in increased expression of DDIT3 mRNA]; Buthionine Sulfoximine promotes the reaction [Curcumin results in increased expression of DDIT3 protein]; Glutathione inhibits the reaction [Curcumin results in increased expression of DDIT3 mRNA]; Glutathione inhibits the reaction [Curcumin results in increased expression of DDIT3 protein]; PRKCD protein promotes the reaction [Curcumin results in increased expression of DDIT3 mRNA]; rottlerin inhibits the reaction [Curcumin results in increased expression of DDIT3 mRNA]; wortmannin inhibits the reaction [Curcumin results in increased expression of DDIT3 mRNA]; wortmannin inhibits the reaction [Curcumin results in increased expression of DDIT3 protein] Curcumin results in increased expression of DDIT3 mRNA; Curcumin results in increased expression of DDIT3 protein |
CTD |
PMID:16613838 PMID:17171638 PMID:18200517 PMID:18719366 PMID:21793155 PMID:29723631 More...
|
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Ddit4l |
DNA-damage-inducible transcript 4-like |
decreases expression increases expression |
ISO EXP |
Curcumin results in decreased expression of DDIT4L mRNA Curcumin results in increased expression of DDIT4L mRNA |
CTD |
PMID:17999991 PMID:18299980 |
|
NCBI chr 2:226,128,273...226,131,044
Ensembl chr 2:226,128,276...226,131,375
|
|
G |
Dffb |
DNA fragmentation factor subunit beta |
increases expression decreases expression |
ISO |
Curcumin results in increased expression of DFFB mRNA; Curcumin results in increased expression of DFFB protein Curcumin results in decreased expression of DFFB protein |
CTD |
PMID:21397623 PMID:22714040 |
|
NCBI chr 5:164,522,446...164,534,733
Ensembl chr 5:164,522,463...164,534,628
|
|
G |
Dhcr24 |
24-dehydrocholesterol reductase |
decreases expression affects expression |
EXP ISO |
Curcumin results in decreased expression of DHCR24 mRNA Curcumin affects the expression of DHCR24 mRNA |
CTD |
PMID:27208389 |
|
NCBI chr 5:121,344,637...121,368,853
Ensembl chr 5:121,344,575...121,371,137
|
|
G |
Dhcr7 |
7-dehydrocholesterol reductase |
affects expression decreases expression |
ISO EXP |
Curcumin affects the expression of DHCR7 mRNA Curcumin results in decreased expression of DHCR7 mRNA |
CTD |
PMID:27208389 |
|
NCBI chr 1:199,015,081...199,031,055
Ensembl chr 1:199,015,081...199,031,055
|
|
G |
Dhrs1 |
dehydrogenase/reductase 1 |
decreases expression |
ISO |
Curcumin results in decreased expression of DHRS1 mRNA |
CTD |
PMID:17198877 |
|
NCBI chr15:29,236,522...29,243,807
Ensembl chr15:29,236,522...29,243,838
|
|
G |
Diablo |
diablo, IAP-binding mitochondrial protein |
affects localization multiple interactions increases expression increases response to substance |
ISO |
Curcumin affects the localization of DIABLO protein [arsenic trioxide co-treated with Curcumin] results in increased expression of DIABLO protein Curcumin results in increased expression of DIABLO mRNA DIABLO protein results in increased susceptibility to Curcumin |
CTD |
PMID:17277231 PMID:23555722 PMID:27430728 |
|
NCBI chr12:33,055,784...33,070,400
Ensembl chr12:33,055,263...33,070,387
|
|
G |
Dkk1 |
dickkopf WNT signaling pathway inhibitor 1 |
decreases expression multiple interactions |
EXP |
Curcumin results in decreased expression of DKK1 mRNA; Curcumin results in decreased expression of DKK1 protein Curcumin inhibits the reaction [bisphenol A results in increased expression of DKK1 mRNA]; Curcumin inhibits the reaction [bisphenol A results in increased expression of DKK1 protein] |
CTD |
PMID:25963729 |
|
NCBI chr 1:228,381,521...228,385,202
Ensembl chr 1:228,381,521...228,385,202
|
|
G |
Dlg4 |
discs large MAGUK scaffold protein 4 |
multiple interactions |
EXP |
Curcumin inhibits the reaction [sodium arsenite results in decreased expression of DLG4 protein] |
CTD |
PMID:29723552 |
|
NCBI chr10:54,740,700...54,769,097
Ensembl chr10:54,739,470...54,767,153
|
|
G |
Dnajb9 |
DnaJ heat shock protein family (Hsp40) member B9 |
increases expression |
ISO |
Curcumin results in increased expression of DNAJB9 mRNA |
CTD |
PMID:17999991 |
|
NCBI chr 6:61,270,385...61,276,795
Ensembl chr 6:61,269,913...61,275,063
|
|
G |
Dnm1l |
dynamin 1-like |
multiple interactions |
EXP |
Curcumin inhibits the reaction [Potassium Dichromate results in increased expression of DNM1L protein] |
CTD |
PMID:32980475 |
|
NCBI chr11:84,581,216...84,632,382
Ensembl chr11:84,581,216...84,631,482
|
|
G |
Dnmt1 |
DNA methyltransferase 1 |
decreases expression affects expression multiple interactions increases activity |
ISO |
Curcumin results in decreased expression of DNMT1 mRNA; Curcumin results in decreased expression of DNMT1 protein Curcumin analog affects the expression of DNMT1 protein Curcumin promotes the reaction [Quercetin results in increased activity of DNMT1 protein]; Quercetin promotes the reaction [Curcumin results in increased activity of DNMT1 protein] Curcumin analog results in decreased expression of DNMT1 protein |
CTD |
PMID:23593078 PMID:26991801 PMID:27132804 PMID:29228771 |
|
NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659
|
|
G |
Dnmt3a |
DNA methyltransferase 3 alpha |
decreases expression |
ISO |
Curcumin results in decreased expression of DNMT3A mRNA Curcumin analog results in decreased expression of DNMT3A protein |
CTD |
PMID:23593078 PMID:26991801 PMID:29228771 |
|
NCBI chr 6:26,791,517...26,902,161
Ensembl chr 6:26,822,609...26,896,687
|
|
G |
Dnmt3b |
DNA methyltransferase 3 beta |
decreases expression |
ISO |
Curcumin results in decreased expression of DNMT3B mRNA Curcumin analog results in decreased expression of DNMT3B protein |
CTD |
PMID:23593078 PMID:26991801 PMID:29228771 |
|
NCBI chr 3:142,130,592...142,169,124
Ensembl chr 3:142,130,592...142,169,124
|
|
G |
Dram1 |
DNA-damage regulated autophagy modulator 1 |
increases expression |
ISO |
Curcumin results in increased expression of DRAM1 mRNA |
CTD |
PMID:21594647 |
|
NCBI chr 7:22,742,794...22,776,888
Ensembl chr 7:22,742,849...22,776,765
|
|
G |
Drd2 |
dopamine receptor D2 |
multiple interactions |
EXP |
Curcumin inhibits the reaction [sodium arsenite results in decreased expression of DRD2 protein] |
CTD |
PMID:27966075 |
|
NCBI chr 8:49,708,903...49,772,888
Ensembl chr 8:49,708,927...49,772,875
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
increases expression multiple interactions |
ISO EXP |
Curcumin results in increased expression of DUSP1 mRNA Curcumin promotes the reaction [Lipopolysaccharides results in increased phosphorylation of DUSP1 protein] |
CTD |
PMID:15713895 PMID:20885979 |
|
NCBI chr10:16,680,489...16,683,276
|
|
G |
Dusp10 |
dual specificity phosphatase 10 |
increases expression |
ISO |
Curcumin results in increased expression of DUSP10 mRNA |
CTD |
PMID:15713895 PMID:17151092 |
|
NCBI chr13:95,613,716...95,651,716
Ensembl chr13:95,614,292...95,651,716
|
|
G |
Dusp5 |
dual specificity phosphatase 5 |
increases expression |
ISO |
Curcumin results in increased expression of DUSP5 mRNA |
CTD |
PMID:17198877 |
|
NCBI chr 1:252,538,408...252,555,320
Ensembl chr 1:252,538,449...252,551,818
|
|
G |
Dvl1 |
dishevelled segment polarity protein 1 |
multiple interactions decreases expression increases expression |
EXP ISO |
Curcumin inhibits the reaction [bisphenol A results in decreased expression of DVL1 mRNA]; Curcumin inhibits the reaction [bisphenol A results in decreased expression of DVL1 protein] Curcumin results in decreased expression of DVL1 protein Curcumin results in increased expression of DVL1 mRNA; Curcumin results in increased expression of DVL1 protein |
CTD |
PMID:19573523 PMID:25963729 |
|
NCBI chr 5:166,456,989...166,468,733
Ensembl chr 5:166,456,686...166,468,664
|
|
G |
Dynll1 |
dynein light chain LC8-type 1 |
increases expression |
ISO |
Curcumin results in increased expression of DYNLL1 mRNA |
CTD |
PMID:17198877 |
|
NCBI chr12:41,312,367...41,314,742
Ensembl chr12:41,312,367...41,314,741
|
|
G |
Dyrk2 |
dual specificity tyrosine phosphorylation regulated kinase 2 |
decreases activity multiple interactions |
ISO |
Curcumin results in decreased activity of DYRK2 protein [Curcumin binds to 4-nitrobenzaldehyde] which results in decreased activity of DYRK2 protein |
CTD |
PMID:33617879 |
|
NCBI chr 7:54,348,724...54,381,363
Ensembl chr 7:54,349,610...54,380,106
|
|
G |
E2f1 |
E2F transcription factor 1 |
decreases expression |
EXP |
Curcumin results in decreased expression of E2F1 mRNA |
CTD |
PMID:18299980 |
|
NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361
|
|
G |
E2f5 |
E2F transcription factor 5 |
decreases expression |
ISO |
Curcumin results in decreased expression of E2F5 mRNA |
CTD |
PMID:15713895 |
|
NCBI chr 2:86,997,331...87,012,901
Ensembl chr 2:86,997,332...87,012,990
|
|
G |
Ech1 |
enoyl-CoA hydratase 1 |
increases expression |
EXP |
Curcumin results in increased expression of ECH1 mRNA |
CTD |
PMID:18539377 |
|
NCBI chr 1:84,114,494...84,120,788
Ensembl chr 1:84,112,751...84,120,795
|
|
G |
Edaradd |
EDAR associated via death domain |
multiple interactions |
ISO |
Curcumin inhibits the reaction [Oxygen deficiency results in increased expression of EDARADD mRNA] |
CTD |
PMID:23452621 |
|
NCBI chr17:85,866,629...85,910,612
Ensembl chr17:85,656,905...85,910,447
|
|
G |
Edil3 |
EGF like repeats and discoidin domains 3 |
decreases expression |
ISO |
Curcumin results in decreased expression of EDIL3 mRNA |
CTD |
PMID:18421014 |
|
NCBI chr 2:19,890,396...20,405,028
Ensembl chr 2:19,890,373...20,405,008
|
|
G |
Egf |
epidermal growth factor |
multiple interactions decreases activity |
ISO EXP |
Curcumin inhibits the reaction [EGF protein results in increased expression of AQP3 protein]; Curcumin inhibits the reaction [EGF protein results in increased phosphorylation of AKT1 protein]; Curcumin inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; Curcumin inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; Curcumin inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; Curcumin inhibits the reaction [EGF protein results in increased secretion of PTHLH protein] Curcumin results in decreased activity of EGF protein Curcumin inhibits the reaction [EGF protein results in decreased expression of PPARG mRNA]; Curcumin inhibits the reaction [EGF protein results in decreased expression of PPARG protein] |
CTD |
PMID:10851300 PMID:15129424 PMID:15486348 PMID:17372590 PMID:18214481 |
|
NCBI chr 2:218,219,408...218,302,370
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions decreases phosphorylation decreases expression |
ISO EXP |
Curcumin inhibits the reaction [Acrylamide results in increased expression of EGFR protein]; Curcumin inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; Curcumin promotes the reaction [Folfox protocol results in decreased expression of EGFR protein]; Curcumin promotes the reaction [Folfox protocol results in decreased phosphorylation of and results in decreased activity of EGFR protein]; Curcumin results in decreased expression of and results in decreased activity of EGFR protein; Curcumin results in decreased phosphorylation of and results in decreased activity of EGFR protein; Fluorouracil promotes the reaction [Curcumin results in decreased expression of EGFR protein]; Fluorouracil promotes the reaction [Curcumin results in decreased phosphorylation of and results in decreased activity of EGFR protein] Curcumin results in decreased phosphorylation of EGFR protein Curcumin results in decreased expression of EGFR mRNA; Curcumin results in decreased expression of EGFR protein Curcumin inhibits the reaction [Carbon Tetrachloride results in increased expression of EGFR mRNA] Curcumin analog results in decreased expression of EGFR mRNA; Curcumin results in decreased expression of EGFR mRNA; Curcumin results in decreased expression of EGFR protein |
CTD |
PMID:10851300 PMID:15129424 PMID:15486348 PMID:17372590 PMID:17918158 PMID:18006644 PMID:18214481 PMID:18332871 PMID:18719366 PMID:24508477 PMID:26409325 PMID:34994998 More...
|
|
NCBI chr14:91,176,931...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions increases expression decreases expression |
ISO EXP |
EGR1 protein affects the reaction [Curcumin results in increased expression of CDKN1A protein]; EGR1 protein promotes the reaction [Curcumin results in increased expression of CDKN1A mRNA]; pyrazolanthrone inhibits the reaction [Curcumin results in increased expression of EGR1 protein]; U 0126 inhibits the reaction [Curcumin results in increased expression of EGR1 protein] Curcumin results in increased expression of EGR1 mRNA; Curcumin results in increased expression of EGR1 protein Curcumin results in decreased expression of EGR1 mRNA |
CTD |
PMID:17198877 PMID:17999991 PMID:18316600 |
|
NCBI chr18:26,463,333...26,465,531
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Eif1 |
eukaryotic translation initiation factor 1 |
decreases expression |
ISO |
Curcumin results in decreased expression of EIF1 mRNA |
CTD |
PMID:17999991 |
|
NCBI chr10:85,246,751...85,248,842
Ensembl chr10:85,246,764...85,427,327
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
multiple interactions decreases expression decreases phosphorylation |
ISO |
calyculin A inhibits the reaction [Curcumin results in decreased phosphorylation of EIF4EBP1 protein]; Curcumin inhibits the reaction [bisphenol A results in increased expression of EIF4EBP1 protein] Curcumin results in decreased expression of EIF4EBP1 protein |
CTD |
PMID:18790744 PMID:23222814 PMID:34634291 |
|
NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
|
|
G |
Eif4g1 |
eukaryotic translation initiation factor 4 gamma 1 |
decreases phosphorylation |
ISO |
Curcumin results in decreased phosphorylation of EIF4G1 protein |
CTD |
PMID:18790744 |
|
NCBI chr11:80,221,919...80,241,958
Ensembl chr11:80,221,919...80,241,941
|
|
G |
Elf2 |
E74 like ETS transcription factor 2 |
decreases expression |
ISO |
Curcumin results in decreased expression of ELF2 mRNA |
CTD |
PMID:15713895 |
|
NCBI chr 2:135,292,291...135,385,942
Ensembl chr 2:135,294,906...135,385,947
|
|
G |
Elk1 |
ETS transcription factor ELK1 |
multiple interactions increases phosphorylation |
ISO |
Curcumin inhibits the reaction [Oxygen deficiency results in increased expression of ELK1 mRNA]; pyrazolanthrone inhibits the reaction [Curcumin results in increased phosphorylation of ELK1 protein]; U 0126 inhibits the reaction [Curcumin results in increased phosphorylation of ELK1 protein] |
CTD |
PMID:18316600 PMID:23452621 |
|
NCBI chr X:1,138,826...1,155,713
Ensembl chr X:1,139,756...1,155,713
|
|
G |
Emb |
embigin |
multiple interactions |
ISO |
Curcumin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of EMB mRNA] |
CTD |
PMID:18200517 |
|
NCBI chr 2:49,070,509...49,125,042
Ensembl chr 2:49,069,087...49,125,050
|
|
G |
Eno1 |
enolase 1 |
decreases expression |
ISO |
Curcumin results in decreased expression of ENO1 mRNA |
CTD |
PMID:16880289 |
|
NCBI chr 5:160,719,951...160,731,337
Ensembl chr 5:160,719,951...160,731,336
|
|
G |
Entpd5 |
ectonucleoside triphosphate diphosphohydrolase 5 |
increases expression |
EXP |
Curcumin results in increased expression of ENTPD5 mRNA |
CTD |
PMID:18299980 |
|
NCBI chr 6:104,019,095...104,055,311
Ensembl chr 6:104,019,185...104,055,530
|
|
G |
Ep300 |
E1A binding protein p300 |
multiple interactions decreases activity decreases expression affects localization |
ISO EXP |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Curcumin affects the localization of EP300 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Curcumin results in decreased expression of EP300 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Curcumin results in decreased expression of EP300 protein]; Curcumin inhibits the reaction [Dihydrotestosterone promotes the reaction [EP300 protein binds to KLK3 enhancer]] Curcumin results in decreased activity of EP300 protein Curcumin inhibits the reaction [AGT protein modified form promotes the reaction [TP53 protein binds to EP300 protein]]; Curcumin inhibits the reaction [Streptozocin results in increased expression of EP300 mRNA]; Curcumin inhibits the reaction [TP53 protein binds to EP300 protein] Curcumin results in decreased expression of EP300 mRNA; Curcumin results in decreased expression of EP300 protein |
CTD |
PMID:17927689 PMID:22228707 PMID:22258452 PMID:26612707 |
|
NCBI chr 7:113,108,476...113,178,529
Ensembl chr 7:113,106,247...113,136,088 Ensembl chr 7:113,106,247...113,136,088
|
|
G |
Epas1 |
endothelial PAS domain protein 1 |
multiple interactions |
ISO |
Curcumin analog inhibits the reaction [Oxygen deficiency results in increased expression of EPAS1 protein] |
CTD |
PMID:20554536 |
|
NCBI chr 6:7,790,236...7,871,246
Ensembl chr 6:7,790,647...7,871,228
|
|
G |
Epcam |
epithelial cell adhesion molecule |
multiple interactions decreases expression |
ISO |
WWTR1 protein inhibits the reaction [Curcumin results in decreased expression of EPCAM mRNA]; WWTR1 protein inhibits the reaction [Curcumin results in decreased expression of EPCAM protein] Curcumin results in decreased expression of EPCAM mRNA; Curcumin results in decreased expression of EPCAM protein |
CTD |
PMID:33539684 |
|
NCBI chr 6:6,880,142...6,896,103
Ensembl chr 6:6,878,237...6,896,127
|
|
G |
Epo |
erythropoietin |
decreases expression |
ISO |
Curcumin results in decreased expression of EPO mRNA |
CTD |
PMID:16880289 |
|
NCBI chr12:19,204,258...19,207,948
Ensembl chr12:19,204,508...19,207,946
|
|
G |
Epx |
eosinophil peroxidase |
multiple interactions |
ISO |
[Dexamethasone co-treated with Curcumin] inhibits the reaction [[Ovalbumin co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased activity of EPX protein]; Curcumin inhibits the reaction [[Ovalbumin co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased activity of EPX protein] |
CTD |
PMID:34998855 |
|
NCBI chr10:72,666,865...72,677,952
Ensembl chr10:72,666,865...72,677,952
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
multiple interactions increases response to substance increases degradation decreases expression |
ISO |
[ERBB2 protein results in increased susceptibility to Curcumin analog] which results in decreased phosphorylation of AK1 protein; [ERBB2 protein results in increased susceptibility to Curcumin analog] which results in decreased phosphorylation of MAPK1 protein; [ERBB2 protein results in increased susceptibility to Curcumin analog] which results in decreased phosphorylation of MAPK3 protein; Curcumin analog inhibits the reaction [ERBB2 protein results in decreased susceptibility to Doxorubicin]; Curcumin analog inhibits the reaction [ERBB2 protein results in decreased susceptibility to Etoposide]; Curcumin analog inhibits the reaction [ERBB2 protein results in decreased susceptibility to Paclitaxel]; Curcumin analog promotes the reaction [Cycloheximide results in increased degradation of ERBB2 protein]; Curcumin promotes the reaction [Fluorouracil results in decreased phosphorylation of and results in decreased expression of and results in decreased activity of ERBB2 protein]; Curcumin promotes the reaction [Folfox protocol results in decreased expression of and results in decreased phosphorylation of and results in decreased activity of ERBB2 protein]; Curcumin results in decreased expression of and results in decreased phosphorylation of and results in decreased activity of ERBB2 protein ERBB2 protein results in increased susceptibility to Curcumin; ERBB2 protein results in increased susceptibility to Curcumin analog Curcumin analog results in increased degradation of ERBB2 protein Curcumin analog results in decreased expression of ERBB2 mRNA; Curcumin analog results in decreased expression of ERBB2 protein; Curcumin results in decreased expression of ERBB2 mRNA; Curcumin results in decreased expression of ERBB2 protein |
CTD |
PMID:17041101 PMID:17918158 PMID:18719366 PMID:25866362 PMID:26409325 PMID:34291863 More...
|
|
NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078
|
|
G |
Erbb3 |
erb-b2 receptor tyrosine kinase 3 |
multiple interactions decreases expression |
ISO |
Curcumin promotes the reaction [Folfox protocol results in decreased expression of and results in decreased phosphorylation of and results in decreased activity of ERBB3 protein]; Curcumin results in decreased expression of and results in decreased phosphorylation of and results in decreased activity of ERBB3 protein; Fluorouracil promotes the reaction [Curcumin results in decreased expression of and results in decreased phosphorylation of and results in decreased activity of ERBB3 protein] Curcumin analog results in decreased expression of ERBB3 mRNA; Curcumin results in decreased expression of ERBB3 mRNA |
CTD |
PMID:15713895 PMID:17918158 PMID:26409325 |
|
NCBI chr 7:994,549...1,015,876
Ensembl chr 7:996,225...1,015,525
|
|
G |
Ercc1 |
ERCC excision repair 1, endonuclease non-catalytic subunit |
multiple interactions decreases expression |
ISO EXP |
[Curcumin results in decreased expression of ERCC1 protein] which results in increased susceptibility to Cisplatin; Curcumin inhibits the reaction [Glucose results in increased expression of ERCC1 mRNA]; Curcumin inhibits the reaction [Glucose results in increased expression of ERCC1 protein] Curcumin inhibits the reaction [Streptozocin results in increased expression of ERCC1 mRNA] Curcumin results in decreased expression of ERCC1 mRNA; Curcumin results in decreased expression of ERCC1 protein |
CTD |
PMID:17596214 PMID:21493726 PMID:22228707 |
|
NCBI chr 1:78,971,310...79,007,963
Ensembl chr 1:78,996,390...79,007,963
|
|
G |
Ercc4 |
ERCC excision repair 4, endonuclease catalytic subunit |
multiple interactions decreases expression |
EXP ISO |
Curcumin inhibits the reaction [Streptozocin results in increased expression of ERCC4 mRNA] Curcumin inhibits the reaction [Glucose results in increased expression of ERCC4 mRNA]; Curcumin inhibits the reaction [Glucose results in increased expression of ERCC4 protein] Curcumin results in decreased expression of ERCC4 mRNA; Curcumin results in decreased expression of ERCC4 protein |
CTD |
PMID:22228707 |
|
NCBI chr10:2,416,259...2,448,364
Ensembl chr10:2,419,038...2,448,369
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signaling 1 |
decreases expression increases expression |
ISO |
Curcumin results in decreased expression of ERN1 mRNA Curcumin results in increased expression of ERN1 mRNA |
CTD |
PMID:17999991 PMID:29723631 |
|
NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions decreases expression |
ISO |
Curcumin inhibits the reaction [bisphenol A results in increased expression of ESR1 protein]; Curcumin inhibits the reaction [Estradiol results in increased degradation of ESR1 protein]; Curcumin inhibits the reaction [Estradiol results in increased phosphorylation of ESR1 protein]; Curcumin inhibits the reaction [fulvestrant results in increased degradation of ESR1 protein] Curcumin results in decreased expression of ESR1 protein |
CTD |
PMID:15899841 PMID:18347134 PMID:23222814 PMID:24211270 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Ets2 |
ETS proto-oncogene 2, transcription factor |
decreases expression |
ISO |
Curcumin results in decreased expression of ETS2 protein |
CTD |
PMID:17332326 |
|
NCBI chr11:35,021,536...35,038,322
Ensembl chr11:35,021,596...35,038,319
|
|
G |
F2 |
coagulation factor II |
multiple interactions |
EXP |
Curcumin inhibits the reaction [F2 protein results in increased expression of ITGA2B protein]; Curcumin inhibits the reaction [F2 protein results in increased expression of ITGB3 protein]; Curcumin inhibits the reaction [F2 protein results in increased expression of SELE protein]; Curcumin inhibits the reaction [F2 protein results in increased expression of SELP protein] |
CTD |
PMID:18565277 |
|
NCBI chr 3:77,596,196...77,609,486
Ensembl chr 3:77,596,198...77,609,486
|
|
G |
F2r |
coagulation factor II (thrombin) receptor |
multiple interactions |
ISO |
Curcumin inhibits the reaction [Oxygen deficiency results in increased expression of F2R mRNA] |
CTD |
PMID:23452621 |
|
NCBI chr 2:26,869,343...26,885,856
Ensembl chr 2:26,868,404...26,885,870
|
|
G |
F3 |
coagulation factor III, tissue factor |
multiple interactions |
ISO |
Curcumin inhibits the reaction [Heme results in increased expression of F3 mRNA] |
CTD |
PMID:18983524 |
|
NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668
|
|
G |
Fadd |
Fas associated via death domain |
multiple interactions |
ISO |
Curcumin inhibits the reaction [Oxygen deficiency results in increased expression of FADD mRNA] |
CTD |
PMID:23452621 |
|
NCBI chr 1:199,743,200...199,745,746
Ensembl chr 1:199,739,994...199,745,653
|
|
G |
Fads1 |
fatty acid desaturase 1 |
affects expression decreases expression |
ISO EXP |
Curcumin affects the expression of FADS1 mRNA Curcumin results in decreased expression of FADS1 mRNA |
CTD |
PMID:27208389 |
|
NCBI chr 1:206,827,724...206,842,734
Ensembl chr 1:206,827,765...206,842,734
|
|
G |
Fads2 |
fatty acid desaturase 2 |
decreases expression affects expression |
EXP ISO |
Curcumin results in decreased expression of FADS2 mRNA Curcumin affects the expression of FADS2 mRNA |
CTD |
PMID:27208389 |
|
NCBI chr 1:206,707,384...206,747,333
Ensembl chr 1:206,708,783...206,748,789
|
|
G |
Fam120b |
family with sequence similarity 120B |
decreases expression |
ISO |
Curcumin results in decreased expression of FAM120B mRNA |
CTD |
PMID:17999991 |
|
NCBI chr 1:56,320,015...56,385,064
Ensembl chr 1:56,339,129...56,385,061
|
|
G |
Fancd2 |
FA complementation group D2 |
multiple interactions decreases expression |
ISO |
Curcumin inhibits the reaction [Mitomycin results in increased expression of and affects the ubiquitination of FANCD2 protein] Curcumin results in decreased expression of FANCD2 mRNA |
CTD |
PMID:24124520 |
|
NCBI chr 4:146,679,014...146,743,422
Ensembl chr 4:146,679,179...146,743,412
|
|
G |
Fanci |
FA complementation group I |
multiple interactions decreases expression |
ISO |
Curcumin inhibits the reaction [Mitomycin results in increased expression of and affects the ubiquitination of FANCI protein] Curcumin results in decreased expression of FANCI mRNA |
CTD |
PMID:24124520 |
|
NCBI chr 1:133,327,264...133,383,661
Ensembl chr 1:133,327,297...133,383,640
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions |
ISO |
[arsenic trioxide co-treated with Curcumin] results in increased expression of FAS protein |
CTD |
PMID:27430728 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Faslg |
Fas ligand |
multiple interactions decreases expression |
ISO EXP |
[arsenic trioxide co-treated with Curcumin] results in increased expression of FASLG protein; Curcumin inhibits the reaction [[vorinostat co-treated with Bortezomib] results in increased expression of FASLG protein]; Curcumin inhibits the reaction [Oxygen deficiency results in increased expression of FASLG mRNA] Curcumin results in decreased expression of FASLG mRNA |
CTD |
PMID:10925121 PMID:16101141 PMID:17351739 PMID:23452621 PMID:27430728 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fasn |
fatty acid synthase |
affects expression decreases expression |
ISO EXP |
Curcumin affects the expression of FASN mRNA; Curcumin affects the expression of FASN protein Curcumin results in decreased expression of FASN mRNA |
CTD |
PMID:27208389 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Fbln2 |
fibulin 2 |
multiple interactions |
ISO |
Curcumin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of FBLN2 mRNA] |
CTD |
PMID:18200517 |
|
NCBI chr 4:123,704,289...123,763,857
Ensembl chr 4:123,704,373...123,763,948
|
|
G |
Fcgr3a |
Fc gamma receptor 3A |
multiple interactions |
ISO |
Curcumin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of FCGR3A mRNA] |
CTD |
PMID:18200517 |
|
NCBI chr13:83,249,905...83,259,921
Ensembl chr13:83,249,872...83,259,921
|
|
G |
Fdft1 |
farnesyl diphosphate farnesyl transferase 1 |
decreases expression |
EXP |
Curcumin results in decreased expression of FDFT1 mRNA |
CTD |
PMID:27208389 |
|
NCBI chr15:37,412,143...37,440,198
Ensembl chr15:37,412,146...37,440,287
|
|
G |
Fdps |
farnesyl diphosphate synthase |
increases expression decreases expression affects expression |
ISO EXP |
Curcumin results in increased expression of FDPS mRNA Curcumin results in decreased expression of FDPS mRNA Curcumin affects the expression of FDPS mRNA |
CTD |
PMID:16713233 PMID:27208389 |
|
NCBI chr 2:174,497,402...174,507,031
Ensembl chr 2:174,486,665...174,507,776
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
decreases expression increases expression |
ISO |
Curcumin results in decreased expression of FGF2 protein Curcumin results in increased expression of FGF2 protein |
CTD |
PMID:23555722 |
|
NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221
|
|
G |
Fgf5 |
fibroblast growth factor 5 |
decreases expression |
ISO |
Curcumin results in decreased expression of FGF5 mRNA |
CTD |
PMID:27237783 |
|
NCBI chr14:11,325,334...11,346,570
Ensembl chr14:11,325,334...11,345,997
|
|
G |
Fgfr2 |
fibroblast growth factor receptor 2 |
decreases expression |
ISO |
Curcumin results in decreased expression of FGFR2 mRNA |
CTD |
PMID:15713895 |
|
NCBI chr 1:184,745,418...184,850,655
Ensembl chr 1:184,745,420...184,850,626
|
|
G |
Filip1l |
filamin A interacting protein 1-like |
increases expression |
ISO |
Curcumin results in increased expression of FILIP1L mRNA |
CTD |
PMID:21594647 |
|
NCBI chr11:42,937,353...43,177,085
Ensembl chr11:42,940,467...43,177,415
|
|
G |
Fis1 |
fission, mitochondrial 1 |
multiple interactions |
EXP |
Curcumin inhibits the reaction [Cisplatin results in increased expression of FIS1 protein] |
CTD |
PMID:28698153 |
|
NCBI chr12:19,708,558...19,723,392
Ensembl chr12:19,708,558...19,723,377
|
|
G |
Flt1 |
Fms related receptor tyrosine kinase 1 |
multiple interactions decreases expression |
EXP ISO |
Curcumin inhibits the reaction [Carbon Tetrachloride results in increased expression of FLT1 protein] Curcumin results in decreased expression of FLT1 protein |
CTD |
PMID:18593936 PMID:23845850 |
|
NCBI chr12:7,296,899...7,468,626
Ensembl chr12:7,297,292...7,468,626
|
|
G |
Fn1 |
fibronectin 1 |
multiple interactions decreases expression |
ISO EXP |
Curcumin inhibits the reaction [Glucose results in increased expression of FN1 mRNA]; Curcumin inhibits the reaction [Glucose results in increased expression of FN1 protein] Curcumin inhibits the reaction [sphingosine 1-phosphate results in increased expression of FN1 protein]; Curcumin inhibits the reaction [Streptozocin results in increased expression of FN1 mRNA] Curcumin results in decreased expression of FN1 mRNA Curcumin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of FN1 mRNA] |
CTD |
PMID:12388107 PMID:18200517 PMID:18555241 PMID:21998146 PMID:22228707 |
|
NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
|
|
G |
Fntb |
farnesyltransferase, CAAX box, beta |
increases expression |
ISO |
Curcumin results in increased expression of FNTB mRNA |
CTD |
PMID:17999991 |
|
NCBI chr 6:95,536,540...95,619,587
Ensembl chr 6:95,470,683...95,619,586
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
decreases expression multiple interactions increases expression |
ISO EXP |
Curcumin results in decreased expression of FOS mRNA Curcumin inhibits the reaction [Tobacco Smoke Pollution results in increased phosphorylation of FOS protein] Curcumin inhibits the reaction [Oxygen deficiency results in increased expression of FOS mRNA] Curcumin results in increased expression of FOS mRNA [Curcumin co-treated with Manganese] inhibits the reaction [Kainic Acid results in increased expression of FOS protein] |
CTD |
PMID:15713895 PMID:17827730 PMID:17999991 PMID:23452621 PMID:26191140 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fosl1 |
FOS like 1, AP-1 transcription factor subunit |
multiple interactions increases ubiquitination |
ISO |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Curcumin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of FOSL1 protein]]; Curcumin inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [FOSL1 protein binds to JUNB protein]]; Curcumin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of FOSL1 protein] Curcumin results in increased ubiquitination of FOSL1 protein |
CTD |
PMID:17148446 |
|
NCBI chr 1:202,754,549...202,763,057
Ensembl chr 1:202,754,529...202,764,930
|
|
G |
Fosl2 |
FOS like 2, AP-1 transcription factor subunit |
decreases expression multiple interactions |
ISO |
Curcumin results in decreased expression of FOSL2 mRNA Curcumin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of FOSL2 protein] |
CTD |
PMID:17148446 PMID:17999991 |
|
NCBI chr 6:24,297,898...24,319,157
Ensembl chr 6:24,300,956...24,320,034
|
|
G |
Foxa1 |
forkhead box A1 |
multiple interactions |
ISO |
Curcumin inhibits the reaction [Dihydrotestosterone promotes the reaction [FOXA1 protein binds to KLK3 enhancer]]; Curcumin inhibits the reaction [Dihydrotestosterone promotes the reaction [FOXA1 protein binds to TMPRSS2 enhancer]] |
CTD |
PMID:22258452 |
|
NCBI chr 6:75,099,907...75,136,534
Ensembl chr 6:75,103,503...75,136,188
|
|
G |
Foxa2 |
forkhead box A2 |
decreases expression |
ISO |
Curcumin results in decreased expression of FOXA2 mRNA |
CTD |
PMID:27237783 |
|
NCBI chr 3:135,470,123...135,474,326
Ensembl chr 3:135,470,131...135,474,326
|
|
G |
Foxf2 |
forkhead box F2 |
decreases expression |
ISO |
Curcumin results in decreased expression of FOXF2 mRNA |
CTD |
PMID:15713895 |
|
NCBI chr17:32,835,730...32,842,555
Ensembl chr17:32,836,777...32,842,176
|
|
G |
Foxo1 |
forkhead box O1 |
increases expression decreases phosphorylation |
ISO |
Curcumin results in increased expression of FOXO1 mRNA Curcumin results in decreased phosphorylation of FOXO1 protein |
CTD |
PMID:18403477 PMID:18790744 |
|
NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790
|
|
G |
Fpr3 |
formyl peptide receptor 3 |
multiple interactions |
ISO |
Curcumin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of FPR3 mRNA] |
CTD |
PMID:18200517 |
|
NCBI chr 1:58,884,400...58,893,475
Ensembl chr 1:58,845,118...58,893,467
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
multiple interactions |
EXP |
Curcumin inhibits the reaction [sodium arsenite results in decreased expression of FSHB protein] |
CTD |
PMID:31199764 |
|
NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370
|
|
G |
Fstl1 |
follistatin-like 1 |
multiple interactions |
ISO |
Curcumin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of FSTL1 mRNA] |
CTD |
PMID:18200517 |
|
NCBI chr11:62,895,391...62,948,581
Ensembl chr11:62,779,783...62,948,677
|
|
G |
Ftl1 |
ferritin light chain 1 |
decreases expression |
ISO |
Curcumin results in decreased expression of FTL1 mRNA |
CTD |
PMID:24634837 |
|
NCBI chr 1:95,936,390...95,938,234
Ensembl chr 1:95,936,387...95,939,725 Ensembl chr10:95,936,387...95,939,725
|
|
G |
Fus |
Fus RNA binding protein |
increases expression decreases expression |
ISO |
Curcumin results in increased expression of FUS mRNA Curcumin results in decreased expression of FUS mRNA |
CTD |
PMID:17198877 PMID:17999991 |
|
NCBI chr 1:182,576,479...182,590,417
Ensembl chr 1:182,576,545...182,590,414
|
|
G |
Fzd1 |
frizzled class receptor 1 |
decreases expression |
ISO |
Curcumin results in decreased expression of FZD1 mRNA |
CTD |
PMID:15713895 |
|
NCBI chr 4:29,310,303...29,314,701
Ensembl chr 4:29,310,091...29,312,643 Ensembl chr 4:29,310,091...29,312,643
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
affects expression |
ISO |
Curcumin affects the expression of G6PC mRNA |
CTD |
PMID:27208389 |
|
NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
increases expression |
EXP |
Curcumin results in increased expression of G6PD mRNA; Curcumin results in increased expression of G6PDX mRNA |
CTD |
PMID:18299980 |
|
NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801
|
|
G |
Gabra1 |
gamma-aminobutyric acid type A receptor subunit alpha 1 |
decreases expression |
EXP |
Curcumin results in decreased expression of GABRA1 mRNA |
CTD |
PMID:18299980 |
|
NCBI chr10:26,595,151...26,650,611
Ensembl chr10:26,595,160...26,650,864
|
|
G |
Gad1 |
glutamate decarboxylase 1 |
multiple interactions |
EXP |
Curcumin inhibits the reaction [Streptozocin results in decreased expression of GAD1 mRNA] |
CTD |
PMID:23267840 |
|
NCBI chr 3:55,369,704...55,410,335
Ensembl chr 3:55,369,704...55,410,333
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
increases expression |
EXP ISO |
Curcumin results in increased expression of GADD45A mRNA |
CTD |
PMID:16101141 PMID:18299980 PMID:18719366 |
|
NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115
|
|
G |
Gas6 |
growth arrest specific 6 |
increases expression |
ISO |
Curcumin results in increased expression of GAS6 mRNA |
CTD |
PMID:21594647 |
|
NCBI chr16:76,045,430...76,075,904
Ensembl chr16:76,045,426...76,075,904
|
|
G |
Gata2 |
GATA binding protein 2 |
multiple interactions |
ISO |
Curcumin inhibits the reaction [Dihydrotestosterone promotes the reaction [GATA2 protein binds to KLK3 enhancer]]; Curcumin inhibits the reaction [Dihydrotestosterone promotes the reaction [GATA2 protein binds to TMPRSS2 enhancer]]; Curcumin inhibits the reaction [GATA2 protein results in increased expression of KLK3 mRNA] |
CTD |
PMID:22258452 |
|
NCBI chr 4:120,654,205...120,667,763
Ensembl chr 4:120,658,986...120,667,761
|
|
G |
Gata4 |
GATA binding protein 4 |
decreases expression |
ISO |
Curcumin results in decreased expression of GATA4 mRNA; Curcumin results in decreased expression of GATA4 protein |
CTD |
PMID:27237783 |
|
NCBI chr15:37,459,601...37,531,291
Ensembl chr15:37,459,601...37,505,636
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases activity multiple interactions increases expression |
ISO EXP |
Curcumin results in increased activity of GCLC protein Curcumin inhibits the reaction [Aflatoxin B1 results in decreased expression of GCLC mRNA]; Curcumin inhibits the reaction [deoxynivalenol results in decreased expression of GCLC mRNA]; Curcumin promotes the reaction [sodium arsenite results in increased expression of GCLC protein]; NFE2L2 gene mutant form inhibits the reaction [Curcumin results in increased expression of GCLC mRNA] Curcumin analog results in increased expression of GCLC mRNA; Curcumin results in increased expression of GCLC mRNA Curcumin inhibits the reaction [Hydrogen Peroxide results in decreased expression of GCLC mRNA]; NFE2L2 mutant form inhibits the reaction [Curcumin analog results in increased expression of GCLC mRNA]; NFE2L2 mutant form inhibits the reaction [Curcumin results in increased expression of GCLC mRNA] Curcumin results in increased expression of GCLC mRNA; Curcumin results in increased expression of GCLC protein Curcumin results in increased activity of [GCLC protein binds to GCLM protein] |
CTD |
PMID:10514034 PMID:17602960 PMID:18299980 PMID:18332871 PMID:19168576 PMID:19183254 PMID:23710286 PMID:23954767 PMID:29571711 PMID:31521693 PMID:34272803 PMID:35063475 PMID:35817260 More...
|
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
multiple interactions increases expression |
EXP ISO |
Curcumin results in increased activity of [GCLC protein binds to GCLM protein] Curcumin promotes the reaction [sodium arsenite results in increased expression of GCLM mRNA] Curcumin analog results in increased expression of GCLM mRNA; Curcumin results in increased expression of GCLM mRNA; Curcumin results in increased expression of GCLM protein NFE2L2 mutant form inhibits the reaction [Curcumin analog results in increased expression of GCLM mRNA]; NFE2L2 mutant form inhibits the reaction [Curcumin results in increased expression of GCLM mRNA] |
CTD |
PMID:17198877 PMID:17535857 PMID:17602960 PMID:17999991 PMID:18332871 PMID:19168576 PMID:19183254 PMID:19188863 PMID:23386263 PMID:23710286 PMID:23954767 PMID:29571711 PMID:34272803 More...
|
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Gda |
guanine deaminase |
multiple interactions |
ISO |
Curcumin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of GDA mRNA] |
CTD |
PMID:18200517 |
|
NCBI chr 1:218,903,045...218,982,360
Ensembl chr 1:218,906,815...218,982,416
|
|
G |
Gfap |
glial fibrillary acidic protein |
decreases expression multiple interactions |
ISO EXP |
Curcumin results in decreased expression of GFAP mRNA Curcumin inhibits the reaction [bisphenol A results in increased expression of GFAP mRNA] |
CTD |
PMID:19555370 PMID:25963729 |
|
NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589
|
|
G |
Ggt1 |
gamma-glutamyltransferase 1 |
increases expression multiple interactions |
EXP |
Curcumin results in increased expression of GGT1 mRNA Curcumin inhibits the reaction [Thioacetamide results in increased expression of GGT1 protein] |
CTD |
PMID:18299980 PMID:24704557 |
|
NCBI chr20:13,074,695...13,104,095
Ensembl chr20:13,074,700...13,108,442
|
|
G |
Ggta1 |
glycoprotein alpha-galactosyltransferase 1 |
multiple interactions |
ISO |
Curcumin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of GGTA1 mRNA] |
CTD |
PMID:18200517 |
|
NCBI chr 3:18,732,985...18,824,916
Ensembl chr 3:18,732,991...18,809,908
|
|
G |
|